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Part I. Bioactive Contaminants 
The analytes researched in this study can all be considered as 
environmental and/or food contaminants and are divided in groups 
based on their origin. The first group of analytes consists of chemicals 
derived from an industrial source (industrial contaminants) that enter 
the food chain through the environment or from their use in household 
products. The second group includes chemicals used for pharmacological 
purposes (pharmaceutical contaminants) entering the food chain 
through contaminated drinking water or as drug residues in treated 
livestock.  
 
Industrial Contaminants  
The chemical industry produces an ever-increasing variety and quantity 
of chemical substances to satisfy the needs of our society.  Either 
accidentally or deliberately, some of these chemicals might wind up in 
the wrong compartment of the ecosystem contaminating the soil, the 
surface water or the atmosphere with detrimental effects to the 
organisms living in these compartments. The concentration of some of 
these chemicals in living organisms might be biomagnified downstream 
the food chain in species of higher hierarchy, depending on their toxicity 
and persistence.  
Xenobiotics are considered those man-made chemical contaminants that 
are present in an organism as a consequence of an external agent but 
which are not normally produced by the organism, or expected to be 
present. A source of human exposure to xenobiotics is the leaking of 
chemicals present in household products. For instance, bisphenol A 
(BPA), a monomer used for the production of epoxy coatings and 
polycarbonate applied in plastic containers, migrates to food [1, 2]. Due 
to the widespread use of BPA, its global production reached 2.7 million 
tons/year in 2003 [3]. In consequence, BPA is an ubiquitous 
environmental contaminant mainly present in raw sewage or wastewater 
effluents up to ppb (µg L-1) concentrations [4], and at ppt (ng L-1) levels 
in surface water and sediments [5-8] 
Many industrial xenobiotics are bioactive by having hormonal activity 
and might disrupt the normal functioning of the endocrine system of 
wildlife or humans. These compounds are considered “endocrine 
disrupting chemicals” (EDCs) if they mimic or antagonize the effects of 
endogenous hormones or if they are able to disrupt the synthesis or 
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metabolism of endogenous hormones and hormone receptors [9]. The 
“endocrine disruptor hypothesis” surged in the late 1980’s from 
observations of Colborn et. al, of environmental contaminants affecting 
the endocrine system of wildlife and laboratory animals [10]. These 
observations were a continuation of the environmental awareness that 
arose from the work of Dr. Carson about the danger of pesticides and 
pollution of the environment by chemical industries [11].  
EDCs are not exclusively industrial contaminants, but also some 
pharmaceuticals or agrochemicals, nevertheless, all the EDCs analyzed 
in this thesis are of industrial sources and their mechanism of action will 
be discussed in this section. EDCs can be classified according to the 
system they disrupt (the endocrine homeostasis system), i.e. the 
estrogen (structure of the 17β-estradiol hormone in Figure 1A), the 
androgen or the thyroid system (stucture of Thyroxine (T4) and 
Triiodothyronine (T3) in Figure 1A).  
 
 
Figure 1. Chemical structures of: (A) Natural hormones of the endocrine system. (B) 
Industrial contaminants disrupting the endocrine system. (C) Fluoroquinolone antibiotics 
considered pharmaceutical contaminants. 
 
Within each system, the EDCs might interfere at different levels of the 
hormone’s pathway, i.e. at the nuclear receptor, at the transport during 
cellular uptake, at the transport from the gland to the tissues (transport 
protein) and the metabolism. However, EDCs can be promiscuous across 
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levels within a system and even between distinct systems [12]. One 
example is again BPA (Structure in Figure 1B), which is considered a 
weak estrogenic substance linked to effects on the reproductive system 
because it binds to the estrogen receptor similar to 17β-estradiol and 
may induce a decrease of sperm quality in humans [13-16]. BPA not 
only mimics estrogens it also mimics thyroid hormone action as an 
antagonist in some organisms [17-20].  
Many polyhalogenated aromatic hydrocarbons (PHAHs) are industrial 
contaminants considered as EDCs (structures shown in Figure 1B). 
PHAHs can become hydroxylated in vivo by the cytochrome P450 
monooxygenase system [21]. Polychlorinated biphenyls (PCBs) are a 
group of PHAHs that are highly persistent and bioaccumulate in lipid 
tissues. The hydroxylated metabolites of PCBs (Figure 1B) display a high 
degree of structural resemblance to the thyroid hormone, tyroxine (T4) 
(Figure 1A). An even closer structural resemblance to T4 is shown by 
metabolites of the flame retardants (Figure 1B), widely used in 
household. Flame retardants such as tetrabromobisphenol A (TBBPA) 
(Figure 1B) and polybrominated diphenyl ethers (PBDEs) are extensively 
used in plastics, electrical components and synthetic textiles. Therefore 
humans are in continuous contact with compounds that structurally 
resemble T4. For instance, PBDEs have been measured in human 
adipose tissues from New York City inhabitants at concentrations up to 
two orders of magnitude greater than those reported in European 
countries [22, 23].  
T4 and its biologically active metabolite, triiodothyronine (T3), are 
essential for the modulation of the cellular metabolic rate and for the 
development and differentiation of several organs, especially the brain 
[24, 25].  The thyroid gland produces and releases T4 in response to the 
thyroid-stimulating hormone (TSH) released by the pituitary. Once T4 
enters the blood stream it is bound to transport proteins (TP) and 
distributed to the target tissues. Thyroxine binding globulin (TBG) is the 
major T4 TP in human plasma and is responsible for 75% of the specific 
T4 binding activity. TBG has been linked to facilitate the iodine supply to 
the fetus that initially has no iodine reserve [26]. Transthyretin (TTR) is 
the second TP carrying about 20% of T4 and is important for maternal 
to fetal transport of thyroid hormones and for delivery of T4 across the 
brain barrier [27]. Finally, human serum albumin (HSA) is the third TP 
carrying about 5% of the total T4. These three TPs form a 
comprehensive T4 buffer system because they circulate in the blood 
stream differing more than three orders of magnitude in concentration 
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(TBG 0.27 M, TTR 4.6 M and HSA 640 M) and have an even larger 
difference in affinity for T4 [26]. When T4 reaches a target tissue in the 
T4-TP complex, it is specifically transported through the cell membrane 
into the intracellular compartment and deiodinated to the biologically 
active T3 metabolite in different tissues [28]. Once inside the cell, T3 is 
non-specifically transported to the nucleus where it exerts its action by 
binding to the nuclear thyroid receptors.  
Several industrial contaminants resembling T4 have been shown to 
interfere at different levels with the thyroid pathway (for review see 
[29]). Hydroxylated PHAHs interact at the T4 transport level binding TTR 
with high affinity [30, 31] and some of them, albeit  with much lower 
affinity, interact with TBG [32, 33]. Displacement of T4 from its TP 
complex during the developmental stage could have consequences in 
fetal development and later in adulthood [34-36]. Therefore, the 
presence and bioaccumulation of these bioactive chemicals in the food 
chain and consequently in humans is a cause of health concern and 
there is a rising need for high throughput screening methods for 
chemicals affecting the thyroid system at different levels.  
 
Pharmaceutical Contaminants 
The pharmaceutical xenobiotics, are chemicals of concern because they 
might either be EDCs (i.e. from hormonal replacement therapies), like 
the industrial xenobiotics, or because they might cause adverse health 
effects when consumed without a specific need. Pharmaceuticals might 
contaminate surface waters and affect wildlife as a consequence of the 
treatment of humans and livestock and a poor or inefficient drug 
residues removal by sewage water treatment plants [37, 38]. Wildlife 
might be directly contaminated with pharmaceuticals at measurable 
levels if it feeds from treated livestock [39].  
A specific example of pharmaceutical contaminants affecting humans are 
the antibiotics. Antibiotics are considered xenobiotics, but are essential 
to cure bacterial-related diseases. Farmers often apply antibiotics to 
livestock to handle specific diseases or as growth promoters [40, 41]. 
Unfortunately, the continuous exposure of bacteria to antibiotics 
generates antiobiotic-resistant strains that might cause bacterial 
infections to the consumers exposed [40]. Because the profitability of 
livestock is often hampered by infectious diseases, the use of veterinary 
antibacterial drugs is expected, not only for treatment, but also for 
prophylaxis. This practice might lead to the acquisition of methicillin-
General Introduction 
 
 14 
resistant Staphylococcus aureus (MRSA) by farmers and their 
communities [42]. As a matter of fact, the presence of antibiotics in 
livestock not only raises the concern of antibiotic resistant bacterial 
strains [43-45], but also, about the occurrence of allergic reactions in 
consumers [46].  
Fluoroquinolones (FQs) (structures shown in Figure 1C) one group of  
antibiotics that target the DNA gyrase in gram-negative bacteria and 
probably topoisomerase IV in gram-positive bacteria leading to inhibition 
of DNA replication and cell death [47]. FQs have widespread use for 
infection treatment, as well as a prophylactic and as growth promoters 
in farmed fish, turkeys, pigs, calves and poultry [48, 49].  
Consequently, there is a rising need for rapid, robust, multi residue 
screening methods complying with EC Council Directive 96/23/EC that 
establishes the need of a residue monitoring plan for these and other 
groups of substances by the EU member countries for these 
pharmaceuticals and their metabolites [43]. The diversity of commonly 
used pharmaceuticals poses a great analytical challenge to their 
detection due to the different matrices in which they are usually 
present. 
  
Part II. Biosensor Screening  
Classical analytical chemistry separation methods like liquid or gas 
chromatography (LC or GC) coupled with a spectrometric detector like 
ultra violet (UV) absorbance, fluorescence emission or mass 
spectrometry (MS) provide information about the presence and the 
structure of the bioactive contaminants described above. Nevertheless, 
the detection is based only on the chemical and physical properties of 
the analyte(s). Hence, these methods are usually unable to generate 
information about on the biological effects of the analytes. Furthermore, 
analyzing the diversity of chemicals in complex food and environmental 
samples with classical analytical techniques requires considerable time 
and specialized human resources. These issues not only limit the 
number of samples that can be analyzed with classical analytical 
techniques, they also restrict the possibility of making cost-effective 
monitoring programmes and are slow to adapt to the market-driven 
evolution of the analytes if compared with other bioassays featuring a 
selectivity based on the biological activity of the analyte(s).  
An interesting alternative is the use of low-cost biosensors for the 
screening process and subsequently, to focus the analytical efforts only 
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on the suspected non compliant samples. The specificity of the biosensor 
assays for the bioactive contaminants can be tailored depending on the 
biomolecule used as biorecognition element. The incorporation of effect-
related biomolecules (i.e. receptors, transport proteins, etc) provides a 
further advantage, since it allows the screening of known bioactive 
compounds and the detection of emerging ones sharing a similar 
biological endpoint. In this study, the application of biosensors for the 
screening of different bioactive contaminants is evaluated and the 
following section describes background information of the biosensor 
screening technology. 
 
History of Screening Methods 
One of the first biomolecule-based screening methods was a 
radioimmunoassay (RIA) for the detection of insulin which was published 
in 1960 by R.S. Yallow [50] and  was  awarded in 1977 with the Nobel 
Prize of Physiology. In this RIA, a known amount of free radiolabeled 
analyte is mixed with the sample and an antibody previously raised 
against the analyte (the antigen). The analyte in the sample and the 
radiolabeled analyte compete for binding to the antibody, the bound and 
unbound fractions are separated and the amount of free radiolabeled 
analyte is proportional to the amount of analyte in the sample. Although 
this method is still used and is very sensitive, the handling of 
radioisotopes requires strict safety conditions and an alternative method 
was sought. The radioisotope label was replaced by an enzyme 
catalyzing a reaction that can be monitored using simple colorimetric 
techniques leading to the widely used enzyme-linked immunosorbent 
assay (ELISA) [51, 52]. The relative simplicity with which an antibody 
can be raised against virtually any type of antigen has made ELISAs the 
most commonly used screening method. 
Further developments of immunochemical screening methods led to the 
use of fluorescent [53], electrochemical and chemiluminescent [54] 
labels to amplify the signal and obtain a higher sensitivity. The binding 
partners in these methods are not restricted to antibody-antigen 
interactions, any other couple of binding partners is feasible, like 
receptor-ligand, binding protein-ligand, DNA-DNA, RNA-DNA, DNA-
receptor, etc. The forces governing the interactions of binding partners 
will be discussed in detail in the next section. Biosensor technology is 
based on these biological molecules integrated with a transducer that is 
sensitive to the generation of a signal in response to a biochemical 
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reaction or a binding event. The different components and types of 
biosensors will be presented later in this introduction.  
 
Biomolecular Binding Forces  
An antibody binds to an antigen or a receptor to a ligand forming a 
supramolecular complex driven by non-covalent intermolecular forces. 
These forces are individually weak, but given the large number of 
possible interactions with a biomolecule, they are collectively strong. 
Intermolecular forces include electrostatic interactions (like dipole-dipole 
interactions, hydrogen bonds and ionic interactions), hydrophobic 
interactions as well as van der Waals forces. The first subset of 
electrostatic interactions are forces between dipoles. Highly polar 
molecules, like the polar amine and carbonyl groups of the polypeptide 
backbone of proteins, lead to permanent dipoles. Dipoles can either 
attract or repel each other and they play an important role in protein 
structure. The hydrogen bonds are a type of dipole-dipole interactions 
that occur between a hydrogen atom bonded to an electronegative atom 
and an unbound pair of electrons in a highly electronegative atom like 
an amine and a carbonyl group. The sharing of the electrons is unequal 
for the hydrogen and creates a partially positive charge that is attracted 
to the partially negative charge in the carbonyl group. Electrostatic 
interactions in an aqueous solution contribute to the binding strength 
and intermolecular stabilization [55, 56]. The ionic interaction or ionic 
bonds are based on the electrostatic attraction between charged 
molecules of opposite sign (ions).  
Hydrophobic interactions are repulsive forces that occur between non-
polar molecules and polar molecules like water. The non-polar regions of 
the molecule interfere with the hydrogen bonding of the solvent and 
tend to cluster together repelling the polar solvent (usually water) to 
attain a more favorable energy level. The strength of the hydrophobic 
interactions results from the system achieving thermodynamic stability 
by minimizing the number of ordered water molecules required to 
surround the hydrophobic portions. Hydrophobic interactions at the 
binding site play an important role in the binding strength and stabilize 
the intermolecular complex [57]. 
Van der Waals forces are weaker than the dipole-dipole interactions and 
are the consequence of random variations in the positions of electrons 
around one nucleus. This creates a transient electric dipole that induces 
an equally transient but opposite dipole in a nearby atom. These 
Chapter 1 
 
 17
transient dipoles attract each other until their electron clouds start to 
repel. 
The interaction of an antigen with an antibody, an enzyme with its 
substrate or a receptor with its ligand may involve several hydrogen 
bonds, one or more ionic, hydrophobic and van der Waals interactions. 
The cumulative effect of all these weak interactions is enormous and is 
responsible for the high affinity, complementarity, flexibility and 
reversibility that interacting biomolecules exhibit. A characteristic 
binding site contains a hydrophobic pocket lined with charged groups 
and hydrogen bond donors and acceptors. Upon collision, mainly the 
electrostatic forces of the binding site interact with the dipoles of the 
antigen aligning and pulling both molecules together. The other forces 
provide supplementary attraction and stabilization of the complex [57, 
58]. Opposed to the attraction forces, are the repulsive forces due to 
steric hindrance. These forces are minimized as the complementation 
between interactants increases.  
 
Binding Kinetics 
The kinetics of the biomolecular binding interactions in solution can be 
described by:  
(1) 
 
Where the equilibrium constant or affinity K, between reactant A and B 
for the formation of the supramolecular structure AB is given by: 
(2) 
 
Being ka and kd respectively the association and dissociation rate 
constants. The equilibrium dissociation constant or KD, is the inverse of 
K. In solution, ka is affected by the diffusion of reactants and the 
collision probability. kd is influenced by the strength and stability of the 
binding interaction, as well as the thermal energy available compared to 
the activation energy needed to break the interactions.  
 AB
k
 BA
a   
dk
d
a
k
k
[A][B]
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Biosensors 
The beginning of the biosensor technology dates back to 1956 when 
Clark and Lyons invented the oxygen electrode. In 1962 they presented 
their work on the integration of the oxygen electrode with the enzyme 
glucose oxidase using a dialysis membrane [59]. The decrease in 
measured oxygen concentration was proportional to the glucose 
concentration in solution. This was the beginning of the successful in-
home glucose biosensor still used nowadays for monitoring blood 
glucose levels [60].  
Biosensors are classified based on the biological sensing element used, 
such as antibody, enzyme, receptor or cell and based on the transducer 
in contact with the biological element such as an electrode 
(electrochemical potentiometric and amperometric sensors), 
piezoelectric acoustic, and optical sensors.  The sensitivity of the 
transducer to selectively transform a parameter of the biological 
element-analyte reaction into a quantifiable electrical signal is crucial for 
the biosensor performance. The specificity of a biosensor is given by the 
properties of the biological sensing element per se. A short description 
of the various types of biosensors will be presented below. Special 
emphasis will be given to surface plasmon resonance-based optical 
biosensors since they are the focus of the present study.  
Electrochemical biosensors are usually based on the detection of an ion 
product of the specific catalytic power given by an enzyme immobilized 
at a working electrode. There are potentiometric and amperometric 
biosensors. The potentiometric sensors measure a change in potential 
between an ion selective electrode and a reference electrode with no 
current flow. The amperometric biosensors measure the current 
produced by the oxidation or reduction of an electro active compound at 
an electrode when a potential is constantly applied with respect to a 
counter electrode. The oxidation or reduction of the analyte (or an 
enzymatic product) proceeds at the working electrode. The current 
generated is proportional to the oxidation or reduction rate, which is 
proportional to the analyte concentration [61]. The glucose biosensor 
mentioned before is amperometric and measures either the hydrogen 
peroxide produced or the oxygen consumed by the glucose oxidase 
immobilized on the electrode surface. When the analyte is not 
susceptible to enzymatic breakdown into electroactive species, an 
enzyme label like horseradish peroxidase or alkaline phosphatase can be 
used in combination with a specific biorecognition molecule [62].  
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Piezoelectric biosensors are based on the principle that a crystal 
oscillates at a specific frequency upon the application of an alternating 
electric field. A change in mass on the surface of the crystal (i.e. when 
an antibody binds to a derivatized surface) is measured from the shift of 
the resonating frequency, wave velocity or amplitude of the oscillating 
crystal  [63].  
 
Optical Biosensors 
Optical biosensors are popular devices used for bioanalysis and offer the 
largest group of transducers. Numerous applications are described in 
literature using either fluorescent, bioluminescent or chemiluminescent 
labels for detection, as well as the direct (label-free) detection of 
analytes on a surface using ellipsometric biosensors, total internal 
reflection spectroscopy (TIRS) and surface plasmon resonance (SPR)-
based biosensors. If linearly polarized light is reflected from a planar 
surface, the light is elliptically polarized. This principle is exploited by 
the ellipsometric optical biosensors that are able to monitor adsorption 
of biomolecules to a planar surface (as changes in refractive index and 
biomolecular layer thickness) by measuring a change in phase and 
amplitude of the reflected light [64]. A drawback of this configuration is 
that the light has to penetrate the liquid carrying the sample and the 
reagents, making the sensitivity of this configuration very susceptible to 
scattering by particles or air bubbles. On the contrary, evanescent wave 
(EW)-based biosensors only probe a small volume of liquid around the 
sensing area and the light path can be outside the bulk sample [64]. 
To better clarify the principle of EW-based biosensors, some optical 
properties will be discussed. When light travels from a medium with a 
high refractive index (n1) to one with a lower refractive index (n2), the 
light beam will be partially reflected at the boundary surface, and 
partially refracted according to Snell’s law (see Figure 2.). 
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Figure 2. Refraction and reflection of light at the surface of two dielectrics. (I, n, Θ are 
explained in the text) 
 
An incident light beam of intensity Ii striking the interface of two 
dielectric materials with different refractive index (n) is reflected or 
refracted with an angle (Θ) 
(3) 
 
n1 and n2 being the refractive indices of the materials, Θi the angle of 
the incident light and Θt, the angle of the refracted light. Total internal 
reflection (TIR) of the incident light occurs if Θi is above the critical 
angle (ΘiCr) and according to Snell’s law for Θt of 90° (4). 
(4) 
 
 
Interestingly, when TIR occurs, an electromagnetic field component 
called the evanescent wave (EW) penetrates into the medium with a 
lower refractive index and it decays exponentially with the penetration 
depth.  
ti ΘnΘn sinsin 21 



1
21
n
nΘ Cri sin
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The penetration depth of the EW is defined as the distance from the 
interface where it decays to 1/e of its value at the interface [65]. The 
penetration depth is described by: 
(5) 
 
where, λ is the wavelength of light, Θi the angle of incidence and n1 and 
n2 the refractive indices of the materials [66]. The penetration depth is 
strongly dependent on the wavelength that can range from 50 nm to 
1000 nm for visible light.  
Different features of the EW phenomenon can be measured to exploit it 
in a biosensor setup. First, when a UV-visible chromophore absorbs light 
within the EW, the change in UV light intensity passed through a 
waveguide or optical fibre can be monitored. Although simple, this setup 
lacks sensitivity due to the small percentage of the light beam that 
actually interacts with the chromophore in the form of EW [67]. Another 
option is the utilization of the EW for exciting fluorophores. By 
monitoring the fluorescence generated at the waveguide interface, 
powerful total internal reflection fluorescence (TIRF) biosensors were 
developed [67-69] reaching femtomolar sensitivity [70]. The common 
limitations of TIRF-based biosensors are the difficulty of labeling the 
reagents and fluorescence quenching due to matrix effects. The third 
possibility is to excite surface plasmons to measure refractive index 
changes at a dielectric-metal interface. The latter phenomenon is called 
surface plasmon resonance and, because of its application throughout 
this study, it will be discussed in detail.  
 
Surface Plasmon Resonance Biosensors 
The beginning of SPR-based biosensors goes back to 1902, when Wood 
observed an anomaly in the absorption bands of polarized light reflected 
from a metal grating [71]. In 1941, Fano concluded that these 
anomalies were linked to surface plasma waves (SPW) of the grating 
[72]. SPW are electromagnetic waves propagating at the surface 
through the collective motion of large numbers of excited metal 
electrons. In 1968 Otto [73], Kretschman and Raether [74] pioneered 
with the configurations used to excite SPW. When a metal film is placed 
)sin( 22
22
12 nn i
pd 



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at the dielectric interface, light in the form of EW arising from TIR can 
be coupled to a SPW. In the Otto configuration, the light goes through 
the high refractive index prism and TIR occurs at the prism-dielectric 
interface generating an EW. A metal layer, separated from the prism by 
a dielectric layer of correct thickness, contains surface plasmons that 
can couple to the EW [73] to generate SPR.  
The outcome of such coupling is the reduction of the intensity of the 
reflected light. The incident light angle at which this reduction 
(“shadow”) occurs is called the SPR angle. Since the waves are on the 
boundary of the metal and the external medium (air or water), the 
plasmon oscillations, and as a consequence the SPR angle, are very 
sensitive to any change of this boundary, such as the adsorption of 
molecules to the metal surface. A plot of the SPR angle against time 
(the sensorgram) displays the progress of the interaction at the sensor 
surface. 
 
 
Figure 3. (A) Kretchmann configuration used in surface plasmon resonance spectrometry 
(B) Shift in the optimum angle of incidence to generate SPR (SPR dip minimum shift). 
 
Most of the commercially available SPR biosensors are based on the 
Kretschmann configuration (Figure 3A). Where the EW penetrates 
through a thin gold film (≈ 50 nm) and couples with the surface 
plasmons at the outer boundary of the gold film, at the metal-dielectric 
interface [75, 76]. 
A metal surface contains free electrons (surface plasmons) that 
collectively oscillate creating an SPW. The SPW propagates along a 
metal dielectric interface and generates an asymmetric electromagnetic 
field that extends into both the metal and mostly in to the dielectric 
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medium (≈ 90%) that decays exponentially and perpendicular to the 
propagation direction. The permittivity (ε) of a material describes how it 
is affected or affects an electric field and is expressed in complex 
numbers. A SPW propagates if the real part of the metal permittivity 
(εm) is negative and its absolute value is smaller than the permittivity of 
the dielectric (εd) [65]. Several metals fulfill this condition; however gold 
and silver are commonly used in SPR sensors.  
The propagation constant (β) of a SPW along a thin metal film is 
described by 
(6) 
 
where, ω is the angular frequency, c is the velocity of light in vacuum 
and Δβ accounts for finite thickness of the metal film and the presence 
of the prism. From Eq. 6, we observe that βSPW is influenced by the 
dielectric present on the opposite side of the metal film and βSPW 
changes if εd  is perturbed.  
The propagation constant of light in the form of EW at the dielectric-
metal interface is defined as 
(7) 
 
where, np is the refractive index of the prism. Surface plasmon 
resonance occurs when a metal surface at a dielectric interface is 
illuminated with p-polarized light (or transverse magnetic (TM)-polarized 
light) through a prism and the light’s wave vector parallel to the 
interface (or βEW) matches that of the SPW. The prism, of high refractive 
index, is used as a coupler to enhance the light’s wave vector [65].  
In other words, surface plasmon resonance occurs when: 
 
 (8) 
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Hence, from Eq. 6 and 7: 
(9) 
 
If this pre-requisite is fulfilled, at a certain angle of incident light the 
energy is transferred to the metal in the form of resonating plasmons 
(when the light’s wave vector couples with the SPW) and is not 
reflected. From eq 8. it is obvious that if the permittivity of the dielectric 
is perturbed (i.e. due to a change in refractive index) on the right side of 
the equation, then a new angle of incident light will be required to 
generate SPR. An increase of the concentration of biomolecules within 
the EW influences the refractive index of the dielectric and hence its 
permittivity (see Eq. 8.) 
 
 
Figure 4. Schematic view of a Biacore system setup. 
 
When the reflected light intensity is plotted against the angle of 
incidence, SPR is evidenced as a sharp dip when the reflected light 
intensity shows a minimum at a certain angle of incidence (Figure 3B).  
If a change in refractive index within the EW occurs within the small 
volume of the dielectric probed by the EW volume, it is observed in the 
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attenuated total reflection (ATR) method described here as a shift in the 
SPR dip minimum (Figure 3B, dotted line). Tracking the change in the 
incident angle of light (∆Θ) by means of the SPR dip minimum over 
time, provides a parameter that is linearly correlated to changes in 
refractive index of the dielectric (usually a fluid) within the EW. The 
width and depth of the SPR dip depends on the type and thickness of 
the metal film used and the incident light wavelength. Silver yields 
narrower dips than gold increasing the signal to noise ratio but is easily 
oxidized. Therefore, most biosensors use a thin gold film. The use of 
stacked heterogeneous metallic layers is a promising technique to 
improve the signal to noise ratio and the sensitivity [77].  
SPR sensors where the angle of incident light is modulated are classified 
as SPR sensors with angular modulation. Other SPR sensor setups use 
the light’s wavelength, intensity and phase modulation to generate SPR. 
Three SPR biosensor systems based on prism couplers and angular 
modulation will be used throughout this thesis, two Biacore systems 
(models 3000 and Q) based on the same setup and a Spreeta 2K optical 
integrated SPR unit from Texas Instruments.  
The Biacore systems were first introduced in 1991 [78]. These systems 
are based on collimated and focused, wedge-shaped, beams of p-
polarized light that strike a gold film through a prism in four sensing 
areas (Figure 4). The angular spectrum of each sensing area is reflected 
on a linear diode array where the light intensity is measured.  
The biosensor signal output is calculated from the shift of the angle of 
incident light at which the SPR dip occurs. This shift plotted against time 
provides a real time sensorgram of the refractive index in the area 
probed by the EW. When biomolecules like antibodies interact with 
antigens immobilized on the sensor surface, there is change in local 
refractive index of the area probed by the EW.  
On the opposite side of the gold film, the microfluidic system features 
four serially connected flow cells (or channels). These flow channels (Fc) 
allow the system to run spatially-resolved immobilizations and assays 
(only in Biacore 3000) on the same sensor chip. Each Fc has an area of 
1.2 mm2, heights of 20 m (Biacore 3000) or 50 m (Biacore Q) and 
volumes of 0.02 (Biacore 3000) and 0.06 μL (Biacore Q). 
The Spreeta SPR sensor (Figure 5) is an integrated optical unit [79]. The 
light from a LED is p-polarized and strikes a tilted gold film through a 
prism. The tilting of the gold film relative to the light source provides a 
continuous change in the angle of incident light. The angular spectrum 
of light is reflected to a mirror and finally to a photodiode array where 
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the light intensity is measured. The biosensor signal output is also 
calculated from the shift in the SPR angle and resembles the Biacore 
systems. 
 
 
Figure 5. Cross section of the Spreeta 2K integrated optical unit with a flow cell. (B) 
Experimental Spreeta SPR biosensor system (portable box) connected to an autoinjector. 
The size of the optical unit is comparable to a medium size coin (insert). 
 
The sensitivity of SPR sensors with angular modulation depends on the 
magnitude of the incident angle shift, elicited by a change in refractive 
index within the EW, usually in the order of 50-100 degrees/refractive 
index unit (RIU). It also depends on the optical properties of the prism, 
the properties of the metal film containing the SPW and the wavelength 
used [80]. 
The resolution is defined as the smallest change in refractive index that 
produces a detectable sensor output [76]. Therefore it is highly 
influenced by the level of noise that originates mainly from the intensity 
of the light emitted in the optical system and the electronics. The 
angular spectrum of light intensities obtained by the diode array is 
mathematically processed to reduce noise. Usually, the spectra are 
normalized and time-averaged. The algorithm used to calculate the 
sensor output also influences the noise. The maximum resolution 
achieved with SPR biosensors based on angular modulation is in the 
order of 3x10-7 RIU [81]. Finally, the presence of reference channels (in 
Biacore 3000) and a post-measurement subtraction of the specific and 
non specific signals (i.e. bulk refractive index changes during 
measurement) further reduces the noise and increases the resolution 
allowing the direct measurement of small molecules (i.e. below 1 KDa) 
[82].  
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Sensor Chips 
A crucial part of SPR biosensors is the surface chemistry on the sensor 
chip for covalent attachment of either the biorecognition element or its 
ligand, depending on the assay format required. The highly hydrophobic 
gold film is usually derivatized with a self-assembled monolayer of 
alkanethiols with suitable reactive groups for immobilizing a monolayer 
of one of the binding partners [83]. This layer yields a limited amount of 
molecules within the EW resulting in a limited biosensor signal output. A 
recent application of this type of chip surface is for the capture of lipid 
monolayers and the study of the interaction between molecules and 
membrane surfaces (for review see [84]). A hydrogel matrix can be 
immobilized on the gold surface, in order to increase the volumetric 
density of the binding partners within the EW. Usually a layer of 
carboxymethylated dextran (CMD) is immobilized on the chip by means 
of a previously covalently linked monolayer of long-chain hydroxyalkyl 
thiols to the gold surface [85]. The CMD forms a thin layer of about 100-
200 nm thick [86]. Variations in the length, number of carboxyl groups 
(charge) and porosity (crosslinking degree) of the CMD are commercially 
available [87, 88]. Alternatively, there are nitriloacetic acid chips based 
on metal chelation for the capture of polyhistidine tagged proteins and 
chips with streptavidin for the capture of biotinylated biomolecules [88]. 
The chip surface properties should also be considered when designing a 
biosensor assay since its non-specific affinity towards components of the 
sample matrix will influence the assays performance and determine the 
applicability of the assay. Molecules containing an amine group can be 
covalently immobilized to CMD chip surfaces. In these cases the 
carboxyl groups on the surface are activated using a mixture of 1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide (EDC) and N-
hydroxysuccinimide (NHS) followed by an exposure of the activated 
CMD surface to the molecule at the appropriate pH. The coupling 
reaction requires uncharged amino groups on the ligand and is therefore 
favored by high pH. A bifunctional linker (ethylenediamine) is typically 
used to immobilize molecules bearing a carboxyl group.  More coupling 
chemistries are available (for instance the thiol-disulphide exchange or 
the aldehyde coupling) which are not within the scope of this study. 
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Biorecognition Elements 
The biorecognition molecules in SPR biosensor assays are usually 
biomacromolecules varying from a few KDa to 800 KDa depending on 
their nature. Antibodies are the most common biorecognition molecules 
in SPR biosensor assays.  
 
 
Figure 6. Biorecognition elements used in this study. Immunoglubulin G (IgG), Thyroxine 
Binding Globulin (TBG) anf Transthyretin (TTR). 
 
Antibodies belong to the family of macromolecules known as 
immunoglobulins which are present at 12-15 mg ml-1 in blood serum, 
amounting to nearly one fifth of its total protein content. There are five 
immunoglobulin classes known in mammals, IgG, IgM, IgA, IgD and IgE 
with molecular masses ranging from 150,000 to 970,000 Da. IgG 
represents 70% of the serum immunoglobulins and constitutes the 
majority of the secondary immunological response to most antigens. IgG 
molecules have three domains (two Fab domains and one Fc domain) 
(Figure 6). The Fab domains (fragment that carries the antigen binding 
site) form the arms of the Y shape and are identical which makes IgG 
molecules bivalent. The domain that is involved in immune regulation is 
termed Fc fragment (for the fragment that crystallizes) and forms the 
base of the Y structure. The two heavy (H)-chain polypeptides (each 440 
amino acids [approximately 55,000 Da]) and the two light (L)-chains 
(each about 220 amino acids [about 25,000 Da]) are identical. One L-
chain associates with the amino-terminal region of one H-chain to form 
an antigen-binding site. The carboxy-terminal regions of the two H-
Chapter 1 
 
 29
chains fold together to form the Fc domain. The four polypeptide chains 
are held together by disulphide bridges and noncovalent bonds. L-chains 
can be divided into two regions, the variable (VL) and the constant (CL) 
region (each about 110 amino acids in length). H-chains can be divided 
in two regions, a variable (VH) and a constant (CH) region. The V 
regions (located at the amino end) of one H-chain and one L-chain 
combine to form one antigen binding site. The heterogeneity in the V 
regions of both L- and H-chains confer the capability to respond to a 
very large number of antigens [89], allowing mammalians to generate 
an immune response with a diversity of up to 105-106 different 
antibodies. 
Small molecules of less than a few thousand Da, such as most of the 
bioactive contaminants relevant in the present study, are not 
immunogenic. Hence, for the production of antibodies the analyte must 
be covalently conjugated to a large carrier protein. The nature and 
position of this conjugation has a direct effect on the properties of the 
resulting antibodies. In general, the best chances of producing high 
quality antibodies result from a linkage of the analyte producing the 
minimum perturbation of the three dimensional structural conformation 
and the electric properties [90]. In principle, the specificity of antibodies 
against substances of low molecular mass is mainly determined by the 
choice of the coupling site. Usually the part of the molecule that is 
opposite to the coupling site acts as the immunodominant portion of the 
hapten-protein conjugate. Structural changes in the vicinity of the 
coupling site cannot be readily recognized by the antibody and will show 
less influence on the immunoreactivity. 
Polyclonal (PAbs), monoclonal (MAbs) and occasionally recombinant 
antibodies (RAbs) derived from libraries are used in immunoassays [91]. 
RAbs are a very interesting alternative that can be derived from present 
MAbs. RAbs can be mutated to generate a library, and later selected, 
thus tailoring the biorecognition element for a required selectivity or 
resistance to specific conditions [92, 93]. 
In this study we have used MAbs and PAbs. PAbs are applied most 
frequently because they are cheap to prepare in host animals. However, 
the main drawback of using PAbs is the serum batch quantity and the 
batch to batch variation. MAbs, in turn, are homogeneous, specific and 
can be produced in unlimited quantities using the hybridoma technology 
[94]. During the production, a specific MAb can be isolated for a unique 
and chosen specificity. A further advantage of hybridoma production is 
that impure antigens can be used to produce specific antibodies. The 
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limitations of hybridoma technology include the specialized cell culture 
facilities, extensive time, labor, expenses, as well as expertise needed to 
prepare and screen large numbers of hybridomas in order to select the 
most suitable ones. PAbs as well as MAbs have been shown to be 
sensitive, robust and specific biorecognition elements in biosensor 
assays. Furthermore, antibodies can even be raised to be group-specfic 
biorecognition elements when a group of structurally related compounds 
has to be detected.  
However, antibodies fail when a group of structurally varied chemicals 
like the EDCs described in Part I has to be targeted in a single assay. In 
this case, if the chemicals share a common biological endpoint like the 
binding to a receptor or a transport protein, these biomolecules can be 
used as biorecognition elements. These natural biorecognition elements 
can either be purified from their containing organism like the thyroxine 
binding globuling (TBG) used in this study (Figure 6) that is purified 
from human serum. TBG is a 54 KDa acidic glycoprotein with one  
external T4 binding pocket responsible for transporting 75% of serum 
T4 [95]. TBG is synthesized in the liver as single polypeptide chain of 
415 amino acids. Alternatively, the biorecognition element can be 
recombinantly produced in to a foreign organism by cloning the coding 
DNA into a vector and transforming the most suitable organism for 
overexpressing the protein. Using this approach the supply of the 
biorecognition element is virtually unlimited and it was used by our 
collaborators for the production of recombinant transthyretin (TTR), a 
human thyroxine transport protein, used in this study [96]. TTR is a 55 
KDa tetramer of identical subunits, each containing 127 amino acids 
[97]. The four subunits form a symmetrical ß-barrel structure with a 
double trumpeted hydrophobic channel that traverses the molecule 
forming the two allosteric iodothyronine binding sites (Figure 6). 
Although TTR is bivalent, only one T4 molecule is usually bound because 
the binding affinity of the second site is greatly reduced through a 
negative cooperative effect [98].  
 
Biosensor Assay Formats 
Various assay formats are possible in SPR biosensors. In the direct 
binding assay (DBA) format, the biorecognition molecule is immobilized 
or captured on the chip surface and is brought into contact with the 
sample containing the analytes and the binding increases the refractive 
index at the sensor surface. The DBA format is in theory the most 
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sensitive [99, 100] and is widely used for fishing high molecular weight 
biomolecules out of complex biological matrices because the biosensor 
signal output depends directly on the mass of the interacting analyte. 
The smaller the analyte to be detected in a DBA format, the more 
biosensor resolution is required to detect it. Additionally, an in-line SPR 
referencing surface is needed to be able to subtract noise and signals 
from bulk responses due to minor refractive index dissimilarities of the 
solutions injected. If these conditions are fulfilled and with the proper 
experimental forethought, the DBA format is effective for the 
determination of kinetic parameters of low molecular weight molecules 
binding to antibodies or receptors [101, 102]. The DBA format has the 
advantage of yielding information about the analyte-biorecognition 
element interaction strength and kinetics. Association and dissociation 
rates are of special interest when dealing with non conventional 
biorecognition elements like receptors or transport proteins. The 
sandwich assay is a variation of the DBA, where secondary 
biorecognition molecules are introduced to enhance the signal of the 
bound analyte. However, sandwich assays do not work with small 
molecules due to the relatively large binding sites of the biomolecules. 
For low molecular weight compounds the inhibition assay format is 
generally preferred in biosensor immunoassays (BIAs) because of its 
flexibility, higher response and robustness [103, 104]. In the inhibition 
BIA (iBIA) format the analyte, or a structural analogue, is immobilized 
on the sensor surface preserving its affinity for the biorecognition 
molecule. The sample containing the analyte is mixed with the 
biorecognition molecule and brought into contact with the analyte 
derivative or structural analogue immobilized on the sensor chip surface. 
The higher the concentration of analyte in the sample, the lower the 
number of biorecognition molecules bound to the chip surface. The 
signal drop due to the inhibition of the binding of the biomolecule to the 
immobilized analyte on the chip surface will be proportional to the 
analyte concentration in the sample.  
The molecular mass of the analyte in this case does not influence the 
detection capabilities of the biosensor assay, because the refractive 
index change at the chip surface is generated by the biorecognition 
molecule. The concentration and affinity of the biorecognition molecule 
used in the inhibition assay ultimately influences the sensitivity of the 
assay.  
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Part III. Interfacing SPR Biosensors with MS 
 
The SPR biosensors presented in Part II have been proposed as an 
alternative to traditional analytical methods on the basis of the analysis 
time required by analytical techniques, the cost of the equipment and 
the specialized human resources required for operation. Although 
biosensors are indeed useful tools for the biospecific determination of 
analytes in various matrices, the information provides no data about the 
analyte structure or identity. On the contrary, analytical techniques like 
liquid chromatography (LC), gas chromatography (GC) and capillary 
electrophoresis (CE) are able to separate the analytes based on their 
physico-chemical properties. Unequivocal structural information can be 
obtained if these high performance separation techniques are 
hyphenated with a spectrometric detection method like mass 
spectrometry (MS). Hence, a synergistic complement can be obtained by 
combining SPR biosensor technology based on molecular biorecognition 
events with analytical techniques based on physico-chemical properties 
of the analytes. The pioneering work of Moorhouse et al. in 1969, who 
added a new dimension to his GC- flame ionization detector by 
hyphenating the antenna of an insect as a parallel detector for the 
discovery of insect pheromones, marked the beginning of several 
successful studies coupling biosensor or other bioassay technologies 
with analytical techniques in the last years [105-108]. SPR biosensors in 
particular have been combined offline with micro preparative HPLC 
[109], online as a detector for IgG when using CE for separation [110], 
in parallel with LC-diode array detector (DAD)-MS for drug screening 
[111] and offline and online with MS [112]. 
The choice of ionization technique amenable for hyphenating with SPR 
biosensor technology with MS greatly depends on the characteristics of 
the molecule to be analyzed and on the assay format chosen to detect 
it. When the DBA format is chosen, the analyte is captured on the chip 
surface and can be eluted for further offline or online analysis. In 
contrast, the iBIA format the analyte interacting with the biorecognition 
element is usually discarded to the waste. In this case, a split flow 
strategy for parallel coupling of the technologies has to be implemented, 
or alternatively, an online strategy to purify and recover the analytes for 
further analysis. These two strategies are investigated in Part III of this 
thesis.  
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One common problem when coupling biosensor or bioassay technology 
with MS is the mobile phase compatibility. To preserve biomolecular 
interactions, the biorecognition element in the biosensor usually needs a 
suitable buffer containing salts that might interfere with the MS analysis. 
Additionally, nonionic detergents, also incompatible with MS analysis, 
are generally used in the mobile phase of biosensors to avoid 
nonspecific adsorption of matrix or analytes to the fluidic system. 
Hence, the mobile phase used in the biosensor analysis has to be 
carefully optimized and considered in the context of the type of 
hyphenation chosen [113]. 
 
Interfacing SPR-MS Using a DBA Format 
Matrix-assisted laser desorption ionization - time-of-flight mass 
spectrometry (MALDI-TOF MS) is the most commonly used technology in 
combination with SPR biosensor assays. MALDI has the advantage of 
generating intact vapor phase ions from a solid of large molecules co-
crystalized with small volatile molecules (matrix). A laser pulse initiates 
the desorption/ionization of the matrix simultaneously generating a 
packet of analyte ions. The matrix absorbs most of the laser energy, co-
ionizes the analyte upon desorption and prevents its fragmentation. This 
gentle ionization technique allowed the mass spectrometric analysis of 
large macromolecules like proteins and protein complexes of 
megadalton masses [114, 115]. MALDI in combination with TOF MS has 
achieved fmol sensitivity. In a TOF MS system, the ions are accelerated 
at the same electrostatic potential, allowed to drift a known distance and 
strike a detector. The flight time of the ions will depend on their 
mass/charge ratio (m/z) that can be related to their masses based on 
the kinetic energy equation. Regardless of the sensitivity, the mass 
accuracy of MALDI TOF MS is in the range of 0.1-0.01% for proteins 
above 30 KDa, hence it cannot be considered a general method for 
protein identification [114]. On the other hand, the 10-50 ppm mass 
accuracy of MALDI TOF MS for small polypeptides, enables the 
identification of enzymatically digested proteins by peptide mass 
fingerprinting based on database search [116].  
The use of MALDI TOF MS in combination with SPR has evolved from the 
direct on-chip analysis, yielding the chip unusable after one binding 
cycle [117, 118], to the elution of the analytes in a small volume 
between two air bubbles that is respotted onto a MALDI plate [119-
122]. Further, the interfacing was improved with completely automated 
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commands, including those for sample preparation needed prior to 
MALDI [123]. The developments of imaging SPR have enabled SPR-MS 
array platforms for the high throughput screening of large numbers of 
interactants in the field of proteomics [124].  
Although MALDI TOF MS has greatly improved, it is still considered 
unreliable for analysis of small molecular weight analytes such as the 
bioactive contaminants described in Part I. The main shortcoming of 
MALDI was its mass resolution and accuracy, with the advent of newer 
instrumentation the main concerns are signal reproducibility and sample 
preparation. The latter aspect concerns the matrix interfering with the 
ionization and detection of small molecules [125].  
A different approach for SPR-MS analysis in a DBA format, is the elution 
of the captured analytes and their offline or online analysis using 
electrospray ionization (ESI) coupled to MS. ESI is a gentle ionization 
technique that produces singly or multiply charged ions in a gaseous 
phase directly from a liquid phase (either organic or aqueous). This 
makes ESI amenable for online hyphenation with other continuous-flow 
liquid-phase analytical techniques like liquid chromatography and 
biosensor technology. ESI solves in one step the transition of ions to gas 
phase needed for MS analysis, simplifying the interfacing if compared to 
MALDI, where the analytes are first brought in to a solid phase and later 
gasified. ESI creates a fine spray of highly charged droplets in the 
presence of a strong electric field. As the droplets evaporate due to the 
dry gas and heat, they are reduced in size increasing the surface to 
charge density and finally expelling the ions in to the MS. ESI 
overcomes the use of an interfering matrix, making it more suitable for 
small molecules in combination with TOF MS instrumentation that allows 
the acquisition of accurate masses within 5 ppm. The high resolving 
power of typical TOF MS instruments provides the unambiguous 
verification of their elemental composition for further confirmation of 
identity through  structure search in databases [126]. 
Previous research attempted the offline ESI-MS analysis of SPR eluates 
containing small molecules by a direct infusion into a nano-ESI- ion trap 
MS. However, it was not satisfactory due to the chemical noise arising 
from the lack of an analytical chromatographic step [127]. Recently, a 
similar off-line approach addressed the lack of chromatographic step 
and successfully achieved the identification of proteins using a larger 
chip surface and nano ESI LC MS/MS analysis of tryptic digests of the 
eluates [128].  An alternative to the laborious handling of the eluates is 
to hyphenate the fluidic system of the biosensor directly with a reverse 
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phase trapping column that is subsequently coupled to LC- electrospray 
ionization (ESI) - MS analysis. This strategy has been successfully tested 
for MS-based amino acid sequencing after on-chip digestion of proteins 
using a simple Biacore X instrument [129]. Bouffartigues et al. 
attempted a similar system setup using a Biacore 2000 instrument for 
the analysis of nucleoproteins. Unfortunately the ion suppression caused 
by a buffer detergent prevented MS identification. The advantage of the 
online strategy is that it prevents sample loss that might be of critical 
importance for some applications where sample volumes are limited. 
 
Interfacing SPR-MS Using an iBIA Format 
Although the strategies presented above are all suited for SPR-MS 
analysis of macromolecules usually detected in the DBA format, they are 
not suited for small molecules when using the iBIA format because the 
analytes are not retained on the chip surface. Hence, a different 
strategy is required for coupling SPR iBIA with MS. 
When the amount of sample is not limited, one option is to use a split 
flow strategy for the parallel coupling of the screening and MS. Such an 
approach was proven using a yeast bioassay for the screening of 
androgens and estrogens in combination with LC ESI quadrupole (Q) 
TOF MS [130, 131]. In this thesis, iBIAs for the detection of 
fluoroquinolones (FQs) replace the yeast bioassay and are able to 
perform a fast screening among a large number of samples and only the 
relevant samples are analyzed with MS. When a sample is considered 
non-compliant during screening for FQs it is fractionated by LC and the 
effluent is splitted toward two 96-well fraction collectors. The 
immunoactive LC fractions in one of the 96-well plates are immuno-
discriminated using the biosensor immunoassay creating an 
immunogram and the positive well’s positions are used in the second 
96-well plate for immunoactive oriented identification with ESI TOF MS 
(Chapter 6 of this thesis).  
Although succesful, the iBIA screening-MS offline strategy has some 
limitations. First, it requires a relatively large sample volume. Second, 
due to the amount of sample handling required, the chances of sample 
contamination are high. Third, the fractionation resolution is limited and 
this might hamper the identification given that complex samples may 
contain hundreds of peaks separated during the chromatographic step, 
but pooled back together in the same fraction. Fourth, the fractionation 
process is unfeasible when screening for bioactive compounds whose 
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half life is short or unknown. Considering these limitations, a fast, online 
system, requiring minimum sample volume and handling was studied.  
Such an iBIA-online affinity chip recovery-MS was tested. The SPR-MS 
interface recovers the analyte in a nanoscale affinity chip that features a 
mirroring immunochemistry to the iBIA screening. The samples 
suspected non-compliant during the SPR immunoassay screening are 
reinjected onto a recovery chip with similar, but reversed, 
immunochemistry. The antibiotic Enrofloxacin (Enro) was used as a 
model analyte with anti-Enro antibodies as the biorecognition element. 
The antibodies in the biosorbent specifically capture the analyte while 
the sample matrix flows through. The analyte captured in the recovery 
chip is eluted into loop-type interface using an MS-compatible buffer. 
The loop-type interface solves the pressure incompatibility between the 
microfluidic system of the biosensor operating at low pressure and the 
nano LC ESI TOF MS system operating at high pressure. Once in the 
loop type interface, the analytes enter the nano-LC system and are 
retained in a trapping column followed by an analytical column 
connected to the nano-ESI TOF MS for mass analysis. Two main 
advantages are found in the online strategy. First, that it uses a 
minimum sample volume and second that the recovery chip interface 
enables the acquisition of in depth information about the performance of 
the biosorbent prior to use and for periodical quality control with SPR 
(Chapter 7 of this thesis).  
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Part IV. Aims and Scope 
SPR biosensors are increasingly used for the detection of xenobiotics of 
biomedical, food and environmental interest [102, 103, 132, 133]. In 
the present study various immuno- and transport protein-based assays 
were developed and tested for xenobiotics in different matrices. These 
include: Immunoassays for the specific detection of BPA (Chapter 2) and 
two thyroxine transport protein (TP)-based iBIAs for the bioeffect-
related detection and discovery of EDCs interfering with the thyroid 
system (Chapter 3). The application of the developed TP-based iBIAs for 
the discovery of new bioactive substances (Chapter 4) is followed by a 
performance evaluation of a low-cost SPR system (Spreeta) (Chapter 5). 
The implementation of combined specific immunoassays for 
fluoroquinolones (Chapter 6) is followed by two strategies for the 
coupling of the biosensor screening to mass spectrometric confirmation  
(Chapters 6 and 7).  
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Abstract 
Bisphenol A (BPA) is a xenoestrogen found in the environment. In 
consequence, for the biosensor detection of BPA we raised antibodies 
(polyclonal (PAbs) and monoclonal (MAbs)) against a structural 
analogue of BPA, 4,4 bis (4-hydroxyphenyl) valeric acid (BVA).  The 
kinetics of the MAb-BPA interaction were evaluated and the MAb 
providing the highest affinity was directly immobilized onto the sensor 
chip surface to evaluate a direct assay. Afterwards, the performance of 
the MAbs and the PAbs was compared in an inhibition assay using a BVA 
coated chip.  
The highest sensitivity (limit of detection (LOD) of 0.4 µg L-1) was 
obtained with MAb 12 in the direct assay.  However, the inhibition assay 
was the most robust and the PAbs showed the highest sensitivity (LOD 
of 0.5 - 1 µg L-1). The antibodies were specific for BVA and BPA as only 
minor cross-reactivities were found toward structurally related 
compounds or other endocrine disruptors. In the inhibition assay (with a 
run time of 6 min), water samples spiked with BPA at different levels 
(0.5-50 µg L-1) resulted in recoveries varying between 68 and 121%. 
The sensitivity of the inhibition assay could be improved 40 times (LOD 
of 0.03 µg L-1 with the Mab 12-based assay) using solid phase extraction 
(SPE). 
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Introduction 
Endocrine disruptors (EDC’s) have concern in human health and wildlife. 
When chemicals with endocrine activity are present in the environment, 
they might affect the development of any organism and the later 
functioning in adult life of an individual, a population and even a 
community [1]. Some of these compounds, called xeno-estrogens, have 
estrogenic activity. One of these compounds, bisphenol A (BPA), is an 
important monomer for the production of epoxy coatings and 
polycarbonate. It is used as a stabilizer or antioxidant in polyvinyl 
chloride (PVC) [2] and as an intermediate in a wide variety of plastics 
for industry and household. Some of these materials are used in food 
and water containers from which BPA migrates [3-5]. 
Due to the widespread use of BPA, with a global production of over 1 
million tons/year [6] it is also an environmental contaminant mainly 
present in raw sewage or wastewater effluents at up to ppb (µg L-1) 
concentrations [7], and at ppt (ng L-1) concentrations in river water and 
sediments [8-11]. 
There is a wide variety of studies available supporting the endocrine 
activity of BPA. First, BPA binds to the estrogen receptor [12], produces 
meiotic aneuploidy in the female mouse [13] and increases cell 
proliferation of the male and female sexual organs [14]. Moreover, 
several cases of reproductive abnormalities have been reported in 
wildlife exposed to estrogenic environmental contaminants [15]. 
Additionally, though still controversial, BPA may even induce a decrease 
of sperm quality in humans [16]. Finally, it seems that BPA would not 
only mimic estrogens, but also the thyroid hormone action as an 
antagonist [17], which might be supported by recent studies where rats 
exposed to BPA evidenced an increase in thyroid gland size [18]. 
The studies mentioned above evidence the necessity to detect BPA in 
the high ppt to low ppb range. This is currently done using classic 
instrumental analytical techniques such as gas chromatography (GC) 
and high-performance liquid chromatography (HPLC) [19-21]. 
Immunochemical techniques were recently reported using monoclonal 
[22] and polyclonal mammalian [23] and chicken [24] antibodies in 
enzyme-linked immunosorbent assays (ELISA’s) with different limits of 
detection (ranging from (0.05  to 500 µg L-1) depending on the 
immunogen and the type of antibody produced). The aim of the present 
study was to evaluate a different approach using a commercially 
available Surface Plasmon Resonance (SPR)-based biosensor (Biacore 
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3000) as a novel method for the detection of BPA. This biosensor is able 
to measure the antigen-antibody binding in real time and without 
labeling the reagents [25]. The results can be obtained within minutes 
and the procedure is fully automated making this system suitable for 
high-throughput screening. Therefore, such an assay might be a useful 
tool for water screening.  Because of a lack of functional groups in BPA 
for coupling to carrier proteins, polyclonal and monoclonal antibodies 
were raised against 4,4 bis (4-hidroxyphenyl) valeric acid (BVA), a 
structural analogue of BPA containing a carboxyl group (Figure 1). 
  
 
Figure 1. Structures of (A) bisphenol A (BPA) and (B) the analogue 4,4 bis (4-
hydroxyphenyl) valeric acid (BVA) used as hapten in the immunogen. 
 
As the affinity of the antibodies is determinant for the further assay 
performance [26], we selected our best monoclonal antibody in the 
biosensor by means of its kinetic parameters. Subsequently different 
assay formats were evaluated and the results were compared with those 
obtained using the polyclonal antibodies. Finally, the selected best 
monoclonal and polyclonal antibodies were compared for their 
performances using water samples with and without the addition of BPA. 
The possibility of improving the LOD of the assay was also evaluated in 
combination with a solid phase extraction (SPE) procedure. 
 
Experimental  
Materials  
Sensor chips (CM5), HBS-EP buffer [pH 7.4, consisting of 10 mM 4-(2-
hydroxyethyl) piperazine-1-ethanesulfonic acid, 150 mM sodium 
chloride, 3 mM EDTA, 0.005% (v/v) surfactant polysorbate (P20)) and 
an amine coupling kit [containing 0.1 M N-hydroxysuccinimide (NHS), 
0.4 M N-ethyl-N'-(3-dimethylaminopropyl) carbodiimide hydrochloride 
(EDC), and 1 M ethanolamine hydrochloride-NaOH (pH 8.5)] were 
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supplied by Biacore AB (Uppsala, Sweden). ELISA microtiter plates were 
supplied by Greiner (Frickenhausen, Germany). Rabbit anti-mouse 
(RAM) and RAM-immunoglobulin-horseradish peroxidase (RAM-HRP) 
were purchased from DAKO (Denmark) and solutions of 
tetramethylbenzidine (TMB) peroxidase substrate and peroxide from 
Kirkegaard and Perry Labs (Gaithersburg, MD, USA). Specol was 
obtained from the Animal Sciences Group (Lelystad, The Netherlands) 
and the BCA protein assay reagents from Pierce (Rockford, IL, USA). 
Murine myeloma P3/NS-1/1-Ag4-1 (NS-1) were supplied by American 
Type Culture Collection, Rockville, MA, USA) and iso-propanol by Merck 
(Darmstadt, Germany). Bovine serum albumin (BSA), ovalbumin 
(OVAL), antifoam A [A5758], bisphenol A (BPA; 2,2-bis-(4-
hydroxyphenyl) propane), BVA (4,4-bis (4-hydroxyphenyl) valeric acid), 
NHS, EDC and all other cross-reactants were obtained from Sigma-
Aldrich Chemie (Zwijndrecht, The Netherlands) unless otherwise stated. 
 
Equipment 
The Biacore 3000 was supplied by Biacore AB (Uppsala, Sweden), the 
ÄKTA purifier and HiTrap protein G columns (5 mL) by Amersham 
Biosciences (Uppsala, Sweden) and the Argus 400 microplate reader by 
Canberra Packard (Downers Grove, IL, USA). 
 
Preparation of the BVA Conjugates 
BVA was coupled to BSA for the immunization of rabbits and mice and 
to OVAL for evaluation purposes in ELISA and in the biosensor. The 
coupling reactions were performed at pH 7 according to the following 
procedure. NHS (23 mg in 2 mL DMF) was mixed with EDC (156 mg in 2 
mL DMF) and BVA (28 mg in 1 mL of DMF) for 30 min at 25 C. Of this 
mixture, 2.5 mL were added drop wise to 5 mL of a BSA or OVAL 
solution (40 mg mL-1 in 0.1 M borate buffer at pH 7). After 1 h 
incubation at 25 C, the products were dialyzed against PBS and the end 
volumes were adjusted to 15 mL with PBS, reaching a final protein 
concentration of 13 mg mL-1 as determined with the BCA test. 
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Production of MAbs 
Immunization of Mice 
Two 10-12 weeks old female Swiss-mice were immunized 
subcutaneously with 100 L of BVA-BSA (0.2 mg mL-1 in PBS) emulsified 
with Specol (1:1; v/v). Booster injections were given every 2 weeks. 
Blood was taken from each mouse prior to the first immunization (pre-
immune) and 1 week after each booster injection. The sera were tested 
for antibodies against BVA using the BVA-OVAL conjugate in an indirect 
ELISA. 
 
Fusion and Cloning 
The mice were primed intraperitoneally with 0.02 mg BVA-BSA in 200 
µL of PBS 4-5 days before spleen cell isolation.  
Hybridoma cells were prepared using murine myeloma (NS-1) as the 
fusion partner following a previously described procedure [27]. The 
MAbs immunoglobulin subclasses were determined by the Mouse 
Monoclonal Antibody Isotyping Kit (IsoStrip) of Roche (Mannheim, 
Germany). 
MAbs were isolated from one liter of raw cell culture medium by 
ammonium sulphate precipitation [28] followed by affinity 
chromatography using a HiTrap Protein G column in accordance with the 
manufacturer's instructions.  
 
Production of PAbs 
Two New Zealand White rabbits were immunized by injecting 250 L of 
a mixture of Freund's complete adjuvant and BVA-BSA (0.5 mg mL-1 in 
PBS) (1:1; v/v). Booster injections with Freund's incomplete adjuvant 
were given every 3 weeks. After the 22nd week, the boosters were 
administered every 6 weeks and 40 mL of blood were obtained each 
time. Serum was extracted from each bleeding and pooled prior to the 
experiments.  
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ELISA 
The ELISA was performed as previously described [27] with the 
exception that the microtiter plates were coated with an OVAL-BVA 
solution (100 ng/100 µl/well) in coating buffer.  
 
Biosensor Immunoassays (BIAs) 
Capture Assay for Kinetic Evaluation of MAbs  
The surface of a CM5 sensor chip in flow channel 4 (Fc4) of the Biacore 
3000 was coated with polyclonal rabbit anti-mouse antibodies (15000 
Response Units (RU)) using the amine coupling kit and following 
manufacturer’s instructions. Fc3 was left unmodified for referencing. 
Each MAb was injected at equivalent concentrations at a flow rate of 5 
L min-1 for five minutes or until at least 1300 RU of MAb was captured. 
The integrated µ-fluidic cartridge (IFC) was washed with HBS-EP buffer 
during 1 min to remove unbound antibodies. The Ab/Ab complex was 
stable within the cycle and it was fully regenerated only after two 
subsequent injections (a mixture of H3PO4 (100 mM) and HCl (100 mM) 
(1:1; v/v) for 30 s followed by NaOH (100 mM) for 10 s) (Figure 2). 
In order to collect detailed kinetic data of BPA binding to the captured 
MAbs, we used a modification of an existent protocol [29]; 100 L of 
BPA  (6.6 µg L-1 (29 nM)) in HBS-EP buffer) were injected in triplicate at 
a flow rate of 100 L min-1.  At least triplicate injections of HBS-EP 
buffer (blanks) for each MAb were used for further double referencing 
[30]. The measured dissociation time was 300 s and the data were 
collected at a rate of 5 Hz.  
The sensorgrams obtained during the binding of BPA were normalized to 
the response of the corresponding maximum response of captured MAb; 
multiplied by the mean of the maximum response of captured MAb in all 
the cycles using NS = ((SR/RMAbc) x RmaxAvg). NS being the normalized 
sensorgram, SR the response of each point of the BPA binding 
sensorgrams, RMAb the maximum response of captured MAb in that cycle 
and RmaxAvg the average maximum response obtained from all the cycles 
using the four MAbs. 
Data were processed as described before [30] with Scrubber software 
and used to obtain kinetic rate constants by fitting to a 1:1 bimolecular 
interaction model using CLAMP software [31]. The equilibrium 
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dissociation constants (KD) shown in Table 1, are the quotients Kd/Ka of 
the constants obtained with CLAMP. 
 
Non-Competitive (Direct) Immunoassay Format 
The MAb with the highest affinity (as determined in the previous 
section) was immobilized (yielding approx. 10,000 RU) on the surface of 
a CM5 sensor chip in Fc2 using the amine coupling kit following 
manufacturer's instructions. Fc1 was left unmodified for further 
referencing. To obtain a calibration graph, standard solutions of BPA in 
HBS-EP buffer (50 - 0.39 µg L-1) were injected (100 µl, at a flow rate of 
20 L min-1). At the end of each cycle the surface was regenerated with 
HCL (50 mM) for 20 s. The data was double referenced as described 
before [30]. The maximum response was recorded 20 s before the 
injection ended.  
 
Competitive Inhibition (Indirect) Immunoassay Format 
BVA was directly immobilized onto a CM5 chip surface. The surface was 
activated by injecting 120 L of a mixture of 0.4 M EDC and 0.1 M NHS 
(1:1; v/v) at a flow rate of 2 L min-1. Ethylenediamine (120 L of a 2 M 
solution with pH 10) was injected at a flow rate of 2 L min-1 over the 
activated surface and was used as a linker between the activated 
surface and the BVA carboxylic groups. A solution of activated BVA was 
prepared by adding 3 mg NHS and 7.5 mg EDC to a solution of BVA (3 
mg BVA in 0.5 mL ethanol and 0.9 mL 10 mM sodium acetate coupling 
buffer (pH 4.5)). The chip surface was incubated for 60 min outside the 
Biacore with the activated BVA solution by directly pipeting 100 L of 
the solution on the CM5 chip surface. The activated BVA solution on the 
chip surface was changed every 10 min or when a white deposit was 
observed. Before the chip was docked into the Biacore, the surface was 
washed with methanol and dried under a stream of nitrogen gas.  
In the Biacore 3000 the antibody solutions (dilution factor of 1/1000 for 
the MAbs, 1/1500 for the PAbs) were mixed with the sample (1:5; v/v) 
and 50 µL were injected over the sensor surface at a flow rate of 25 µL 
min-1. Triplicate injections were performed for each concentration within 
each cycle. The surface was regenerated by injecting 20 µL NaOH (0.2 
M) containing 20% acetonitrile. The total run time between samples was 
11 min. Maximum responses were recorded 10 s after the injections 
ended. The LODs were measured as the concentration of BPA 
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corresponding with the average of the blank’s average response minus 
three times its standard deviation. 
 
Determination of Inter- and Intra-Assay Variation  
 Water samples were obtained in the city of Wageningen from the 
laboratory tap, the river Rhine, the city canal and an irrigation lagoon.  
The samples were spiked to a final concentration of 1, 5, 10, 25 and 50 
µg L-1 and were centrifuged for 5 min at 10,000 rpm prior to the 
measurements for a fast and easy clean up of the material in 
suspension. To reduce the run time between samples, each supernatant 
was pre-mixed (5:1; v/v) with antibody solutions in five times 
concentrated HBS-EP buffer and 50 L were injected at a flow rate of 25 
L min-1. The total run time of a cycle was 6 min. Recoveries were 
determined from a standard calibration graph in millipore water which 
was mixed like the other water samples. The calibration graphs were 
fitted to a four-parameter logistic equation using Biacore BIAevaluation 
software. Intra-assay variation was calculated from the analysis of three 
replicates of each dilution on a single day. Inter-assay variation was 
calculated from the analysis of three replicates of each dilution carried 
out on three different days.  Intra- and inter-assay variation, as well as 
recoveries at all spiked concentrations, were averaged for each water 
sample source as shown in Table 3. 
 
Solid Phase Extraction  
Tap Water samples were spiked with BPA (0.03, 0.1, 0.3, 0.9 µg L-1) in 
duplicate, acidified to pH 3 with HCL and extracted using OASIS 
cartridges (20 mg N-vinylpyrrolidone/divinylbenzene-based sorbent; 
Waters – Milford, MA, USA) and according to the manufacturer’s 
protocol for phenols in tap water [32]. Briefly, 50 mL of water were 
passed through the cartridge after proper condition and equilibration 
steps, the cartridge was washed, dried and eluted (methanol/methyl t-
buthyl ether (1:10; v/v)). The eluate was evaporated to dryness under 
a gentle nitrogen stream and the residue was resuspended in 500 µL of 
HBS-EP buffer for further measurement. 
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Results and Discussion  
Development of Antibodies  
Antisera from two mice and two rabbits were tested in the ELISA and all 
four animals developed antibodies reacting with the OVAL-BVA coated 
plates.  
 
 
Figure 2. Six overlayed sensorgrams of complete antibody/antibody/ligand binding cycles 
obtained in the capture assay format. The different MAbs were captured by the rabbit anti-
mouse surface yielding a response of approx. 1700 RU, the surface was washed for 60 s, 
the ligand was injected yielding approx. 4-6 RU depending on the captured MAb.  The 
insert is a view in larger scale of the area inside the dashed square. It shows the 
sensorgrams of the MAb-BPA interactions of triplicate injections of BPA (6.6 µg L-1) over 
the captured MAb surface. Black lines depict the global fit of the data to a simple 1:1 
bimolecular interaction model. The four MAbs were globally fitted. 
 
After spleen cells fusion of the two mice with myeloma cells, the 
screening of 872 hybridoma-containing wells in the ELISA resulted in 
101 wells with culture supernatants reactive to the BVA-OVAL coated 
plate. Finally, limiting dilutions of the hybridoma cells resulted in 15 
stable clones. The 15 supernatants were screened in the Biacore with 
the competitive inhibition assay. Inhibition with BPA (10 µg L-1) was 
found with 9 of these supernatants and 4 of them (MAbs 2, 7, 10 and 
12) were selected based on the best inhibition values. These MAbs were 
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further isolated from the culture supernatants by affinity 
chromatography. The total amounts of IgG isolated from 1 L portions of 
medium, as determined with the BCA protein test, were: 6.5 mg (MAb 
12), 12 mg (MAb10), 6.6 mg (MAb 7) and 3.8 mg (MAb 2). The 
subclasses of these MAbs were identified as IgG1 with kappa light chain. 
 
Capture Assay and the Binding Kinetics of Bisphenol A   
A capture assay was used to compare binding kinetics of the MAbs to 
BPA (228 Da) in the Biacore. Each cycle (Figure 2) was started by 
injecting the MAb onto the chip surface containing the immobilized anti-
mouse antibody. Once captured, the surface was washed to remove any 
unbound antibodies. The flow was set to 100 µl min-1, BPA was injected 
for 60 s and the BPA dissociation was monitored for 300 s, followed by 
the regeneration of the surface. All capture experiments were performed 
on the same chip with no significant reduction in binding capacity. Six 
cycles were run for each MAb, three of them were running buffer 
injections for further referencing.  
The sensorgrams were double referenced by subtracting the sensorgram 
of the reference channel and an average of the running buffer injections 
(blanks). Furthermore, the sensorgrams were normalized to the 
captured antibody response, although differences among the cycles 
were small (< 5%), and fitted to a 1:1 bimolecular model, using CLAMP 
software [30]. 
 
Table 1. Affinity and rate constants for MAb/BPA interactions as determined in the capture 
assay. 
 
Interaction Ka (M-1 s-1) Kd (s-1) KD (nM) 
MAb 2 3.1 x1006 3.3 x10-02 10.5 
MAb 7 2.1 x1006 3.2 x10-02 15.1 
MAb 10  1.7 x1006 2.0 x10-02 11.5 
MAb 12 5.5 x1006 1.7 x10-02 3.1 
 
The BPA-MAb interactions were successfully monitored as can be 
observed in Figure 2 insert, binding responses were reproducible among 
the different cycles. From the affinity parameters shown in Table 1, it 
can be observed that MAb 12 showed the highest association constant 
(Ka = 5.5 x1006) and the lowest dissociation constant (Kd. = 1.71 x 10-
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02) in comparison with the other MAbs. Therefore, MAb 12 was 
considered as the most appropriate MAb for further evaluation in the 
different BIAs. 
 
Non Competitive (Direct) Immunoassay 
As MAb 12 showed the highest affinity for BPA, which is essential for the 
future assay sensitivity [26], MAb 12 was immobilized onto a CM5 
sensor chip surface for its evaluation in a non-competitive (direct) 
immunoassay. Figure 3A shows the overlayed sensorgrams of injections 
with different concentrations of BPA in HBS-EP buffer (45.6, 22.8, 11.4, 
5.7, 2.9, 1.4, 0.7, 0.4, 0.2 µg L-1) over the MAb surface. Figure 3B is the 
correspondent calibration graph, using the responses obtained 20 s 
before injections ended. The sensitivity of this immunoassay, the 
concentration corresponding to 50% of the maximum binding response 
(B50), was 1.6 µg L-1. The limit of detection (LOD) was 0.4 µg L-1.  
 
 
Figure 3. (A) Overlayed sensorgrams of BPA standard solutions (200, 100, 50, 25, 12.5, 
6.25, 3.12, 1.56, 0.79 nM µg L-1) obtained in the direct assay format. (B) Calibration 
graph of BPA, using the relative responses measured 20 s before injections ended.  
 
As the direct assay format is in theory the most sensitive [26], this 
sensitivity is probably close to the best that MAb 12 can achieve in this 
biosensor immunoassay. However, in this direct format we encountered 
losses of binding sites after regeneration and after storage of the chip. 
These problems together with the low responses obtained (max. 23 RU) 
due to the low molecular mass of BPA did not make this format suitable 
for routine analysis.  
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Evaluation of Inhibition Immunoassays  
To obtain a more robust assay, a competitive inhibition assay format 
was evaluated using a chip with immobilized BVA (see Experimental 
section). A response of around 700 RU was obtained after the injection 
of 50 L of PAB K66 (d.f. 1/1500 in HBS-EP) buffer at a flow rate of 25 
Lmin-1.  
Proper AB dilutions were mixed with BPA standard solutions (100, 33.3, 
11.1, 3.7, 1.1 µg L-1) (1:5; v/v) in the Biacore. The mixtures were 
injected in triplicate and at random to check for possible cross-
contamination. Calibration graphs are shown in Figure 4 comparing the 
most sensitive PAb and MAb-based BIAs. From these graphs and Table 2 
a rather small difference between the MAb-based BIAs can be noted. 
Although the LODs of the MAbs were comparable, MAb 12 shows the 
lowest IC50 value (9.1 µg L-1) and the highest inhibition at the maximum 
concentration of BPA (100 µg L-1), as would be expected based on the 
affinity parameters.  
 
  
Figure 4.  Normalized BPA calibration graphs obtained with the most sensitive antibodies 
(PAb K66 and MAb 12) in the competitive inhibition format and after a pre-concentration 
with SPE in combination with the Mab 12-based assay.    
 
There was no significant difference in IC50 values between the two PAbs 
evaluated (Table 2), but PAb K66 showed a higher inhibition at the 
maximum concentration of BPA as well as a steeper slope of the 
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calibration graph. The PAb K66-based BIA was twice as sensitive when 
compared with the MAb 12-based BIA.  The BVA-coated chip was used 
for over 1000 cycles with no evident decrease in binding capacity.  
 
Table 2. Sensitivity of the biosensor inhibition immunoassays with different antibodies. 
 
Antibody LOD (ppb) IC50 (ppb) 
MAb 2 1.1 13.6 
MAb 7 0.9 18.0 
MAb 10 1.6 11.8 
MAb 12 1.2 9.1 
PAb K66 1.0 4.9 
PAb K67 0.5 4.8 
 
Competitive Inhibition Immunoassays Performance with Water 
Samples 
The level of BPA found in surface waters is generally in the level of parts 
per trillion (ng L-1), however, levels of BPA above 1 µg L-1 have been 
found in 7% of the samples out of a whole-country survey of 135 
samples [33] in the surrounding of industrialized areas or near 
discharge points of sewage treatment plants. Consequently, we decided 
to conduct a small spike and recovery experiment using the inhibition 
immunoassays previously described to evaluate the possible use of the 
assays for the screening of BPA in water samples at levels of concern to 
the aquatic wildlife  [33, 34]. 
Real water samples were spiked and correspondent calibration graphs 
were performed in millipore water. Assay performance parameters were 
comparable to those obtained in HBS-EP buffer. The inter and intra-
assay variation for real water samples are shown in Table 3. The 
average recoveries and variation were acceptable even though the 
samples spiked at 1 µg L-1 were included in the average, this 
concentration is in the lower end of the calibration curve where greater 
variance is commonly found. Recoveries ranged from 68 to 118% 
depending on the matrix, these values were considered acceptable as 
almost no pre-treatment was performed except for the centrifugation 
step. 
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Intra-assay variation values were all below 5% for both immunoassays, 
inter-assay variation values were below 25% in all cases with the 
exception of the PAb K66-based immunoassay in lagoon water, where a 
40% inter-assay variation was found. 
The throughput of the system was 10 samples per hour and up to 425 
samples were measured in a single experiment. 
 
Evaluation of SPE Extraction in Combination with BIA 
To be able to measure lower concentrations of BPA in water, we 
evaluated the possibility of combining the MAb 12-based inhibition assay 
with a fast extraction procedure like solid phase extraction.  
 
Table 3. Intra- and inter-assay variations obtained in the inhibition assay format with 
water samples from four different sources fortified with BPA (1, 5, 10, 25, 50 ppb)a. 
 
Intra-assay Inter-assay 
Recovery (%) CV (%) Recovery (%) CV (%) 
Water 
Source 
MAb 12 PAb K66 MAb 12 PAb K66 MAb 12 PAb K66 MAb 12 PAb K66 
Tap 91 85 3 2 81 80 16 14 
Rhine 102 68 1 2 85 78 21 7 
Canal 118 118 4 1 98 97 18 19 
Lagoon 92 121 5 2 77 109 21 40 
 
a Recovery (%) and CV (%) values at all concentrations were averaged for each water 
source. 
 
A calibration curve was performed extracting BPA spiked tap water 
samples (0.03, 0.1, 0.3, 0.9 µg L-1) (see experimental Section 2.7.4. 
and Figure 4) and the eluates were measured with the MAb 12 
competitive inhibition immunoassay described in the previous section. 
The samples were concentrated 100 times with the SPE procedure and 
the calibration curve reached an IC50 of 0.14 µg L-1and an LOD of 0.03 
µg L-1. Although  the throughput of the system decreased to 4 samples 
per hour in combination with this manual SPE procedure, this could be 
improved in the future by an off-line coupling of an automated SPE 
system [35] with the BIA. 
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Specificity of the Assays 
Cross-reactivities of various structurally related compounds were 
evaluated for PAb K66 and for MAb 12-based BIAs (see Table 4) and 
were calculated as CR (%) =(BPA IC50)/(Cross reactant IC50) x 100.  
 
Table 4. Cross-reactivities of the inhibition assays with selected endocrine disruptors. 
 
Cross-Reactivity (%) 
Compound 
MAb 12 PAb K66 
Bisphenol A 100 100 
BVA 73 118 
Bis-(4-hydroxyphenyl)-methane 2.3 1.5 
4-Cumylphenol 1.3 1 
4,4'-(ethylidene)bisphenol 12 2 
17-β-Estradiol <0.1 <0.1 
17-α- Ethynylestradiol <0.1 <0.1 
Bisphenol A diglycidyl ether (BADGE) <0.1 <0.1 
Zearalanone <0.1 <0.1 
Estrone <0.1 <0.1 
Estriol 0.2 0.15 
Dienestrol  <0.1 <0.1 
Nonylphenol 1.5 0.7 
Diethylstilbestrol <0.1 <0.1 
Hexestrol <0.1 <0.1 
Coumestrol <0.1 <0.1 
Genistein <0.1 <0.1 
4,4'Cyclohexylidenebisphenol <0.1 2.21 
 
Calibration graphs of the compounds were prepared in running buffer. 
Both, MAb 12-and PAb K66-based BIAs showed high cross-reactivity 
towards BVA (73% and 118%, respectively), as expected, because it 
was used as immunogen. Interestingly MAb 12 showed an even higher 
affinity for BPA than for BVA. MAB 12 also showed a high cross-
reactivity (< 10%) with 4,4'-(ethylidene) bisphenol and a small cross-
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reactivity  (< 2.5%) with nonylphenol, bis-(4-hydroxyphenyl)-methane 
and 4-cumylphenol. On the other hand, PAb K66 showed an overall 
lower (< 2%) cross-reactivity than MAb 12 with 4,4’ (ethylidene) 
bisphenol. PAb K66 cross-reacted (2.2%) with 4,4’ 
cyclohexylidenebisphenol. Cross-reactivities of both BIAs towards most 
of the estrogenic compounds were very low (<0.1%) making these BIAs 
very specific. 
 
Conclusions 
It was possible to raise MAbs and PAbs against a BVA conjugate that 
showed strong cross-reactions towards the target compound, BPA. The 
kinetic parameters of the MAb-BPA interaction were useful and reliable 
for predicting assay performance. The direct (non-competitive) assay 
proved that a small analyte like BPA (228 g/mol) can be directly 
detected and it was also shown that this is the most sensitive format, 
something which is in accordance to the theory [26]. However, the 
direct assay was also the least robust due to the fast decrease in 
binding capacity of the immobilized MAbs. Future research using 
techniques of protein engineering which can potentially provide more 
robust biorecognition molecules would significantly improve this assay. 
 The inhibition immunoassay with BVA immobilized directly on the chip 
was very robust due to a stable chip (>1500 cycles were run under the 
mentioned conditions) and high maximum responses (700 RU). 
Both MAb 12- and PAb K66-based BIAs were fast (6 min/sample), 
specific as well as accurate and repeatable for the screening of BPA in 
real water samples at low µg L-1 levels. 
We have shown that if lower concentrations, in the order of ng L-1, are 
to be measured, the sensitivity of the assays can be improved by using 
solid phase extraction (SPE) to obtain a pre-concentration of the 
samples. This approach proved to be useful at the expenses of the 
throughput of the system The validation of the system and 
measurements of environmental samples are issues which will require 
further attention. 
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Abstract 
 
Novel surface plasmon resonance-based biosensor assays for the 
bioeffect-related screening of chemicals with thyroid disrupting activity 
are described. Two thyroid transport proteins (TPs), thyroxine binding 
globulin (TBG) and recombinant transthyretin (rTTR), were applied in an 
inhibition assay format in a Biacore 3000 using CM5 biosensor chips 
coated with L-thyroxine (T4), the main hormone of the thyroid system.  
Assay conditions were optimized for the natural thyroid hormones and 
known thyroid disruptors and structurally related compounds were 
selected as model compounds to be tested in both assays for their 
relative potency (RP) compared to T4. The chosen compounds were 
halogenated phenols, halogenated bisphenols, bisphenol A and 3,5-
dichlorobiphenyl and its hydroxylated metabolite 4-hydroxy-3,5-
dichlorobiphenyl (4-OH PCB 14). The TBG-based assay was highly 
specific for T4 and the rTTR-based assay was sensitive toward several 
compounds, the highest sensitivity (RP = 4.4) being obtained with 4-OH 
PCB 14, followed by tetrabromobisphenol A (RP = 1.5) and 
tetrachlorobisphenol A (RP = 0.75).   
For the bioeffect-related screening of known and identification of 
possible new thyroid disruptors, the TPs-based biosensor assays were 
more sensitive (IC50 of 13.7 ± 1.3 nM and 8.6 ± 0.7 nM for the rTTR and 
the TBG-based assay respectively), easier to perform and faster 
alternatives (10 min per sample) compared to the currently used 
methods such as radioligand binding assays and immunoprecipitation-
HPLC. 
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Introduction 
 
Diverse groups of chemical compounds are released in to the 
environment and some of these are considered endocrine disrupting 
chemicals (EDCs). A chemical is considered an EDC if it mimics or 
antagonizes the effects of endogenous hormones or if it is able to 
disrupt the synthesis or metabolism of endogenous hormones and 
hormone receptors [1]. The different EDCs can be roughly grouped by 
their biological effect. One of these compound classes is the thoroughly 
studied group of estrogenic compounds [1, 2]. Another group of 
compounds, which has received less attention, are the compounds with 
thyroid activity. Previous investigations show that organohalogen 
compounds can affect thyroid gland morphology and hormonal status in 
rats [3]. These compounds can disrupt the thyroid hormone system at 
least at three different levels; at the thyroid gland, at the thyroid 
hormone transport proteins and at the thyroid hormone metabolism [4]. 
The polyhalogenated aromatic hydrocarbons (PHAHs) are lipophilic 
compounds present in the environment and known to bioaccumulate in 
the trophic chain [3]. PHAHs are hydroxylated in vivo by the cytochrome 
P450 monooxygenase system [5]. Some hydroxylated polychlorinated 
biphenyls, hydroxylated polychlorinated ρ-dioxins and hydroxylated 
polybrominated diphenyl ethers strongly resemble the structure of 
thyroxine (T4), the natural hormone of the thyroid system. 
Some of the PHAHs and several hydroxylated metabolites interact with 
high affinity with transthyretin (TTR) [6, 7], one of the three thyroxine 
transport proteins (TPs) which carries ~20% of the total T4 in humans 
and larger eutherians. Likewise, although with a lower affinity, 
hydroxylated PHAHs bind to thyroxine binding globulin (TBG) [8, 9]. 
TBG is the major T4 TP in human plasma responsible for 75% of the T4 
binding activity. Human serum albumin (HSA) is the third TP (carrying 
about 5% of the total T4).  
Even though TTR carries only a minor part of the T4 pool in plasma in 
large eutherians, it is important for maternal to fetal transport of thyroid 
hormones and for delivery of T4 across the brain barrier [10]. TTR 
binding has also been suggested as predictive of interactions with other 
proteins involved in the T4 pathway [11]. 
It is hypothesized that one of the thyroid disruption mechanisms is 
through the displacement of the natural ligand T4 from TTR by the 
endocrine disruptors with a consequent increase in T4 clearance which 
induces hypothyroidism [12]. In smaller eutherians and vertebrates, 
Biosensor Recognition of Thyroid-Disrupting Chemicals Using Transport Proteins 
 
 76 
TTR is the major T4 transport protein, hence, in some wildlife like birds, 
amphibians, fish and rodents, the impact of EDCs binding to TTR would 
have greater effects than in humans [13]. Thyroid hormone transport is 
therefore a true pathway for thyroid disruption and T4 displacement 
from thyroid transport proteins is one biochemical marker for the 
screening of potential endocrine disruptors. Based on this concept, 
radioligand binding assays (RLBA), using [I125] T4 as label, were 
employed to demonstrate the affinity of xenobiotics for these purified 
human and rat TTR and TBG [8, 14, 15]. Additionally, purified chicken 
and bullfrog TTR have been successfully used as the biorecognition 
elements in RLBAs to obtain the average thyroid activity of a complex 
environmental sample using  [I125] T3 as label [16].   
Although these widely used techniques have been shown to be sensitive 
and reliable, they involve the use of isotopes of which the handling and 
disposal are subjected to stringent regulations. Furthemore, a 
separation or wash procedure is involved to separate the free 
radioactive T4 fraction from the fraction bound to TTR or TBG. This 
separation step not only lowers the throughput but might also cause a 
deviation in the reaction equilibrium between the TPs and the ligands.  
An alternative to these methods is the biosensor-based approach in 
which the same biochemical entities could be used for the bioeffect-
related recognition of endocrine disruptors. Advantages of the 
biosensor-based approach and in particular of the surface plasmon 
resonance (SPR) technique are the speed of automated analysis, 
simplicity, quantitative and label-free analysis in real time as well as the 
possibility of kinetic and affinity analysis [17].  
We investigated the use of human TPs, TBG and recombinant TTR 
(rTTR), as recognition elements using the SPR-based biosensor (Biacore 
3000) in the inhibition assay format. To obtain a successfull assay, the 
ligand (T4) linking chemistry to the chip surface was optimized to 
preserve its biochemical properties. The nature of the rTTR-T4 
interaction was compared to that of the purified human TTR (pTTR) and 
to that of rTTR-T4 analogue immobilized on the sensor chip. 
The assays were optimized to obtain the highest sensitivity and 
robustness by evaluating the optimum binding pH, ionic strength and 
buffer composition. Seven endocrine disruptors, belonging to three 
different structural groups were evaluated for inhibition in these assays 
and their relative potencies (RP) to T4 were measured. 
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Experimental Section 
 
Chemicals and Equipment 
Sensor chips (CM5 and NTA), the amine coupling kit [containing 0.1 M 
N-hydroxysuccinimide (NHS), 0.4 M 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC) and 1 M ethanolamine hydrochloride 
(pH 8.5)] and the Biacore 3000 were supplied by Biacore AB (Uppsala, 
Sweden). The PCB 3,5-dichlorobiphenyl (PCB 14) and 4-hydroxylated-
3,5-dichlorobiphenyl (4-OH PCB 14) were purchased from Accu Standard 
(New Haven, CT). L-Thyroxine ((T4) 3,3’,5,5’-tetraiodo-L-thyronine), 
3,3’,5-triiodothyronine (T3), bisphenol A (BPA; 2, 2-bis (4-
hydroxyphenyl) propane), tetrabromo-BPA, tetrachloro-BPA, 
pentachlorophenol, pentabromophenol, 5-aminovaleric acid (AVA), 
glycine, purified TTR (pTTR) and all other reagents were obtained 
from Sigma-Aldrich Chemie (Zwijndrecht, The Netherlands) unless 
otherwise stated. 
The recombinant His-tagged transthyretin (rTTR) was a kind gift from 
the Toyama Medical and Pharmaceutical University (Toyama, Japan). 
Thyroxine Binding Globulin (TBG) was a kind gift from Scipac (Kent, 
UK).  
 
Biosensor Chip Immobilization Procedures   
Five different spacers and two different chemistries were evaluated for 
the immobilization of T4 to the carboxymethylated dextran surface of 
the CM5 sensor chip. The spacer structures and immobilization 
chemistries are depicted in Figure 1. First, we evaluated the 
immobilization of T4 via the carboxyl group of the alanyl side chain 
(Figure 1B) using ethylenediamine (EDA) as we previously described for 
bisphenol A [18]. 
In the other four immobilization procedures, T4 was immobilized via the 
amino group of the alanyl side chain using spacers of different length: 
(1) no spacer, creating a direct amide bond between the amino group 
and the carboxylmethylated dextran (Figure 1C), (2) with glycine (Gly) 
as the bifunctional spacer (Figure 1D), (3) with 5-aminovaleric acid 
(AVA) as spacer (Figure 1E) and (4) with two molecules of AVA as 
spacer (Figure 1F). Figure 1G shows the binding of rTTR (18.2 nM) to 
the different immobilized conjugates. 
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The CM5 sensor chip surface was activated by injecting 140 L of a 
mixture of 0.4 M EDC and 0.1 M NHS (1:1; v/v) at a flow rate of 5 L 
min-1. The activation was followed by 140 L injections, at a flow rate of 
5 L min-1, of either the T4 (2 mM in 10 mM borate buffer pH 8.5) or the 
spacer (2 mM in 10 mM borate buffer pH 8.5) depending on the applied 
immobilization procedure.  
The double AVA spacer was constructed on the sensor chip surface by 
the immobilization of AVA followed by a new AVA immobilization 
procedure on the AVA surface. After the immobilization of the proper 
spacer and activation with EDC/NHS, T4 was immobilized as described 
above.  
The T4 stock solution (10 mM) was prepared by dissolving T4 in a 
solution containing DMSO (94%) chloroform (5%) and 1 M NaOH (1%). 
 
 
Figure 1. Conjugation position and structures of the different spacers used to immobilize L-
thyroxine (T4) to the carboxymethylated dextran surface of the CM5 biosensor chip. (A) 
Structure of T4 without the terminal alanine group (Rn). (B) Immobilization of T4 via the 
alanine’s carboxyl group using ethylenediamine (EDA) as spacer. (C-F) Immobilizations of 
T4 via the alanine’s amino group, (C) direct to the dextrane without a spacer (D), with 
glycine (Gly) as the bifunctional spacer, (E) with 5-aminovaleric acid (AVA) as spacer, and 
(F) with two molecules of AVA as spacer. G) Binding sensorgrams of rTTR (18.2 nM) to the 
different conjugates.  
 
Optimization of Transport Protein Binding Conditions. 
In previous studies [6, 8, 12, 19], the in vitro T4-TTR radioligand 
competitive binding assays were performed at pH 8 in a Tris-HCl buffer 
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(0.1 M Tris-HCl, 0.1 mM NaCl, 1 mM EDTA). This buffer was found 
unsuitable for use in the biosensor due to the nonspecific binding of Tris 
to the sensor chip surface. Borate, phosphate and carbonate buffers 
were evaluated, and their compositions (pH, NaCl and EDTA 
concentrations) were optimized.   
To evaluate the different T4-modified sensor chip surfaces and the 
optimum conditions for binding and inhibition, 50 µL of either TTR or 
TBG (18.2 nM in phosphate buffer pH 8.5) without (blank) or with T4 
solution (100 nM) were injected at a flow rate of 25 µL min-1. The 
responses (R) used for comparison were measured 20 s after the 
injection ended. The surface was regenerated in two steps, first by a 5 
µL injection with H3PO4 (0.1 M) which was followed by 10 µL of NaOH 
(0.1 M).  
Percentage of inhibition (PI) during these experiments was calculated as 
PI = ((B0-B)/B0)x100%, where B0 is the TP response obtained with 0 nM 
T4 (blank) and B is the TP response in the presence of 100 nM T4. 
 
Direct Capture Assay for the Measurement of the rTTR- T4 
Kinetics.  
In order to evaluate the nature of the rTTR-T4 kinetic interaction under 
the chosen conditions, the rTTR was captured on a nickel chelating 
sensor chip surface (NTA Chip) by means of its His tag. For this 
purpouse, 5 µL of a NiCl solution (100 mM in water) were injected at a 
flow rate of 10 µL min-1 over the sensor surface followed by 10 µL of 
rTTR (10 µg mL-1). Phosphate buffer pH 8.5 (10 mM Na2HPO4, 0.1 M 
NaCl) was used as the running buffer. A serial (3-fold) T4 dilution (9 µM 
- 0.1 nM) was injected for 60 s at a flow rate of 100 μL min-1 over the 
captured rTTR and the binding response of T4 was measured 5 s after 
the injection ended, which was at the beginning of the dissociation 
phase. Regeneration of the surface was possible in three steps, at a flow 
rate of 10 µL min-1, in which an injection of 10 µL of EDTA (0.35 M) was 
followed by 5 µL of NaOH (0.1 M) and finally by 5 µL of a BSA solution 
(2 mg mL-1 in phosphate buffer pH 8.5).  
A suitable reference surface was constructed by capturing denaturated 
rTTR (heated at 100 ºC for 5 min) following the same protocol as 
described above. The sensorgrams were double referenced as described 
elsewere [20] and the calibration curve obtained was fitted to a suitable 
model using Scrubber software. 
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Transport Protein Biosensor Inhibition Assays. 
For the evaluation of the RPs of the different compounds, inhibition 
assay formats were evaluated for rTTR, pTTR and TBG. The principle of 
the assay is similar to an inhibition immunoassay. In solution, the T4 TP 
under evaluation is mixed with the analyte of interest and injected over 
a sensor surface with an immobilized T4-conjugate. If there is no 
binding of the analyte to the TP, the maximum amount of TP will bind to 
the sensor surface and a maximum response is obtained. If there is an 
interaction between the analyte and the TP in solution, the binding of TP 
to the sensor surface will be inhibited resulting in a lower response. The 
inhibition of response depends on the concentration of the T4-like 
analyte as well as on the affinity of this compound for the TP. Therefore, 
calibration curves (injected concentrations versus responses) of the 
analyte of interest were compared with a T4 curve and the RP was 
calculated as the ratio of T4 concentration at 50% inhibition (IC50) 
versus the IC50 of the analyte [IC50 (T4)/IC50 (analyte)]. 
 
 
Figure 2. Overlayed sensorgrams showing the binding of rTTR (18.2 nM) mixed (1:9; v/v) 
with different concentrations of T4 (0 nM, 12.5 nM, 100 nM). 
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The protocol used was as follows, 10 µL of the TP (182 nM) was mixed 
in the Biacore with 90 µL of the analyte solution and, immediately after 
mixing, 50 µL was injected over the sensor chip surface at a flow rate of 
25 µL min-1 and the response was measured 5 s after the injection 
ended.The surface was regenerated as described above (Optimization of 
transport protein binding conditions). Overlayed sensorgrams of the 
rTTR inhibition assay, corresponding to three different concentrations of 
T4, are presented in Figure 2. The total run time between samples, 
including the time for mixing and washing steps in the Biacore, was 10 
min. Triplicate injections were performed for each analyte at each 
concentration. 
 
Results and Discussion 
 
Binding of the TPs to the T4 Sensor Chip Surface. 
Table 1 presents the relative responses obtained from the sensorgrams 
of rTTR and TBG (in phosphate buffer, pH 8.5) binding to the T4 chips 
coated with the different immobilization chemistries and spacers. The 
immobilization of T4 via its carboxyl group seriously hindered the 
binding of the TPs to the sensor chip surface, as shown by the very low 
responses obtained. This is supported by previous studies where it was 
found that the side-chain carboxyl group plays a major role in the T4-
TTR binding [19]. 
 
Table 1. Relative responses obtained with rTTR and TBG binding to the different T4-coated 
biosensor chips made with different immobilization chemistries (via the carboxyl or the 
amino group of T4) and with different spacers.  
 
Relative responses (%) 
Spacer Length (atoms) 
T4 functional  
group rTTR TBG 
EDA 4 Carboxyl 0.2 1.5 
No 0 Amino 39 64 
Glycine 3 Amino 63 76 
AVA 6 Amino 100 100 
2xAVA 12 Amino 87 68 
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Immobilization of T4 via its amino group yielded high responses for both 
TPs, and responses increased with increasing spacer lengths up to a 
maximum with the six-atoms spacer ((AVA) 5 carbons plus 1 nitrogen). 
The almost 2-fold higher response obtained with the TBG with the same 
conjugate could be explained by the previously reported higher affinity 
of TBG for T4 compared with TTR [21]. Further increase of spacer length 
did not result in higher responses, therefore the T4-AVA sensor chip 
surface was used in all the subsequent inhibition experiments. 
 
Optimization of the Inhibition Assay Conditions  
Of the three buffers tested, only phosphate was suitable for long term 
use. The use of borate and carbonate buffers with the T4-AVA sensor 
chip resulted in an increasing baseline, which was difficult to regenerate 
and led to a reduced binding capacity of the chip. The results obtained 
with the phosphate buffer optimization experiments in the rTTR-based 
assay are shown in Table 2.  
 
Table 2. Results obtained with the phosphate buffer optimization experiments in the rTTR-
based assaya. 
 
pH rR1  rPI NaCl  
(mM) 
rR2 EDTA  
(µM) 
rR3 
7.5 96 
49 
0 32 
0 100 
8 100 
81 
50 91 
1 77 
8.5 94 
100 
100 100 
10 42 
9 66 
74 
200 97 
100 37 
9.5 33 
38 
500 87 
1000 30 
- - - 1000 45 - 
- 
 
aThe relative Responses (rR = % of the highest obtained response) were measured at 
different pH (rR1) and the Percentage of Inhibition (PI) during these experiments was 
calculated as PI = ((B0-B)/B0x100), where B0 is the rTTR response obtained with 0 nM T4 
(blank) and B the rTTR response in the presence of 100 nM T4. The relative PI (rPI) was 
the percentage of the highest obtained PI. At optimum pH for rPI, various NaCl 
concentrations were evaluated (rR2) and at optimum pH and NaCl concentrations, 
different EDTA concentrations were tested (rR3).  
 
 
Chapter 3 
 
 83
The highest response was obtained at pH 8 (700 RU). However, the 
largest relative percentage of inhibition (rPI, the relative difference in 
response between a blank and 100 nM of T4) was obtained at pH 8.5 
and, as we aimed for maximum sensitivity of the assays, this pH was 
considered optimum. The addition of  NaCl improved the assay with an 
optimum of 100 mM, and the presence of micromolar levels of EDTA 
inhibited the rTTR binding to the T4-AVA sensor chip surface with a IC50 
= 3.1 μM. All the following experiments were performed in 10 mM 
phosphate (Na2HPO4) buffer with pH 8.5 and 0.1 M NaCl added, which 
was found optimal for the TBG assay as well. 
 
Nature of the T4 -Transport Proteins Interaction  
The aim of this study was to set up an inhibition assay using rTTR to 
facilitate large scale screening in the future. Therefore we compared the 
T4 binding properties of the rTTR with those of pTTR. It has been 
previously reported that the rTTR used in the present study had the 
same biochemical characteristics as those found with the pTTR with 
regard to tetramer formation at neutral pH and fibril fomation at acidic 
pH [22]. TTR has two non cooperative T4 binding sites, meaning that 
upon binding of the first T4 molecule with high affinity (Ka1 ≈ 100 – 10 
nM), the second T4 molecule binds to the second site with a lower 
affinity (Ka2 ≈ 1 µM) at physiological conditions [19, 23]. We 
investigated whether both binding sites of the rTTR were able to bind T4 
or the AVA-T4 sensor chip surface under the chosen conditions because 
this would have a direct effect on the geometry of the inhibition curve 
and therefore on the working range and linearity of the assay. 
First, we investigated whether both rTTR binding sites were active for 
binding T4 at the chosen conditons. Therefore, we evaluated the 
equilibrium dissociation constants (KD) of the T4-rTTR interaction using 
the direct capture assay (see Experimental section). The calibration 
curve obtained (Figure 3) clearly shows a biphasic binding response 
indicating that both sites are active for binding T4. The data obtained 
showed a poor fitting to a non cooperativity model and were fitted to a 
two independent binding sites model with a KD1 of 9.2 ± 1.2 nM for the 
high affinity binding site and a KD2 of 5.3 ± 3.1 µM for the low affinity 
binding site. The second binding site did not show full occupancy 
because the T4 concentration could not be increased beyond 9 μM due 
to its poor solubility. This fact induced a high uncertainty in the KD2 
value and gave a poor fit using the negative cooperativity model. 
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Nevertheless, the present results indicate that, under the assay 
conditions used, the binding affinity of the second site is found at µM 
levels of T4.  
 
 
Figure 3. Calibration curve of the binding of T4 to rTTR as obtained in the direct capture 
assay. The calibration curve shows a biphasic binding response, and the data were fitted 
to a two independent binding sites model with a KD1 of 9.2 ± 1.2 nM for the high affinity 
binding site and a KD2 of 5.3 ± 3.1 µM for the low affinity binding site showing that both 
sites are active. 
 
Secondly, a T4 calibration curve was measured using the rTTR inhibition 
assay and it was succesfully fitted to a one binding site bimolecular 
model with a KD of 13.7 ± 1.3 nM. This affinity constant of rTTR for T4 is 
in the same range as the KD1 obtained for the high affinity binding site 
using the direct binding assay. These results indicate that with the rTTR 
inhibition assay setup we are able to measure the inhibition of the high 
affinity binding site and that if T4 is bound to rTTR, then the T4-rTTR 
complex is not able to bind the AVA-T4 sensor chip surface with the low 
affinity binding site in significant amounts due to the approximately 
500-fold difference in affinity between the two sites under these 
conditions. Furthermore the comparable KDs for T4 in both assays mean 
that T4 has the same affinity for rTTR when it is immobilized by its 
amino group as when it is free in solution.  
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The effect of EDTA on the equilibrium dissociation constants (KDs) was 
investigated using the direct capture assay in the presence 3 μM of 
EDTA which was added to the phosphate buffer.   
Under the influence of EDTA, the calibration curve was fitted to a one 
binding site bimolecular model with a KD of 51.9 ± 1.7 nM and the 
previously obtained biphasic response was not found (data not shown). 
These results indicate that the presence of 3 μM EDTA lowered the 
affinity between T4 and rTTR by a factor of 5 and, in principle, that the 
affinity of T4 for the low affinity binding site is also lowered by an 
unknown factor. These results are in good agreement with the low 
binding observed of rTTR to the AVA-T4 sensor chip surface at 
increasing concentrations of EDTA. 
 T4 calibration curves were compared using pTTR and rTTR. The 
response obtained with the pTTR (18.2 nM) was about six times lower 
(112 RU) if compared to rTTR at the same concentration. We speculate 
that this difference is probably due to a loss in T4 binding activity during 
the pTTR purification procedure. The IC50 value for T4 obtained with the 
rTTR-based assay (IC50 = 13.5 nM) was comparable to that obtained 
using the pTTR-based assay (IC50 = 14.9 nM) and both calibration 
curves were fitted to a one-binding site model using Graphpad Prism 
software.  
The T4-TBG interaction was also evaluated using the inhibition assay 
format. The curve fitted to a one-binding site model yielded an affinity 
constant KD of 8 nM. All further calibration curves were fitted to a four-
parameter equation using BIAevaluation software (Biacore), and the IC50 
was the parameter used for sensitivity comparison.  
 
Biosensor Tyroid Transport Protein Inhibition Assays for T4 and 
T3  
The rTTR and TBG inhibition assays were tested with the natural ligands 
T4 and T3 and inhibition curves were determined in triplicate of which 
the averages are shown in Figure 4. The TBG assay (Figure 4B) was 
found to be the most sensitive toward the natural ligands with IC50 
values of 8.6 nM for T4 and 14.2 nM for T3. In comparison, the IC50 
values with the rTTR assay (Figure 4A) were 13.7 nM for T4 and 216.3 
nM for T3. The IC50 values obtained for T4 in both assays were used as 
the reference value for the calculation of the RPs of the EDCs. The RP for 
T3 using the rTTR inhibition assay (RP = 0.06) is consistent with 
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previous studies where the reported RPs for T3 were 0.036 [24] and 
0.08 [25]; however the RP for T3 found in this study using the TBG 
inhibition assay (RP = 0.6) is higher than the reported RPs of 0.09 [24] 
and 0.3 [26] (Table 3).  
 
 
Figure 4. Calibration curves of the natural ligands T4 and T3 in (A) the rTTR-based 
biosensor inhibition assay and, (B) in the TBG-based biosensor inhibition assay. 
 
Table 3. Structures of the Compounds Tested with the TP Inhibition Assays. 
 
A  C  
B             D  
Compound Structure R1 R2 R3 R4 R5 
Thyroxine A I - - - - 
Triiodothyronine A H - - - - 
Pentachlorophenol B Cl Cl Cl Cl Cl 
Pentabromophenol B Br Br Br Br Br 
Bisphenol A C H H H H H 
TBrBPA C Br Br Br Br - 
TClBPA C Cl Cl Cl Cl - 
4-OH PCB 14 D Cl OH Cl - - 
PCB 14 D Cl H Cl - - 
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The limit of detection (LOD = concentration at average blank response 
minus three times the SD) for T4 in buffer was calculated as 0.7 nM in 
both assays.  
 To have an impression of the reproducibility (intra day CV%) and 
accuracy, responses obtained with one T4 standard solution (12.5 nM) 
were used in both assays to calculate the corresponding concentrations 
with different calibration curves (n = 3) which resulted in an average of 
10.8 ± 0.6 nM in the rTTR-based assay (CV = 5%, accuracy = 86%) 
and 11.0 ± 0.9 nM in the TBG-based assay (CV = 8%, accuracy = 
88%).  
Compared with previous studies performed with [125I]T4 binding assays 
[8, 9], with IC50 values for T4 in the rTTR assay of 62 -138 nM and 52-
85 nM in the TBG assay, the rTTR and the TBG biosensor assays were 
respectively four and six times more sensitive. As a consequence of the 
simple biosensor assay format, which does not involve the separation of 
free and bound fractions, the assays were more reproducible and TP 
consumption was ~ 30% lower.  
 
Relative Potencies of Model EDCs in the Transport Protein-Based 
Biosensor Inhibition Assays. 
In addition to the natural ligands (T4 and T3) we selected seven 
chemicals, as model compounds for EDCs belonging to three different 
structural groups (Table 3). These compounds were evaluated for 
inhibition in the rTTR- and TBG-based biosensor inhibition assays. The 
tested EDCs were pentachlorophenol (PCP) and pentabromophenol 
(PBP), belonging to the halogenated phenols (group B). Bisphenol A 
(BPA) and its halogenated forms tetrabromobisphenol A (TBrBPA) and 
tetrachlorobisphenol A (TClBPA) in group C. Finally, group D is 
composed of two meta-subsituted polychlorinated biphenyls (3,5 
dichlorobiphenyl (PCB 14) and its 4-hydroxylated metabolite (4-OH PCB 
14).  
The calibration curves obtained for the halogenated phenols (Figure 5A) 
in the rTTR-based assay show that these compounds have lower affinity 
for TTR than T4 and the calculated RPs were 0.64 ± 0.1 for PBP and 
0.53 ± 0.1 for PCP (Table 4). These results differ from those obtained 
previously using the RLBA where a RP of 7.14 was observed for PBP [14] 
and 1.74 for PCP [15]. 
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The BPA curve (Figure 5B) showed no inhibition at the highest tested 
concentration (10 µM) and the halogenated forms (TBrBPA and TClBPA) 
showed a comparable or lower inhibition compared to T4 with RPs of 1.5 
± 0.2 for TBrBPA and 0.75 ± 0.2 for TClBPA. The RP obtained with 
TBrBPA is significantly lower than the previously reported RP of 10.6 
[14]; however the RP for TClBPA obtained with the biosensor inhibition 
assay is comparable to the reported value of 0.75 as well as the trend of 
higher relative potencies of brominated compounds over chlorinated 
compounds for the bisphenols [14] which is confirmed here using the 
biosensor inhibition assay. 
 
Table 4. Experimental and literature values of the Relative Potency (RP) of the thyroid 
disrupting chemicals evaluated using the rTTR and TBG-based biosensor inhibition Assaysa.  
 
RP values RP values from lit. 
Compound 
TBG rTTR pTTR TBG pTTR 
L-Thyroxine (T4) 1 1 1 1 1 
Triiodothyronine (T3) 0.6 ± 0.05* 
0.06 ± 
0.01*d - 
0.09 [24]  
0.3 [26] 
0.036 [24] 
0.08 [25] 
Pentachlorophenol <0.001 0.53  ± 0.1* 
0.64 ± 
0.13d 0.001 [15] 1.74 [15] 
Pentabromophenol <0.001 0.64 ± 0.1* 
0.4 ± 
0.18d - 
7.14 ± 1.11 
[14] 
Bisphenol A (BPA) <0.001 <0.001* <0.001* - <0.001 [14] 
TBrBPA <0.001 1.5 ±  0.2d 
1.06 ± 
0.2d - 
10.6 ± 1.29 
[14] 
TClBPA <0.001 0.75 ± 0.2*d 
0.66 
±0.04*d - 
0.76 ± 0.07 
[14] 
4-OH PCB 14 <0.001 4.36 ± 0.5* 
3.04 ± 
0.25* <0.001 [9] 3.9 [9] 
PCB 14 <0.001 <0.001 <0.001*  0.59 [25] 
 
aResults  shown are means ± SD of triplicate measurements performed in different days. 
Values that differ significantly (Student’s t test, P < 0.05), from T4 are indicated (*), from 
the following compound with higher RP (d). 
 
Finally, the polychlorinated biphenyl, PCB 14, showed no inhibition 
(Figure 5C), but its para-hydroxylated metabolite, 4-OH PCB 14 showed 
a RP of 4.36 ± 0.5, confirming the previously reported high interaction 
with TTR [9]. The ranking of RPs was 4-OH PCB 14 (RP = 4.36 ± 0.5) > 
TBrBPA (RP = 1.5 ± 0.2) ≥ T4 (RP = 1) > TClBPA (RP = 0.75 ± 0.2) ≥ 
PBP (RP = 0.64 ± 0.1) ≥ PCP (RP = 0.53 ± 0.1).     
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The performance of the rTTR biosensor inhibition assay with the 
different compounds evaluated shows that the spectrum of detectable 
compounds is similar to the spectrum of compounds detectable with 
previously described assays; however, the RPs for PBP and TBrBPA 
measured are respectively 10 and 7 times lower than the previously 
reported RPs using RLBA. 
 
 
Figure 5. Calibration curves obtained in the rTTR-based biosensor inhibition assay for (A) 
Halogenated phenols, (B) halogenated bisphenols and (C) (hydroxy-) polychlorinated 
biphenyls. 
 
To put aside the factor that the rTTR would have affinities different from 
TTR for the EDCs tested, we performed calibration curves (data not 
shown) for PBP, PCP, TBrBPA, TClBPA, 4-OH PCB14 and PCB14 using the 
pTTR. The results of the biosensor inhibition assay show a similar 
ranking of affinities as well as absolute RP values (4-OH-PCB 14 
(RP=3.04 ± 0.25) > TBrBPA (RP=1.06 ± 0.2) ≥ T4 (RP=1) > TClBPA 
(RP=0.66 ±0.04) ≥ PClP (RP=0.64 ± 0.13) ≥ PBP (RP=0.4 ± 0.18) 
indicating that the difference in RP is not caused by the rTTR origin. 
 The magnitude of the inconsistency in RP values between methods is 
comparable to the difference in RPs reported by different groups, 
working with radioligand assays with the estrogen receptor [27] or using 
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other methods [28]. For example, one study reported 26 parent PCBs 
binding to TTR with significant RPs (0.05-8.23) using the RLBA [25]. In 
contrast, a different study selected eight of these parent PCBs and 
reported that they could only confirm the interaction of two of the PCBs 
with TTR using an immunoprecipitation-HPLC method [29]. In 
agreement with the mentioned study, we could not find any interaction 
between rTTR and PCB14, although an RP of 0.59 was previously 
reported [25]. 
 
 
Figure 6. Calibration curves obtained in the TBG-based biosensor inhibition assay for (A) 
Halogenated phenols, (B) Halogenated bisphenols and (C) (Hydroxy-) polychlorinated 
biphenyls. 
 
The complex nature of the TTR binding sites and kinetics are a further 
issue to consider as the source of the RP inconsistency. Dissimilar 
binding kinetics were reported for TTR ligands depending on their 
structures, some compounds were able to bind to TTR with negative 
cooperativity (like T4), other compounds were found to bind with 
positive cooperativity (the binding of the ligand to one binding site 
increases the affinity of the second site for the ligand), and even with 
non cooperativity (the binding of the ligand is independent in both sites) 
[30].  
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Different binding kinetics for some compounds might result in higher or 
lower dissociations rates of the TTR-ligand complex which, in methods 
where separation steps are needed, could displace the equilibrium 
reached during the incubation giving results unrelated among the 
different ligands. Hence the different RPs obtained with the TP-biosensor 
inhibition assay are probably due to differences between methods, as 
well as from the previously suggested sensitivity of TTR to the buffer 
conditions used [26]. For instance, in our assay the presence of EDTA 
was shown to specifically inhibit TTR binding to the chip and also 
significantly alter rTTR-T4 interaction kinetics. Other possible sources of 
variation are the higher pH (8.5), higher temperature (25 ºC), and lower 
incubation time. 
 As shown in Figures 6, the TBG-based biosensor inhibition assay was 
very specific for T4, consistent with previous studies in which diverse 
groups of compounds and metabolites were tested for competitive 
interactions and only a few compounds bound to TBG showing in all 
cases RP values below 0.03 [6, 9, 15]. However, T4 is one of the top 200 
most widely prescribed drugs in the United States (top 200 prescribed 
drugs www.rxlist.com) and it is a potential endocrine disruptor if present 
in the environment like some other prescribed drugs known to bind TBG 
[21, 31]. Moreover, and given that TBG plays a major role in T4 
transport in humans the biosensor TBG-based assay is a usefull 
complement to the rTTR-based assay for the assessment of potentially 
new hazardous endocrine disruptors interacting with the thyroid system.  
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Conclusions 
 
In the present study, we developed novel SPR-based biosensor inhibition 
assays for the bioeffect-related screening of chemicals with thyroid 
disrupting activity using the thyroid transport proteins rTTR and TBG as 
biorecognition elements.  
The automated biosensor assays are more sensitive for the natural 
ligands (T4 and T3) compared with current methods, they are fast (run 
time between samples is 10 min), easy to perform (no labels), robust 
(the sensor chip was used for hundreds of cycles) and can be performed 
with a high reproducibility and accuracy. The rTTR-based biosensor 
inhibition assay was sensitive toward the model EDC compounds 
(halogenated phenols and bisphenols and hydroxylated PCB). The 
spectrum of detectable compounds is comparable to other methods; 
therefore, the rTTR inhibition assay can be a useful tool for the 
identification and ranking of the relative potencies of new chemicals with 
thyroid-disrupting activity and for the screening of samples with 
potential thyroid activity.  
The TBG-based biosensor inhibition assay is suitable for a sensitive and 
specific detection of T4 and for the assesment of potentially new 
hazardous endocrine disruptors interacting with the thyroid system.  
Further research will focus on screening a larger panel of compounds 
and on validating the TP-based biosensor inhibition assays for the 
screening of real environmental and food samples for thyroid activity. 
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Abstract 
Ubiquitous chemicals may interfere with the thyroid system that is 
essential in the development and physiology of vertebrates. We applied 
a surface plasmon resonance (SPR) biosensor-based screening method 
for the fast screening of chemicals with thyroxine (T4) transport 
disrupting activity. Two inhibition assays using the main thyroid 
hormone transport proteins, T4 binding globulin (TBG) and transthyretin 
(TTR), in combination with a T4-coated biosensor chip were optimized 
and automated for screening chemical libraries. The transport protein-
based biosensor assays were rapid, high throughput and bioeffect-
related.   A library of 62 chemicals including the natural hormones, 
polychlorinated biphenyls (PCBs), polybrominated diphenylethers 
(PBDEs) and metabolites, bisphenol A (BPA), synthetic fluorinated 
phenols, pharmaceuticals, pesticides and other potential 
environmentally relevant chemicals was tested with the two assays. We 
discovered ten new active compounds with moderate to high affinity for 
TBG with the TBG assay. Strikingly, the most potent binding was 
observed with hydroxylated metabolites of the brominated diphenyl 
ethers (BDEs) BDE 47, BDE 49 and BDE 99, which are commonly found 
in human plasma. The TTR assay confirmed the activity of previously 
identified hydroxylated metabolites of PCBs and PBDEs, halogenated 
BPA and genistein. These results show that the hydroxylated 
metabolites of the ubiquitous PBDEs not only target the T4 transport at 
the TTR level, but also, and to a great extent, at the TBG level where 
most of the T4 in humans is circulating. The optimized SPR biosensor–
based transport protein assay is a suitable method for high throughput 
screening of large libraries of potentially thyroid hormone disrupting 
compounds. 
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Introduction  
Thyroid Hormones (TH), such as L-thyroxine (T4) and its biologically 
active metabolite, triiodothyronine (T3), are essential for the modulation 
of the cellular metabolic rate and for the development, and 
differentiation of several tissues, specially the brain [1, 2]. The thyroid 
gland produces and releases T4 in response to the thyroid-stimulating 
hormone secreted by the pituitary. Once T4 enters the blood stream it is 
bound to transport proteins and distributed to the target tissues. 
Thyroxine binding globulin (TBG) is the major T4 transport protein in 
human plasma and is responsible for 75% of the specific T4 binding 
activity. Transthyretin (TTR) is the second transport protein carrying 
about 20% of T4 and finally, human serum albumin (HSA) is the third 
transport protein carrying about 5% of the total T4. The affinity of the 
three transport proteins for T4 varies greatly, as well as their plasmatic 
concentration (0.2 M for TBG, 5 M for TTR and 600 M for HSA) 
providing a redundant buffer system for free T4 [3]. T4 is specifically 
transported through the cell membrane into the intracellular 
compartment and deiodinated to the biologically active T3 metabolite in 
different tissues [4]. Once inside the cell, T3 is non-specifically 
transported to the nucleus where it exerts its action by binding to the 
nuclear thyroid receptors. Several chemical contaminants resembling T4 
have been shown to interfere at different levels with the thyroid 
pathway (for review see [5]). The disruption of the T4 transport has 
received special attention since several polyhalogenated aromatic 
hydrocarbons (PHAHs) become bioactivated in vivo upon hydroxylation 
by the cytochrome P450 monooxygenase system [6].  These 
hydroxylated PHAHs interact with TTR [7, 8] and some of them, albeit  
with much lower affinity, interact with TBG [9, 10].  Some studies 
exclude the dependence of thyroid hormone homeostasis on any 
transport protein per se [11]. However, TTR is important for maternal to 
fetal transport of thyroid hormones and for delivery of T4 across the 
brain barrier [3]. TBG has also been linked to facilitate the iodine supply 
to the fetus that initially has no iodine reserve [12]. Displacement of T4 
from its transport protein complex during the developmental stage could 
have consequences in fetal development and later in adulthood  [13, 
14]. For instance, disturbances in the retinoid and TH levels by 
environmental chemicals during development has been linked with 
susceptibility to schizophrenia [15], with effects on brain development 
[16] and with lower IQ levels in adulthood [17]. Moreover, obesity is 
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increasingly been linked to environmental chemicals and this could be 
mediated through an impaired TH homeostasis [18-20]. Therefore, the 
presence and bioaccumulation of these bioactive contaminants in the 
food chain and finally in humans is a cause of concern. PCBs have been 
shown to interfere with the TH homeostasis. However, the PCBs 
concentration in human tissues is gradually declining due to the 
regulations imposed in the 1970s [21].  
 
 
Figure 1. (A) Principle of the biosensor transport protein-based inhibition assay. (B) 
Overlayed sensorgrams showing the responses in time obtained during a whole cycle 
(mixing, injection (binding), dissociation and regeneration) and the inhibition of TBG 
binding to the T4 chip surface when mixed with 0, 22.2 and 200 nM of T4.  
 
On the contrary, the widely used polybrominated diphenyl ethers 
(PBDEs) flame retardants that were later introduced, have been 
measured in human adipose tissues from inhabitants of the United 
States at concentrations of 35 ng/g lipid. This is 10-100 times greater 
than those reported in European countries and their concentrations have 
been increasing exponentially for the last 30 years, with a doubling 
period of about 5 years [21, 22]. Although the influence of PBDEs on 
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human T4 levels is unknown, one epidemiological study found a 
significant negative correlation between thyroid stimulating hormone 
and BDE 47 levels in Scandinavian men [5]. Therefore, there is a rising 
need for high throughput screening methods to determine whether 
chemicals are affecting the thyroid system at different levels. In the 
present study we used two previously developed transport protein-
based surface plasmon resonance (SPR) biosensor inhibition assays 
[23]. The principle of these biosensor assays is similar to an inhibition 
immunoassay (see Fig. 1 A). If there is no binding of the analyte to the 
transport protein, the maximum amount of transport protein will bind to 
the sensor surface and a maximum response is obtained. The binding of 
transport protein to the sensor surface will be inhibited given an 
interaction between the analyte and the transport protein in solution, 
resulting in a lower response. The inhibition of the response depends on 
the concentration of the T4-like analyte as well as on the affinity of this 
compound for the transport protein. 
The biosensor assays were optimized to endure long periods of 
automated operation and used to screen a library of 62 chemicals for 
compounds affecting the T4 transport. This library, shown in Table 1 and 
Table 2, included the thyroid hormones, polyhalogenated biphenyls, 
polyhalogenated diphenyl ethers and metabolites, bisphenol A (BPA) and 
synthetic haloginated derivatives, pharmaceuticals, pesticides and other 
environmentally relevant chemicals providing a wide range of structural 
classes. 
 
Experimental 
Chemicals and Equipment  
The recombinant transthyretin (rTTR) was produced at the Toyama 
Medical and Pharmaceutical University (Toyama, Japan) [24]. Chemical 
standards (Tables 1 and 2) had a purity above 95 % and were obtained 
from AccuStandard (New Haven, CT), LGC Promochem (Teddington, 
UK), Honeywell Riedel de Haën (Seelze, Germany) or Dr. Ehrenstorfer 
GMbH (Augsburg, Germany). Thyroxine Binding Globulin (TBG) was 
obtained from Scipac (Kent, UK). CM5 sensor chips, the amine coupling 
kit [containing 0.1 M N-hydroxysuccinimide (NHS), 0.4 M 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC) and 1 M 
ethanolamine hydrochloride (pH 8.5)] and the Biacore Q biosensor 
were supplied by GE Healthcare (Uppsala, Sweden). The 5-aminovaleric 
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acid (AVA), L-thyroxine and the ovalbumin (OVA) and all other reagents 
were obtained from Sigma-Aldrich Chemie (Zwijndrecht, The 
Netherlands) unless otherwise stated. 
 
Transport Protein Inhibition Assays   
The transport protein assays, of which the principle is shown in Figure 
1A, were performed as described previously [23] with some 
modifications on the conditions to improve the transport protein stability 
and maximize the unattended operation time. T4 was immobilized to the 
CM5 biosensor chip surface via the amino group of the alanyl side chain 
using AVA as spacer. The transport protein assays were performed in a 
Biacore Q that automatically mixed 20 µL of the transport protein 
solution (91 nM) with 80 µL of the analyte solution and immediately 
injected 50 µL of the mixture over the T4-coated sensor chip surface at 
a flow rate of 25 µL min-1. The variation in response over time of each 
transport protein binding to the T4-coated sensor chip surface under 
different buffer conditions was used as a parameter of transport protein 
stability. The response, measured 15 s after the injection ended was 
used for data comparison and the surface was regenerated by injecting 
15 µL of a mixture of 0.1 M NaOH and acetonitrile (ACN) (4:1; v/v).  
In the final format, a phosphate buffer (NaH2PO4 (0.6 g), Na3PO4*12H2O 
(1.9 g), NaCl (0.59 g) per liter adjusted to pH 8.5) was used as running 
buffer. The transport protein stock solutions were prepared in running 
buffer with the addition of OVA (40 g mL-1) to preserve the transport 
protein stability. A typical maximum response of a blank buffer injection 
was 750 response units (RU). Stock solutions of the chemical standards 
(10 mM) were prepared, if possible, in DMSO, or otherwise in the 
organic solvent recommended by the provider. The T4 stock solution (10 
mM) was prepared by dissolving T4 in a solution containing DMSO 
(94%), chloroform (5 %) and 1 M NaOH (1 %). The buffer used for 
dilution of the chemical standards was running buffer with the addition 
of 2% DMSO and ascorbic acid (0.5 g L-1) as antioxidant. At least one T4 
calibration curve was included in each set of analyte calibration 
standards.  
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Transport Protein Binding Affinity 
 The binding affinity of a chemical to either rTTR or TBG was expressed 
as the relative potency (RP) of the compound compared to the natural 
hormone, T4. Therefore, concentrations inducing 50% inhibition (IC50) 
were obtained from calibration curves of the compounds and T4. The RP 
is defined as the ratio between the IC50 of T4 and the IC50 of the 
compound [IC50 (T4)/IC50 (analyte)]. The mean IC50 of all the T4 
calibration curves was used for the RP calculations. The mean IC50 of T4 
in the TTR assay was 18.4  4.4 nM (n = 15) and 17.2  1.2 nM (n = 
10) in the TBG assay. The RPs of the analytes were calculated based on 
at least two full dose response curves based on six different 
concentrations. The chemicals were classified either as active or 
inactive, according to their percentages of inhibition at the highest 
tested concentrations. Active chemicals were those with an inhibition 
higher than 50% and were further classified based on their calculated 
RP. Namely designated as very strong binder (VSB) (RP > 1), strong 
binder (STB) (1>RP>0.1), moderate binder (MB) (0.1>RP>0.01), or 
weak binder (WB) (RP < 0.01). Those that did not reach an inhibition of 
50 % at the highest tested concentration were differentiated in two 
groups. Those chemicals inhibiting transport protein binding in the 0-15 
% range were designated as “non binders” (NB) and those showing 
inhibition in the 16-49 % range were designed as “slight binders” (SlB).  
 
Results  
Optimization of the Assays  
Typical sensorgrams obtained with the TBG assay for three different 
concentrations of T4 are shown in Figure 1B. There is a relatively large 
bulk response in the sensorgrams caused by the presence of DMSO in 
the dilution buffer. After the injection finishes, the specific binding 
response is measured. The regeneration conditions effectively disrupted 
the transport protein-T4 interaction without damaging the T4-coated 
chip surface. The total run time for each cycle was 8 min, including 
mixing the transport protein stock solution with the sample and the 
washing steps. The T4-coated chip surface was very stable and could be 
used for over 1000 cycles. To allow long periods of unattended 
operation, it is critical that the T4 binding activity of the transport 
proteins remains stable. One of the factors affecting the stability of TTR 
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in binding assays is its concentration in solution [25]. rTTR was exposed 
to different conditions to study the decrease of  binding response to 
immobilized T4. When rTTR was used as previously [23], the response 
obtained after injection of (18.2 nM) rTTR decreased 43 % after 240 min 
(30 cycles). At this concentration, the rTTR stability was greatly 
improved after the addition of (182 nM) OVA as a stabilizing agent and 
the response decreased only 12 % after 240 min of serial injections. 
OVA has a reported low affinity for T3 and T4 [26] and is therefore 
interesting as stabilizing agent because it would have a minor effect on 
the relative affinities of the analytes to the transport proteins. The 
stability of rTTR was further improved by preparing a five-fold more 
concentrated transport protein stock solution. The OVA concentration in 
this solution was five-fold increased as well. Prior to each injection, the 
Biacore Q mixed the transport protein stock solution with the analyte 
solution (1/5; v/v). The measurement of a full set of 7 calibration curves 
(three analytes in duplicate and T4) took 960 min. Under these 
conditions, the transport protein stock solutions remained stable and 
showed minimum response decrease (< 5 % for rTTR and < 2% for 
TBG). Additional improvements were the presence of 2% DMSO in the 
dilution buffer, which enhanced the solubility of hydrophobic chemicals 
allowing the screening of chemicals over a wider range of Log P values, 
and the presence of 2.8 mM ascorbic acid to prevent oxidation of less 
stable metabolites [27].  
Under the improved conditions, both biosensor transport protein-based 
assays were more robust than under the conditions used previously 
[23]. The RP values obtained previously with the same stock solutions of 
4-OH PCB14, TBBPA, TCBPA, PBP, PCP and T3 were similar to the RP 
values under the optimized conditions. The IC50 values for T4 increased 
in the TTR assay from 13.7 to 18.4 nM, and from 8.6 to 17.2 nM in the 
TBG assay. However, as other chemicals had concomitant IC50 
increases, the RP value was not significantly changed. The only 
exception was 4-OH PCB14, which showed a significant IC50 increase 
from 3.1 nM to 16.9 nM, indicating that an interaction of 4-OH PCB 14 
with OVA cannot be excluded as the cause. Hence, 4-OH PCB14 was 
excluded from further analysis.  
The TBG assay with improved conditions showed a RP increase for T3 
from 0.6 to 0.8 compared to the previous conditions. 
A library of 18 chemicals (T4, T3, 4-OH PCB 69, 4-OH PCB 106, 3-OH-
BDE 47, 5-OH-BDE 47, 6-OH-BDE 47, 4'-OH-BDE 49, 6'-OH-BDE 49, 6'-
OH-BDE 99, TCBPA, TBBPA, DBP, TBP, PCP, PBP, Na Dic, Me Ac) was 
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tested in the TTR assay with the old and the new conditions, obtaining 
similar RP values, with a regression equation RP(New Conditions) = 1.06 RP(Old 
Conditions) - 0.03  (R2 = 0.86). These results indicate that the addition of 
DMSO, OVA and ascorbic acid to the transport protein-based assays had 
minor effects on the RP values.  
 
 
Figure 2. Distribution of the RP values compared to T4 of the 62 tested chemicals 
determined with the TTR- and TBG inhibition assays. The compounds are classified based 
on their percentage of transport protein inhibition if they do not reach 50%, or based on 
their relative binding potency. The categories distinguished are, weak binders (WB, 
RP<0.01), moderate binders (MB, 0.01<RP<0.1), strong binders (StB, 0.1<RP<1) and 
very strong binders (VSB, RP>1). Non binders (NB) and slight binders (SlB) inhibited the 
transport proteins less than 16% and 50 % respectively. 
 
Screening of a 62 Chemicals Library  
From the 62 chemicals tested with the two transport protein-based 
assays, 25 were classified as active for producing more than 50 % 
inhibition of TTR and 15 for TBG (Figure 2). Of the compounds, 28 were 
non binders (producing less than 16 % inhibition) to TTR and 37 to TBG. 
The remaining 9 chemicals for TTR and 10 for TBG, were slight binders 
(SlB) with more than 15% inhibition but less than 50%. The 25 
compounds active towards TTR had RPs ranging from more than 0.01 up 
to more than 1. For the more specific TBG, 15 compounds were active, 
but none of them was more potent than T4 itself. The RPs of the TTR 
active chemicals mostly were centered around the STB category (17 
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chemicals) and around the MB category for TBG (7 compounds) (Figure 
2).  
Detailed information about each chemical, i.e., the chemical name, 
structure, source, CAS number and measured binding affinity, as well as 
those found in literature (IC50 and RP) are presented in Table 1 and 
Table 2. Structures of the compounds from Table 2 (pharmaceuticals, 
pesticides and other chemicals), are presented in Figure 3.  
The active hormone (T3) is also active for binding the pro-hormone (T4) 
transport proteins and had an RP compared to T4 of 0.04 in the TTR 
assay and 0.8 in the TBG assay (Table 1). All tested polychlorinated 
biphenyls (PCBs) were inactive in both biosensor transport protein-
based assays. Even PCBs structurally resembling T4 (PCBs 73, 80, 121, 
127), did not interact with TTR nor with TBG. The 5 para-hydroxylated 
PCBs (OH PCBs) were strong TTR binders (RPs ranging from 0.4 till 2.5). 
The highly substituted, hydroxylated polyfluorinated biphenyl (4-OH 
PFB) showed a very strong affinity for TTR (RP = 1.4). The general 
affinity ranking of this group of chemicals for TTR was 4-OH PCB72 > 4-
OH PFB >4-OH PCB 14 >4-OH PCB121 >4-OH PCB 69 >4-OH PCB 106 
>3-OH PCB 61 (NB) (Table 2).  The OH polyhalogenated biphenyls 
(PHBs) did not bind to TBG, except for the moderate binder 4-OH PCB 
72 and the weak binder 4-OH PFB. 
All polybrominated diphenyl ethers (PBDEs) tested were inactive in the 
TTR assay.  In the TBG assay, BDE 49 and BDE 99 were weak binders 
(WB) with RPs of 0.01 and 0.003, respectively. However, all 
hydroxylated polyhalogenated diphenylethers (OH PHDEs) tested were 
moderate to strong binders to TTR. The most potent binder to TTR was 
3-OH BDE 47 (RP of 0.8), the least potent was Tricl ( RP of 0.03). The 
affinity ranking for the OH-PBDEs for TTR was 3-OH BDE 47> 5-OH BDE 
47 > 6’-OH BDE 49 > 6’-OH BDE 99 = 6-OH BDE 47 = 4’OH BDE 49 
followed by Tricl.  
The OH PHDEs tested were also slight (6-OH BDE 47 and 6’-OH BDE 99) 
to moderate binders (including Tricl) in the TBG assay. The TBG affinity 
ranking was 6’-OH BDE 99 > 6-OH BDE 47 > 6’-OH BDE 49 > 3-OH BDE 
47 > 5-OH BDE 47 > 4’OH BDE 49 followed by Tricl. From the two 
methoxy (MeO) PBDEs tested, only 6-MeO BDE 47 had a slight affinity 
for both transport proteins and 2’-MeO BDE 68 for TBG only. Although 
the unsubstituted diphenyl methane (BPA) tested in the transport 
protein-based assays was inactive, the halogenated congeners were 
strong binders in the TTR assay with RP values of 0.6 for TCBPA and 1 
for TBBPA, but both were inactive in the TBG assay.  
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None of the fluorinated phenols was active in the transport protein-
based assays, of the chlorinated phenols only pentachlorophenol had 
affinity for binding TTR (RP = 0.6) (Table 1).  Interestingly, all the 
brominated phenols were active TTR binders with RPs up to 0.9 for 
tribromophenol (TBP). In the TBG assay only DFP, PCP and PBP were 
slight binders, but showing less than 20 % inhibition.  
 
 
Figure 3. Structures of pharmaceuticals (A) and pesticides and other chemicals (B) 
presented in Table 2 and tested in the transport protein-based assays.  
 
Three of the ten common pharmaceuticals tested (Figure 3A) were 
active in the TTR assay (Table 2), with the T4 like Tetrac being the most 
potent (RP of 1.1). Sodium diclofenac (Na Dic) and mefenamic acid (Me 
Ac) were less potent (RPs of 0.02). In the TBG assay only Tetrac (RP of 
0.6) and NaDic (RP = 0.01) were active.  
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Of the 10 pesticides and other compounds with environmental relevance 
tested (Figure 3B), only the natural isoflavonoid, genistein (Gen), was 
active in the TTR assay. All these chemicals were inactive in the TBG 
assay.  
To compare the affinity of TTR and TBG toward the chemicals tested, the 
RP of the active chemicals for TTR was plotted versus the RP of the 
chemicals active for TBG in Figure 4. Those chemicals that inhibited the 
transport protein-based assay less than 50 % were plotted using the – 
Log10 of the percentage of inhibition (PI%) at the highest concentration 
tested. Inactive compounds showing a PI% for either of the transport 
proteins below 1 were assigned a Log10 value of 0 and are therefore 
aligned with the axis.  
 
 
Figure 4. Affinity of the 62 chemicals tested for TTR and TBG binding. The –Log10 of the 
percentage of inhibition (PI%) was used to plot compounds not reaching 50% inhibition. 
Compounds for which the relative potency (RP) compared to T4 was calculated were 
plotted based on their RP. Those compounds in the shaded quadrant have a strong affinity 
for both TTR and TBG. 
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The shaded quadrant of the plot contains a group of 13 chemicals that 
were both active for TTR and TBG. Most of these compounds are located 
below the T4 diagonal and along the rTTR axis showing in general a 
higher RP for TTR than for TBG. Four active compounds (Tricl, 6-OH 
BDE47, 6’-OHBDE99 and NaDicl) are aligned with the T4 diagonal 
indicating similar relative affinity for both TTR and TBG. Only T3, located 
above the diagonal, was more potent for TBG than for TTR. The 
following quadrant clockwise depicts 12 compounds active only in the 
TTR assay, one of them, 4-OH PCB14, being a very strong binder. A 
subgroup of four compounds (PCP, PBP, TClBPA and PCB121) all highly 
substituted and strong binders for TTR are located in the SlB strip for 
TBG. 
The next quadrant clockwise contains 36 compounds showing less than 
50 % inhibition in both transport proteins, 24 were non binders for both 
TBG and TTR, 10 were slight binders with one of the transport proteins. 
Interestingly, 2 compounds (6-Me BDE47 and BDE47) were slight 
binders with both transport proteins and were aligned with the T4 
diagonal. The last quadrant is virtually empty except for two compounds 
(BDE49 and BDE99) that had a much higher relative affinity for TBG 
than for TTR. 
 
Discussion 
In our previous study we characterized rTTR and TBG using a SPR-based 
biosensor and this allowed us to develop two T4 transport protein 
inhibition assays using this system [23]. In the present study these 
assays were successfully optimized to endure the conditions needed for 
screening a large library of 62 chemicals. We discovered, in this libray, 
that several hydroxylated metabolites of commonly used brominated 
flame retardants have an unexpectedly strong affinity for TBG. All of 
these compounds also have a strong affinity for binding TTR.   
When our results are compared with those reported in literature (Tables 
1 and 2), the first issue that arises is the difference in the RPs obtained 
with those previously reported. One fundamental reason to explain 
these differences is the TTR source. The classical T4 radioligand binding 
assay (RBA) uses TTR purified from human serum that is probably less 
stable than the recombinant TTR used in this study. Additionally, TTR 
has two allosteric binding sites, a low and a high affinity one. Our TTR 
assay is only sensitive to the binding of a ligand to the high affinity 
binding site [23]. On the contrary, the classical TTR RBA reported 
Chapter 4 
 
 
117
measures in principle the displacement of T4 from both binding sites. 
The structure of the ligands also plays a crucial role in the TTR binding 
kinetics [44]. This could generate very complex binding kinetics when 
the isotope-labeled T4 and the ligand are both present during binding in 
the TTR RBA. When a ligand is bound to one of the binding sites, it 
influences the binding kinetics of the other ligands. Another important 
difference between our TTR assay and the TTR RBA is that the latter is 
performed in a pure aqueous solution, whereas our assay includes 
ascorbic acid, 2% DMSO and OVA creating more stable conditions for 
lipophilic compounds. 
Furthermore, it has been reported that even in similar experiments 
using TTR radioligand binding assays, the RP values for a single 
compound may differ up to 6 fold (i.e. TBBPA) [35, 38]. The RP 
variations reported confirm previous studies indicating that TTR is very 
sensitive to slight changes in assay conditions [23, 33]. The dissimilar 
methods and assay protocols used make quantitative inter method or 
inter laboratory comparisons unfeasible. However, qualitatively most of 
the RP values from different studies, including ours, are in accordance 
with each other. 
The RP of T3 (0.04) in our study was comparable with the average RP 
values (0.06±0.03) reported in literature. The RP for T3 in the TBG 
assay was 0.8, which is almost ten times higher than previously 
obtained [32]. This difference could be explained by the pH (7.4-7.8) 
that was reported as optimum for TBG RBAs  [26]. In this study, Korcek 
and Tabachnick show that the affinity of TBG for T3 increases more at 
higher pHs than for T4. Therefore, using a pH of 8.5 for the TBG assay, 
as in the present study, probably increases the RP for T3. 
In our transport protein-based assays all the PCBs tested were inactive, 
in contrast with the results of Chauhan et al., who reported that several 
of these compounds interacted strongly with TTR using a RBA [33]. 
Later, Purkey et al. could only confirm an interaction of TTR with only 
two out of the eight PCBs used by Chauhan, albeit with a method based 
on immunoprecipitation-HPLC [34]. Most of the previous studies show 
that parent PCBs were inactive, contrary to their meta or para 
hydroxylated metabolites of PCBs with one or more adjacent halogens 
substituents that were potent T4 analogues [8, 25]. Our results with the 
TTR assay confirmed the TTR binding affinity for OH-PCBs and 
discovered that 4-OH PFB was a very strong TTR binder.  
Of the 4 PBDEs tested, 2 were weak binders, inhibiting TBG more than 
50% and 3 were slight binders to TTR, inhibiting TBG less than 50%. 
Biosensor Recognition of Thyroid-Disrupting Chemicals Using Transport Proteins 
 
  
118 
The OH-PBDE metabolites, however, were all active and strong binders 
in both transport proteins. For TTR, the 3 meta OH group with two 
adjacent halogens, as present in 3-OH BDE47, provided the optimum 
structure for binding to TTR, which is in accordance with previously 
reported results performed with OH PCBs [8, 25]. The presence of the 
OH group in the 5 meta position with only one adjacent halogen, as in 
5-OH BDE47, reduced the RP 2-fold. The RP decreased a further 2-fold 
when the OH group was in the ortho position without an adjacent 
halogen group (6-OH BDE 47). This trend in RP decrease is in 
accordance with the literature (see Table 1), with the exception of 4-
OHBDE49 that in our study it had a RP 2-fold lower than 5-OH BDE47 
whereas in the literature, the difference was of one order of magnitude 
lower (Table 1). In contrast with all what has already been reported 
about compounds binding to TTR, our study is the first to show that 
environmentally relevant compounds can also bind to TBG. We observe 
a different structure-related trend for TBG if compared with TTR. The 
presence of a OH group in the ortho position without an adjacent 
bromine group seems to favor the binding to TBG, as seen for 6-OH BDE 
47 and 6’-OH BDE 99. However, Tricl shows the lowest RP of the group 
even though it bears a OH group in the ortho position and lacks adjacent 
chlorines. This suggests that there is a strong effect of the ligand’s 
halogen subtituent size for binding TBG and would explain why in the 
past hardly any TBG binding has been shown for PCBs [10]. The two 
strongest TTR binders in the group of the OH PHBs were also active in 
the TBG assay and had the same affinity ranking as for TTR. We could 
confirm the previously reported inactivity of 4-OH PCB 106, 4-OH PCB 
121 and 4-OH PCB14 for TBG, but not the medium affinity of 4-OH PCB 
69 for TBG (Table 1). 
The number of halogens also plays a role, since all the compounds that 
were slight binders for TBG were at least tetra-substituted as shown in 
the second quadrant of Figure 4. The presence of one bromine adjacent 
to the OH group reduces the RP by about 2-fold, as seen with 6-OH BDE 
49. This reduction is also seen with one or two bromines adjacent to the 
meta positioned OH group with 3-OH BDE 47 and 5-OH BDE 47. The fact 
that OH PBDEs are medium to strong binders of TTR and TBG is of 
special interest because of the abundant presence of OH-PBDEs in the in 
vivo situation. PBDEs are easily hydroxylated and are persistent in 
blood, contributing to the PBDE mediated toxicity [6, 45]. Of special 
interest are the OH metabolites of BDE 47 because they are the most 
common ones in humans [46]. 6-OH BDE 47 showed comparable RPs for 
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both transport proteins suggesting that high levels of this metabolite in 
human blood are of health concern because it targets equally T4 
displacement from their binding proteins. The strong binding affinity for 
the transport proteins can explain the persistence of OH-PBDEs in blood 
because they are protected against secondary metabolism when bound 
to transport proteins. In addition, it has been reported that OH-PHAHs 
can be transported to the fetus bound to TTR [14, 47]. 
From the 2 methoxylated PBDEs (MeOPBDEs) tested, only 6-MeO BDE 
47 showed a very limited affinity for both rTTR and TBG, much lower 
than that of the OH-PBDEs. Although MeOPBDEs have been found in the 
marine environment [48], they seem unlikely to pose a risk based on 
their limited affinity for the transport proteins according to our results.  
Triclosan (Tricl) is a hydroxylated polychlorinated diphenyl ether that, as 
the OH PBDEs strongly resembles the structure of T4 and equally 
targeted both rTTR and TBG. Both humans and the environment are 
exposed to Tricl because it is intensively used as antibacterial agent for 
example in dishwashing liquid, soap, toothpastes, mouthwashes, etc 
[49, 50]. This continuous exposure and strong transport protein binding 
affinities makes Tricl an important candidate for future studies. 
BPA hardly inhibited transport protein binding. This widely used weak 
estrogenic compound contaminant, however, can be transformed into 
compounds like tetra chlorinated BPA (TCBPA), with thyroid hormone 
disrupting activity during aqueous chlorination in sewage treatment or in 
contaminated drinking water hoses [51, 52]. Evidencing the need for 
future studies were the endocrine disrupting chemicals assessment is 
performed in a more holistic approach using multi-system assays or 
multiple assays representing different systems and not only using 
chemical standards but also real samples were the total bioactive 
toxicity load is determined. Both TCBPA and the widely used flame 
retardant tetrabrominated BPA (TBBPA), were strong TTR binders in our 
studies. TCBPA had a RP (0.6) comparable with literature (0.8) and 
TBBPA had a RP (1) that could only be compared with one of our 
previous studies were a RP of 1.6 was found (Table 1).  
The RPs we observed for the halogenated phenols in the TTR assay are 
in accordance with an interesting trend previously reported by Meerts et 
al. [38]. Given equal structures, the affinity increase with increasing 
atomic weight of the halogens substituents, for instance, TCBPA < 
TBBPA, DFP < DCP < DBP, TFP < TBP, PCP < PBP.  Apparently, the 
emerging exclusively fluorine-substituted phenolic compounds are 
unlikely have an effect as thyroxine transport disruptor.  
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Several environmentally relevant pharmaceuticals (for review see [53, 
54]were tested with the transport protein assays. In accordance with 
previous studies Tetrac had a high RP for TTR in the range from 0.8 to 
11.5 and Na Dic and Me Ac were moderate binders to TTR. Although 
MeAc was reported to be one order of magnitude more potent than 
NaDic, in our study their potency was comparable for TTR (Table 1). In 
the TBG assay, we found a RP for Tetrac of 0.6, compable to the RP of 
0.4 reported in literature and a RP for NaDic that was 25 times higher 
(table 1). Previous studies reported an interaction of Furosemide (Fur), 
NaDic and MeAc with TBG, but in our study Fur and MeAc only were 
slight binders due to the lower maximum concentration tested compared 
to the one used in literature.  
Of the pesticides and other compounds of environmental relevance 
tested, only the natural isoflavonoid, genistein (Gen) was active in the 
TTR assay. The IC50 of Gen was 43.8 nM, roughly comparable with the 
previously reported equilibrium dissociation constant (KD = 40 nM) for 
Gen binding to TTR [43]. This compound also has a weak estrogenic 
activity and is considered a beneficial nutraceutical for menopausal 
women. On the other hand, the health implications of the strong TTR 
binding potency still is unknown and of interest for future research. 
 
Toxicological Relevance of T4 Transport Protein Binding 
The T4 binding site of TBG has recently been solved and is located on 
the surface of TBG [55]. Apparently, TBG is an active T4 carrier 
specifically adapted to allow triggered and modulated release of T4 to 
specific tissues including the placents [55, 56]. Given that the fetus 
initially has no iodine reserve it is dependent on the iodine transferred 
by the mother. Consequently, there is an increased concentration of T4-
TBG in the mother during pregnancy in order to supply an avid placental 
uptake [12, 29]. Therefore, one could speculate that during ontogenesis 
the displacement of the T4-TBG complex by the OH-PBDEs commonly 
found in humans, could have consequences in fetal development. TTR 
also mediates the maternal to fetal T4-transport through the placenta, 
in addition to the delivery of T4 across the blood–brain barrier. It has 
been shown before that compounds bound to TTR are transported to the 
fetal compartment and fetal brain, decreasing fetal brain T4 levels [57, 
58].  
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The OH-PBDEs were the most active compounds toward both T4 
transport proteins. However, these compounds usually occur in mixtures 
combined with the OH-PCBs which are more potent toward TTR. This 
study is the first to show that some OH-PHAHs have a strong binding 
affinity for TBG and one important requirement for binding is the 
presence of the bulkier bromine substituents found in OH-PBDEs. Hence, 
there are good reasons to expect a relevant inhibition of T4 transport to 
the fetus. In addition to transport protein-binding, T4 and T3-like OH-
PBDEs also have been shown to induce T3-dependent cell proliferation in 
the T-screen and activate the nuclear TH receptors TRα and TRβ in 
specific reporter gene assays [59]. Furthermore, OH-PHAHs, have also 
been shown to interfere with sulfonostransferases [60, 61] and 
deiodinases [62]. Apparently especially the OH-metabolites of PHAHs, 
including the ubiquitous PCBs and PBDEs, have been shown to hamper 
the TH homeostasis at several physiological levels and via multiple 
thyroid hormone-related mechanisms. As, in addition, the effects of 
mixtures of PHAHs not only are additive, but sometimes even 
synergistic, this could mean a serious risk for thyroid hormone 
disrupting effects of such mixtures, especially in developing fetuses.   
The currently presented fast and reproducible optimized SPR biosensor –
based transport protein assay offers a suitable method for high 
throughput screening of a large library of compounds, their metabolites 
and even biological samples. As the T4 is immobilized on the chip 
surface in this method, it could be further expanded to measure binding 
of compounds to T4 sulfono- and glucuronyltransferases and T4-
iodinases. We speculate that the T4 binding sites of these enzymes 
might share features with those of the transport proteins, allowing their 
binding to the immobilized T4. For example, Tricl has been shown to 
interact strongly with both TBG and TTR in the present study and 
previous research reported a strong interaction with sulfonotransferases 
and glucuronyltransferases [63], suggesting a possible predictive value 
of  the transport protein-based assays for other binding assays. Multiple 
T4- and T3-assays that are currently under study, possibly in 
combination with multiple SPR biosensing spots [64, 65], would allow a 
drastic reduction in the number of tests needed for the screening of TH-
disrupting potencies of compounds as required for EU regulations of 
toxic compounds such as REACH [66]. 
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Abstract 
The construction and performance of an automated low-cost SpreetaTM –
based prototype biosensor system for the detection of endocrine 
disrupting chemicals (EDCs) is described.  
The system consists primarily of a Spreeta miniature liquid sensor 
incorporated into an aluminum flow-cell holder, dedicated to support a 
Biacore chip frame, in combination with a simple pressurized air-driven 
fluid system.  
During the optimization, a monoclonal antibody (MAb)-based 
immunoassay for the estrogenic compound bisphenol A (BPA) was used 
as a model. After the optimization, two thyroxine transport protein 
inhibition assays for thyroid endocrine disruptors were implemented. 
The average noise of the system for 1 min of baseline was 1.1 µRIU 
(Refractive Index Units) and it could be operated in the range of 18-22 
°C with a minimum baseline drift (5-10 µRIU/100 min). Optimum signal 
to noise ratio (S/N R) was obtained using a flow cell height of 100 µm 
and a flow rate of 180 µL/min. The sensitivity of the Spreeta-based 
biosensor inhibition assays implemented (50% inhibition concentration 
(IC50) of 30.2 nM for BPA using MAb 12 and 12.3 and 11.6 nM for 
thyroxine (T4) using thyroxine binding globulin (TBG) and recombinant 
transthyretin (rTTR), respectively) was comparable to the sensitivity 
previously obtained using a Biacore 3000 (IC50 of 39.9 nM for BPA and 
8.6 and 13.7 nM respectively for T4). The results indicate that the 
alternative prototype system can be used in combination with ready-to-
use biosensor chip surfaces and it is potentially a useful tool for the 
bioeffect-related screening of EDCs.  
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Introduction  
Contaminants originating from a variety of sources (i.e. industrial waste, 
pesticides, pharmaceuticals and certain household products) are present 
in the environment and bio accumulate through the trophic chain posing 
a threat to human health and wildlife. 
Some of these chemicals can mimic or antagonize the effects of 
endogenous hormones in an organism and are considered endocrine 
disrupting chemicals (EDCs). 
EDCs can be roughly grouped by their biological effect (i.e. estrogenic, 
androgenic, thyrogenic, etc.) depending on which receptor, enzyme or 
transport protein they target. However, EDCs might be promiscuous and 
elicit more than one biological effect.  
EDCs can be detected using classic instrumental analytical techniques 
like high performance liquid chromatography (HPLC), gas 
chromatography (GC) or, at a lower cost, using immunochemical 
techniques like enzyme linked immunosorbent assays (ELISA) [1] with 
the disadvantage that the specificity of the method only allows the 
detection of a single compound or a group of structurally related 
compounds [2]. However, the main drawback is that EDCs are 
structurally diverse and there is a continuous market-driven evolution in 
the type of compounds produced. Therefore, the discovery and detection 
of EDCs through their biological effects is a feasible alternative. EDCs 
usually exert their biological effects by specifically binding to at least 
one hormone receptor site or a transport protein. Hence, mimicking or 
antagonizing the effects of the endogenous hormone or disrupting the 
synthesis or metabolism of endogenous hormones or hormone receptors 
[3]. Thus, the implementation of a method that uses of the same 
receptors or transport proteins which are targeted by the EDCs as their 
biorecognition elements allows a bioeffect-related detection of the total 
load of endocrine disrupting potency from a chemical or a complex 
group related to that receptor in a certain sample. This principle has 
been widely used in radioligand binding assays [4, 5], enzyme linked 
receptor assays (ELRA)[6-8], and biochemical detection coupled with 
mass spectrometry [9].  
The development of high-throughput, low-cost, bioeffect-related 
screening methods is of high interest for the detection of the EDCs in 
certain samples and for the assessment of emerging contaminants like 
bisphenol A (BPA) and polybrominated compounds (flame retardants), 
veterinary and human medicines [10] and their metabolites. 
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Automated surface plasmon resonance (SPR)-based biosensors are 
capable of monitoring biospecific interactions in real time with no need 
of labels. This has allowed the widespread use of this technology as a 
laboratory tool for the qualitative and quantitative assaying of a wide 
variety of biomolecules to obtain their kinetic constants. This 
technology, using Biacore SPR biosensors, was previously applied for the 
bioeffect-related screening of thyroid-disrupting chemicals using the 
thyroxine (T4) transport proteins (TP) (thyroxine binding globulin (TBG) 
and recombinant transthyretin (rTTR)) [11].   
Further use of SPR biosensors for the assessment of potential EDCs or 
their detection in fields like food safety or environmental monitoring is 
challenged by the high costs of the commercially available systems and 
the lack of portability for in situ analysis [12].  
The SpreetaTM TSPR2K11 is a compact, low-cost and commercially 
available SPR-based sensor manufactured by Texas Instruments. The 
units consist of a near- infrared diverging LED light source, a polarizer, a 
gold sensing layer, a reflecting mirror and a photodiode-array detector  
The working principle is as follows; first, the polarized light is emitted 
toward the gold sensing surface and reflected at different angles. At 
certain angles of light incidence resonance of the gold surface plasmons 
occurs and the intensity of the reflected light drops dramatically. 
Second, the light is reflected a on a mirror and projected onto the 
photodiode array where the light intensity is measured. Third, the 
position of this light intensity minimum is extremely sensitive to 
changes in refractive index (RI) of the fluid at the sensing area. 
Therefore the concentration of molecules in solution near to the sensing 
area changes the local RI which can be measured by monitoring the 
light intensity minimum shift over time (SPR profile). Hence, if a 
molecule is immobilized (i.e. hormone, antigen) on the sensing surface 
and a second molecule with a certain affinity for the immobilized one is 
introduced (i.e. receptor, antibody). The molecules introduced will 
accumulate at the sensing surface over time producing a measurable RI 
change. This principle has been used in SpreetaTM SPR sensors with a 
proper instrumentation system [13] for the setup of direct and 
competitive inhibition assays for the detection of toxins [14, 15], food 
allergens [16], bovine kappa-casein in milk and milk powder [17] and 
genetically modified organisms [18]. For the detection of EDCs,  a model 
immunoassay for estrone-3-glucoronide has been reported, with a 
detection range between 20-300 nM and an analysis time of 70 min. 
[12]. However, the small molecule (hapten) conjugates on the gold 
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sensor surface had to be stripped and newly physisorpted in each cycle. 
The Spreeta sensor surface can also be modified for covalent 
immobilizations [18], nevertheless, in the present work we used the 
Spreeta sensor in combination with CM5 biosensor chips (Biacore). CM5 
biosensor chips are composed of a plastic frame holding a glass slide 
covered on one side with a gold layer coated with covalently immobilized 
carboxymethylated dextrane (CMD). The CMD matrix of the CM5 chip 
enhances the hapten immobilization level due to the higher number of 
available sites for derivatization in its 3 dimensional structure and blocks 
non specific binding to the gold surface. These biosensor chips were 
found suitable and robust in previously described applications in which 
haptens were immobilized [11, 19]. 
In the present article we optimized the use of a compact, automated 
single channel Spreeta biosensor in combination with exchangeable pre-
functionalized and commercially available CM5 sensor chips A simple, 
pressure-driven and pulse-free fluidic system provided low noise and a 
robust sample delivery method. 
In the present study we used an inhibition immunoassay for the specific 
detection of the estrogenic compound bisphenol A (BPA) as a model for 
optimization of the system and further implemented two assays for the 
bioeffect-related screening of thyroxine transport disrupting chemicals 
using TBG and rTTR. 
 
Experimental 
Reagents 
Sensor chips (CM5), the amine coupling kit [containing 0.1 M N-
hydroxysuccinimide (NHS), 0.4 M 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC) and 1 M ethanolamine hydrochloride 
(pH 8.5)], HBS-EP buffer [pH 7.4, consisting of 10 mM 4-(2-
hydroxyethyl) piperazine-1-ethanesulfonic acid, 150 mM sodium 
chloride, 3 mM EDTA, 0.005% (v/v) surfactant polysorbate (P20)] and 
the BIACORE 3000 were supplied by Biacore AB (Uppsala, Sweden). 
Ethylenediamine (EDA) was obtained from Merck (Haarlem, The 
Netherlands). L-Thyroxine ((T4) 3,3’,5,5’-tetraiodo-L-thyronine), 3,3’,5-
triiodothyronine (T3), bisphenol A ((BPA) 2, 2-bis (4-hydroxyphenyl) 
propane), 4,4 bis (4-hydroxyphenyl) valeric acid, (BVA),  5-aminovaleric 
acid (AVA), ovalbumin (OVAL), dimethyl sulfoxide (DMSO), acetonitrile 
(ACN), and all other reagents were obtained from Sigma-Aldrich Chemie 
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(Zwijndrecht, The Netherlands) unless otherwise stated. Aqua regia was 
prepared by mixing 100 µl concentrated nitric acid with 300 µl 
concentrated hydrochloric acid. 
The T4 stock solution (10 mM) was prepared by dissolving T4 in a 
solution containing DMSO (94%) chloroform (5%) and 1 M NaOH 
(1%).The monoclonal antibody 12 (MAb 12) was originally raised toward 
a BVA conjugate and it strongly cross-reacted with BPA [19]. 
The recombinant his-tagged transthyretin (rTTR) was a kind gift from 
the Toyama Medical and Pharmaceutical University (Toyama, Japan). 
Thyroxine Binding Globulin (TBG) was obtained from Scipac (Kent, UK).  
 
Apparatus  
The scheme of the Spreeta-based automated prototype biosensor 
system is presented in Figure 1. The system consists of an aluminum 
holder which combines a SpreetaTM Miniature liquid sensor (TSPR2K11, 
Texas Instruments, USA) with a Biacore CM5 chip frame (removed from 
its holder) and an aluminum flow cell. The sensor is controlled by a 
digital signal processor (DSP)-controller box and pc-based evaluation 
software (Box version 16, software version 5.21, Nomadics, Inc., USA). 
The removal of the gold sensor surface with aqua regia from the Spreeta 
sensor left a transparent glass-like surface available for coupling with a 
CM5 sensor chip. The two glass surfaces were optically coupled with a 
glass-like refractive index film of poly (vinyl chloride) (PVC) [20].  The 
refractive index matching polymer (RIMP) interface was brought in 
contact with the glass side of a CM5 biosensor chip and the sliding flow 
cell pressed the system together and allowed the contact of the fluid 
with the CM5 sensor chip surface (see insert Figure 1). In the final 
system setup, the gold surface present in the CM5 sensor chip is used 
as the sensing surface of the SpreetaTM sensor, with the advantage of an 
easy exchange of the sensor chip surface for different applications. 
The flow system is connected via Teflon tubing (diameter 0.5 mm) and 
based on a pressurized air-fluid supply, driven by a 12 V dc miniature 
membrane pump (Nater, The Netherlands). The buffer container has a 
capacity of 50 ml and the flow is controlled by using capillaries of 
various diameters as flow restrictors. The liquid sensor, controller box 
and fluid system were built in an isolated hard case incorporating a 
Maxim MAX1978 integrated temperature controller (Getronics, The 
Netherlands) and a Marlow Industries thermoelectric cooler (Farnell In 
One, The Netherlands).  
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Figure1. Schematic illustration of the SpreetaTM-based automated prototype biosensor 
system. The sample can either be injected using an autosampler or a syringe. The 
pressurized air-driven fluidic system delivers the sample to the biosensor chip surface 
where the biospecific interaction takes place (see insert). The system scheme is not at 
scale except for the Spreeta TSPR2K11 sensor unit. 
 
During the evaluation study the system was connected to a Perkin-Elmer 
ISS-100 auto injector with a 200 µl sample loop. The system can also be 
operated manually by means of a stainless steel injection valve 
(Instrument Solutions, The Netherlands) equipped with a sample loop. 
The three flow cells evaluated had a flow path of 1 mm width, 4 mm 
long and heights of 100 µm (small volume = 0.4 µl), 400 µm (medium 
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volume = 1.6 µl) and 1000 µm (large volume = 4 µl). BIAevaluation 3.1 
(Biacore AB, Sweden) software was used to evaluate and handle the 
sensorgrams generated with the Spreeta-based biosensor. 
 
Biosensor Chip Immobilization Methods 
The CM5 sensorchip surfaces are prefunctionalized with a dextrane layer 
that contains free carboxy groups for the formation of amide bonds with 
the molecule immobilized for the assay. Two different CM5 sensor chip 
surfaces were prepared on the bench top. For the BPA inhibition 
immunoassay, BVA was immobilized to the CMD sensor chip surface. For 
the T4 transport protein inhibition assays (rTTR and TBG), T4 was 
immobilized using a spacer (AVA). 
In both cases the CM5 sensorchip surface was activated by directly 
pipetting 100 µl of a mixture of 0.4 M EDC and 0.1 M NHS (1:1; v/v). 
The activated carboxylated dextran surface was washed with water and 
100 µl of the corresponding spacer were added and left to react for 30 
min.  
 
Preparation of the BVA Sensorchip Surface 
Ethylenediamine (2 M solution, pH 10) was used as the bifunctional 
spacer. BVA (2.1 mg/ml in ethanol (35%) and 10 mM sodium acetate 
coupling buffer (pH 4.5) (65%)) was activated by mixing with 0.4 M 
EDC and 0.1 M NHS (2:1:1; v/v/v) and incubated for 30 min with the 
previously derivatized ethylenediamine-sensorchip surface. The 
activated BVA solution on the chip surface was changed every 10 min or 
when a white deposit was observed.  
 
Preparation of the AVA-T4 Sensorchip Surface 
AVA (20 mM in carbonate buffer pH 9.6) was used as bifunctional spacer 
for the immobilization of T4. Once immobilized, the AVA surface was 
washed and its carboxyl groups were re-activated with 100 µl of a 
mixture of 0.4 M EDC and 0.1 M NHS (1:1; v/v) for 30 min. T4 (2 mM in 
carbonate buffer pH 9.6) was incubated for 30 min with the activated 
AVA surface and the amino group present in the alanyl side chain of T4 
created an amide bond with the activated AVA carboxyl group 
immobilizing T4 to the chip surface.  
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Competitive inhibition assays 
The assays were based on the competitive inhibition format in which the 
absence of a compound binding to the biospecific molecule (BSM) (i.e. 
receptor or antibody) results in maximum BSM binding to the 
derivatized sensor chip surface. Increasing concentrations of compounds 
binding to the BSM will compete for binding with the hapten immobilized 
on the sensor surface and the signal will drop proportionately. One 
might ask why the direct detection of the compounds was not evaluated 
where the BSM would be immobilized on the sensor chip surface and the 
binding of the compounds directly measured. Given the small molecular 
mass of the present compounds, the refractive index change produced 
by these compounds binding to the immobilized antibodies would be 
around the detection limit of the present system. In a previous study we 
evaluated the direct assay approach for BPA [19] and it was found that 
although it was possible to measure directly BPA responses using the 
BIACORE 3000 system, the signal was limited and the stability of the 
immobilized BSM was not satisfactory.  
The inhibition assay procedure was as follows, the corresponding 
biospecific molecule at appropriate concentrations were mixed (1:5 v/v) 
with analyte dilution series. The mixture was injected for 1 min at a flow 
rate of 180 µl/min in the biosensor system over the corresponding 
sensor chip surface (BVA for MAb 12 and T4 for TBG and rTTR). In order 
to prepare the chip for the following injection cycle, 180 µl of 
regeneration solution (0.2 M NaOH  20% Acetonitrile) were injected. 
Calibration curves of BPA and T4 were generated with the MAb 12 and 
T4-transport protein inhibition assays respectively. To evaluate the 
reproducibility of the assays, at least two calibration curves were 
measured with each assay in different days, and the IC50 was used to 
calculate the Inter assay CV%. 
 
Results and Discussion 
Sensor System 
In the present system we removed the original gold sensing surface and 
added a RIMP film of about 5 µm thick and a CM5 sensorchip (including 
glass slide). Figure 2 depicts the shift of the SPR dip for distilled water 
with the original gold layer (SPR minimum at pixel 91.86 ± 0.003) and 
after the gold was removed and the RIMP was used in combination with 
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the CM5 sensor chip (SPR minimum at pixel 75.62 ± 0.005). The SPR 
dip shift is due to two reasons. First, the polarized light has to travel a 
longer optical path until it reaches the sensing surface, this shifts the 
position of the sensing surface as well as the position from where the 
light is projected, which finally shifts the pixel where the SPR minimum 
is detected [21]. Second, to the change in RI induced by the 
carboxylmethylated dextrane on the CM5 sensor chip surface. 
 
 
 
Figure 2. SPR profiles in water measured with the original gold sensor surface and the 
modified sensor surface using the RIMP film and a CM5 chip. Each profile is an average of 
3 consecutive measurements. If error bars are not visible, they were smaller than the data 
marker. 
 
Given that a SPR minimum shift of one pixel is equivalent to a 500 μRIU 
change, the shift due to the RIMP film is equivalent to 8120 uRIU, or a 
loss of only 12% of the dynamic range (70.000 μRIU) above the RI of 
water. The expected responses in inhibition immuno- and receptor 
assays are in the order of 10-10.000 µRIU, therefore well within the 
dynamic range left in the sensor.  
The SPR curve is analyzed by the software and the SPR minimum shift is 
expressed as refractive index change (∆RI) and plotted over time. A ∆RI 
of 1x10-6 (1 μRIU) is comparable to about 1 pg/mm2 of proteins bound 
to the chip surface [22] and to one response unit (RU) in the Biacore 
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3000 system. For convenience the RI change in all sensorgrams will be 
expressed in μRIU.  
The optimization of the RI noise is crucial for obtaining maximum 
sensitivity in the system. Hence, we compared the noise (as the 
standard deviation of the RI monitored in one minute) in the bare gold 
sensor surface and the CM5 sensor surface modified with the RIMP film 
and the CM5 chips. Fitting of the SPR profiles with polynomial functions 
from second to ninth order were evaluated for both sensors and the 
noise obtained with both systems was very similar across the 
polynomials functions. The minimum noise (1.1 μRIU) was obtained 
using a 4th order polynomial function at 1.22 Hz acquisition rate with 
both the bare gold sensor surface and the CM5 sensor surface modified 
with the RIMP film. These results indicate that the introduction of the 
RIMP film does not introduce measurable noise at this magnitude and 
that the same polynomial fitting functions used with the bare gold 
sensor can be used with the RIMP film. It should be noted that the noise 
can be further lowered to sub μRIU levels by spectral averaging and 
sum normalization. Both have proven effective ways of further noise 
reduction in Spreeta TM systems [13]. 
Temperature drift was evaluated and, once the system was stabilized 
(30min), it could be operated in the range of 18-22 °C and compensated 
by the software with a minimal baseline drift (5-10 µRIU/100 min). 
Given the inherent sensitivity of SPR biosensors to temperature change, 
a portable device should include strong temperature compensation [23]. 
If otherwise, the assays should be designed to be as fast as possible to 
minimize the effects of baseline drift due to temperature change during 
the measurement. 
 
Fluidic System Optimization 
The pressurized air-driven fluidic system was first tested using the BVA-
derivatized sensor chip by injecting a two-fold dilution series of MAb 12 
(48-6 nM). As shown in Figure 3A, each MAb 12 concentration was 
injected for 1 min (in duplicate) at a flow rate of 180 µl/min and was 
followed by a 1 min injection of regeneration solution (0.2 M NaOH with 
20% ACN). The binding of MAb 12 to the BVA-derivatized sensor surface 
has a linear phase and a non-linear phase repeatable among duplicates 
in each binding cycle. This non-linear phase is due to the dilution of the 
sample plug tail in the dead volume between the sample loop and the 
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flow cell and it does not affect the maximum responses measured after 
each binding cycle.   
The maximum responses obtained decreased linearly with decreasing 
MAb 12 concentrations and the average CV% for all the duplicate 
injections of MAb 12 was 3.9% indicating a robust and repeatable 
sample delivery using the pressurized air-driven fluidic system. The 
pressurized air-driven fluidic system was pulse-free and it could be used 
for up to 4.5 hours without buffer change. 
Given the strong influence that flow cell height has on mass transport in 
surface-based binding assays [24], the fluidic system was first optimized 
with three flow cells of different height and volume and three different 
flows (48, 78 and 180 µl/min) using the BVA-derivatized sensor chip in 
combination with MAb 12 (12 nM). Figure 3B shows the signal to noise 
ratios (S/N R) obtained after 1 min injections of MAb 12. The noise in 
these measurements remained constant within different flow cells and 
flow rates therefore the average was used (1.1 μRIU) for the S/N R 
calculations. The bar graph clearly illustrates the dramatic effect of flow 
cell height on the maximum antibody binding response achievable at a 
fixed time.  
 Applying the small flow cell at a flow rate of 180 µl/min provided the 
maximum signal to noise ratio (S/N R) which decreased geometrically 
with increasing flow cell heights.  In contrast, in the small flow cell, a 
flow rate decrease of 74% resulted in a S/N R reduction of only 37%. 
These results agree in general terms with the mass transport theory for 
continuous flow biosensors which only applies under laminar flow 
regimes. The theory briefly states that; the higher the flow and the 
lower the height of the flow compartment the higher the mass transport 
and therefore the signal obtained. 
Although the small flow cell at 180 µl/min provided the highest S/N R, at 
this flow it also consumed the highest amount of biospecific molecule 
and therefore had the lowest binding efficiency (E (µRIU/fmol) =  
(biospecific molecule bound (µRIU)/biospecific molecule injected 
(fmoles))*100). The binding efficiency of MAb 12 increased from 0.25 
µRIU/fmol at 180 µl/min to 0.6 µRIU/fmol at 48 µl/min.   
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Figure 3. (A) Sensorgrams of duplicate injections of a two-fold dilution series of MAb 12 
over the BVA-sensor chip surface. Each 1 min injection (flow rate of 180 µl/min) was 
followed by a 1 min injection of regeneration solution (0.2 M NaOH with 20% ACN). The 
insert shows a zoomed view of the noise of the sensorgram monitored at 1.22 Hz. (B) 
Signal to noise ratios obtained for 1 min injections of MAb 12 (12 nM) in the Spreeta-
based BPA inhibition assay using flow cells of different heights at three flow rates. 
 
BPA calibration curves were generated at the three mentioned flows 
using the small flow cell to evaluate the effect of the flow on the future 
sensitivity of the assay (data not shown). Decreasing flow rates lowered 
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the sensitivity of the assay (180 µl/min IC50=30.2 nM, 78 µl/min 
IC50=52.7 nM, 48 µl/min, IC50= 496.6 nM). We also observed 
incomplete inhibition at maximum BPA concentrations (1000 nM) in the 
calibration curves obtained at flow rates 78 μl/min and 48 μl/min 
indicating that non specific binding of MAb 12 to the BVA-sensor chip 
surface occurs. Probably, this relatively large flow cell (i.e. compared to 
a Biacore 3000 flow cell of 20µm height) with a geometry which should 
still be optimized, does not allow an efficient sample removal at low flow 
rates. Hence, the small flow cell at a flow rate of 180 μl/min was used 
for all further experiments. However, it should be noted that flow cell 
height can be easily decreased down to 16 µm using soft 
photolithographic techniques in poly (dimethylsiloxane) [25]. If these 
micro fabrication techniques are implemented, considerably higher S/N 
R, binding efficiency and lower flow rates can be achieved consequently 
lowering biospecific molecule consumption.  
Given that short time injections are preferred in portable sensor 
subjected to temperature change to minimize the temp drift within a 
single measurement we chose to make 1 minute injections in all further 
measurements. 
 
Implementation of Competitive Inhibition Assays for Endocrine 
Disruptors 
In the Spreeta prototype, the specific MAb 12-based inhibition assay for 
the estrogenic compound BPA yielded a comparable sensitivity (IC50 = 
30.2 nM) to that previously obtained in the Biacore 3000 (IC50 = 39.9 
nM) (Table 1) [19]. However, due to the larger flow cell in the Spreeta-
based biosensor system, the concentration of MAb 12 required to obtain 
a comparable signal with a 1 min injection had to be increased 5 times.   
TBG and TTR are responsible for the transport of T4 (75 and 20% 
respectively) in human plasma and are potential targets for chemicals 
contaminants affecting the endocrine system. Therefore, they were 
previously used to develop two T4 transport protein inhibition assays for 
bioeffect-related screening of such chemicals in a Biacore 3000 SPR-
based biosensor [11]. In the present study we implemented both T4 
transport protein inhibition assays in the Spreeta-based biosensor (as 
described in section 2.3.1) to compare the system’s performance with 
the Biacore.  
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Table 1. Comparison of sensitivity between assays implemented in the Biacore 3000 and 
the SpreetaTM -based biosensor.  
 
 
* Response of the biospecific molecule at 0 nM of analyte. 
**The concentration of MAb 12 in the Biacore 3000 inhibition assay for BPA was 2.4 nM. 
 
The response obtained after a 1 min injection of TBG (18.2 nM) was 
about 7-fold lower than that obtained in the Biacore 3000. However, the 
overlayed sensorgrams of TBG mixed with increasing concentrations of 
T4 (Figure 4) show a strong inhibition of TBG binding to the AVA-T4 
sensor chip surface and are very repeatable (average CV% for all T4 
concentrations = 0.7%). The calibration curve for T4 with the TBG 
inhibition assay is shown in Figure 5B, the sensitivity (IC50 = 12.3 nM) 
(Table 1.) is slightly lower than the one previously obtained with the 
Biacore 3000 (IC50 = 8.6 nM ). Inter assay CV% was comparable in both 
systems for this inhibition assay. 
The response obtained with the Spreeta-based biosensor system using 
rTTR (18.2 nM) was about 18-fold lower than previously obtained with 
the Biacore 3000. Despite the low response obtained we generated a 
calibration curve for T4 to evaluate the limit of the system with regard 
the minimum response required for an inhibition assay. The calibration 
curve for T4 in Figure 5C clearly shows that the magnitude of the 
response (36 µRIU for 0 nM T4) was still sufficient to generate a 
calibration curve for T4 and a sensitivity comparable to the Biacore 3000 
(Table 2) was obtained. However, the inter assay associated error 
increased significantly (CV = 24%) at these low signals. An increase in 
rTTR concentration (182 nM) greatly increased the signal (455 µRIU) 
with minimum effect on the sensitivity (IC50= 17.6 nM) however at the 
expense of higher rTTR consumption.  
 
Inhibition Assay  Spreeta (180 μl at 180 µl/min)  
Biacore 3000 
(50 μl at 25 
µl/min) 
Biospecific 
Molecule 
 
Analyte  B0 Response ± SD (µRIU)* (n= 3) IC50 (nM)
Inter assay 
CV%  IC50 (nM) 
Inter 
assay 
CV% 
MAb 12 (150 Kd) BPA  546.9 ± 34 (12 nM) 30.2 18  39.9 ** 3 
TBG (54 Kd) T4  108.6 ± 8.8 (18.2 nM) 12.3 9  8.6 8 
rTTR (55 Kd) T4  36.2 ± 3.7 (18.2 nM) 11.6 24  13.7 9 
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Figure 4. Overlayed sensorgrams showing the TBG binding inhibition to the AVA-T4 
sensorchip surface at increasing concentrations of T4.   
 
 
Figure 5. Representative normalized calibration curves obtained with the SpreetaTM-based 
biosensor system for (A) BPA using the MAb 12 inhibition assay (Average relative standard 
deviation (RSD) 1.4%), (B) T4 using the TBG inhibition assay (Average RSD 0.7%) and 
(C) T4 using the rTTR inhibition assay (Average RSD 3%). Each concentration was 
measured at least in duplicate. If error bars are not visible, they were smaller than the 
data marker. 
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The throughput of the system for these inhibition assays was 8 
cycles/hour. Although not currently in the market, the three channel 
Spreeta SPR biosensor under development by Texas Instruments [26] 
seems a very promising tool for further throughput increase or multiple 
analyte detection. 
 
Conclusions 
We have optimized and tested the performance of an automated low-
cost SpreetaTM –based prototype biosensor system in combination with 
commercially available CM5 sensor chips.  
The system was successfully used to setup assays previously used for 
EDCs, an inhibition immunoassay for BPA and two T4 transport protein 
inhibition assays. The sensitivities obtained are comparable to those 
previously obtained with the Biacore 3000, moreover the sensitivity of 
the rTTR and TBG inhibition assays in this system are comparable to 
that of competitive radioligand binding assays [27, 28]. To the best of 
the author’s knowledge, this is the first time that human biospecific 
molecules are successfully combined with a fast, simple and affordable 
SPR biosensor, which is a promising tool for the bioeffect-related 
screening of compounds with endocrine disrupting activity.   
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Abstract 
Fluoroquinolones (FQs) are synthetic antibiotics of broad-spectrum 
antibacterial activity widely used to treat infections in farmed fish, 
turkeys, pigs, calves and poultry. Monitoring these substances residues 
is therefore regulated by law. For the detection of FQs, we studied the 
feasibility of coupling the simultaneous screening of several FQs, using a 
dual surface plasmon resonance (SPR) biosensor immunoassay (BIA), in 
parallel, with an analytical chemical methodology for their identification. 
Six FQs were simultaneously screened at or below their maximum 
residue level (MRL) in chicken muscle using a multi-FQ BIA for 
norfloxacin, ciprofloxacin, enrofloxacin, difloxacin and sarafloxacin, and 
a specific BIA for flumequine. The two BIAs were serially coupled in a 
multi-channel SPR biosensor featuring a dual BIA in a competitive 
inhibition format. The samples noncompliant during the screening with 
the dual BIA were further concentrated and fractionated with gradient 
liquid chromatography (LC). The effluent was splitted towards two 96-
well fraction collectors resulting in two identical 96-well plates. One was 
re-screened with the dual BIA to identify the immunoactive fractions and 
direct the identification efforts toward the relevant fractions in the 
second well-plate with high resolution LC-Electrospray Time-of-Flight 
Mass Spectrometry (ESI-TOF-MS). The system not only allows the 
possibility to screen and identify known FQs, but also to discover 
unknown chemicals of similar structure which show activity in the dual 
BIA. 
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Introduction  
Profitability of livestock is often hampered by infectious diseases, 
therefore the use of veterinary antibacterial drugs is expected for 
treatment and prophylaxis. Fluoroquinolones (FQ) belong to a new 
generation of broad-spectrum antibiotics capable of inducing bacterial 
death by inhibiting DNA gyrase [1]. FQs are active against Gram 
negative and Gram positive bacteria [2] and are widely used to treat 
infections, as prophylactic and growth promoters in farmed fish, turkeys, 
pigs, calves and poultry [3]. Therefore raising public health concerns 
relating to allergic reactions and the generation of antibiotic resistant 
bacterial strains [4, 5]. In consequence, a national veterinary residue 
monitoring plan for these and other groups of substances should be 
established by the EU member countries in accordance to EC Council 
Directive 96/23/EC [6]. Consequently, there is a rising need for rapid, 
robust, multi residue screening assays coupled to identification methods 
for these low molecular weight compounds. Several methods have been 
described for the determination of quinolone residues using liquid 
chromatography (LC) with fluorescence detection [1, 7, 8], with Ultra 
Violet (UV) detection [1, 9, 10] and LC-Mass Spectrometry (MS) [11]. 
Alternative methods like a microbiological assay [12, 13], specific and 
multi-FQ immunoassays have also been reported [14-17]. Within the 
scope of the EU project BioCop (www.biocop.org) several biosensor-
based screening methods are being developed for chemical 
contaminants in food. Our challenge within this project is to evaluate 
strategies for coupling the biosensor screening methods with MS for 
confirmation of identity and/or the identification of unknowns having 
activity in the biosensor assays. In the present study we coupled a dual 
inhibition biosensor immunoassay (BIA) in a multi-channel surface 
plasmon resonance (SPR) biosensor for the screening of FQs in chicken 
muscle samples in parallel with high resolution LC/MS identification. This 
concept was previously evaluated using yeast bioassay-directed 
identification of estrogen and androgen residues in urine [18, 19]. In the 
dual BIA for the FQs, a multi-FQ BIA was developed for the detection of 
norfloxacin (Nor), ciprofloxacin (Cipro), enrofloxacin (Enro), difloxacin 
(Diflo) and sarafloxacin (Sara) was coupled to a specific BIA for 
flumequine (Flu). Samples considered positive during the screening with 
the dual BIA were concentrated with solid phase extraction (SPE) and 
separated with a standard HPLC of which the effluent was splitted 
toward two identical 96-well fraction collectors. The fractions in the 96-
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well plate were re-screened for immunoactivity using the dual BIA, this 
generated an immunoaffity chromatogram or immunogram [20]. In the 
immunogram the immunoactive fractions positions were clearly 
distinguished and this the immunoactive wells positions were used in the 
second 96-well plate for immunoactive oriented identification using high 
resolution HPLC, electrospray ionization (ESI) time-of-flight mass 
spectrometry (TOF MS).  
 
Experimental  
Materials  
Sensor chips (CM5), HBS-EP buffer [pH 7.4, consisting of 10 mM 4-(2-
hydroxyethyl) piperazine-1-ethanesulfonic acid, 150 mM sodium 
chloride, 3 mM EDTA, 0.005% (v/v) surfactant polysorbate (P20)] and 
an amine coupling kit [containing 0.1 M N-hydroxysuccinimide (NHS), 
0.4 M N-ethyl-N'-(3-dimethylaminopropyl) carbodiimide hydrochloride 
(EDC), and 1 M ethanolamine hydrochloride-NaOH (pH 8.5)] were 
supplied by Biacore AB (Uppsala, Sweden). Ethylene diamine (EDA) was 
obtained from VWR International (Amsterdam, The Netherlands). ELISA 
microtitre plates were supplied by Greiner (Frickenhausen, Germany). 
Polyclonal antisera were raised in rabbits against a Flu conjugate (PAb 
MH41) [16] and a Nor-COOH derivative (see Figure 2) conjugated to a 
carrier protein (PAb CA65) [17, 21]. Acetonitrile HPLC far-UV grade was 
from Lab-Scan Ltd. (Dublin, Ireland). Water was purified using a Milli-Q 
gradient A10 system (Millipore, Bedford, MA). Solid Phase Extraction 
(SPE) (20 mg N-vinylpyrrolidone/ divinylbenzene based sorbent) OASIS 
HLB cartridges were from Waters (Milford, MA, USA). The 0.45 μm 
Durapore and 30 kD cutoff Amicon filters were from Millipore 
(Amsterdam, The Netherlands). Cipro and Enro were from Fluka Chemie 
(Zwijndrecht, The Netherlands). Diflo was from Abbott Laboratories 
(North Chicago, Illinois, USA). Sara was from Dr. Ehrenstorfer 
(Augsburg, Germany). Nor, Flu, 5-aminovaleric acid (AVA) and all other 
reagents where obtained from Sigma-Aldrich Chemie BV (Zwijndrecht, 
The Netherlands) unless otherwise stated.  
 
Solutions and samples 
The FQs mixture (FQs mix) was prepared using standards of Nor, Cipro, 
Enro, Diflo, Sara and Flu in methanol (10 mg L-1).  Muscle samples from 
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blank broilers and broilers treated with Enro were obtained from an 
animal experiment performed at the Animal Sciences Group (ASG; 
Lelystad, The Netherlands). The spiked blank chicken muscle samples 
were prepared by adding 100 μl of a FQs mix (1 mg L-1) to 1 g of 
chicken muscle, achieving a level of 100 ng g-1 for each of the FQs 
before extraction. To prepare the incurred chicken muscle samples, 
chickens were dosed with Enro at 30 mg kg-1 total body weight through 
the drinking water for five consecutive days. This resulted in 2700-6800 
μg kg-1 levels, far above the MRL levels, hence the samples were diluted 
with blank chicken samples until a level of 0.5 MRL (50 µg kg-1) was 
reached. The official Dutch committee for ethics on animal experiments 
(DEC) approved these animal experiments.  
 
 
Figure 1. Scheme of the analysis procedure for FQ in chicken muscle samples. (1) 
Screening using a dual BIA (2), separation and fractionation using gradient LC (3) and BIA 
/LC/TOFMS for oriented identification (4). 
 
Equipment 
The experimental system setup (Figure 1) consisted of a dual SPR-based 
inhibition BIA, a gradient LC, an autosampler, a dual 96-well fraction 
collector and a high resolution LC QTOF MS. The BIACORE 3000 was 
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supplied by Biacore AB (Uppsala, Sweden). The gradient LC system 
consisted of two Knauer (Berlin, Germany) model WellChrom K-1001 
pumps, a Knauer high pressure dynamic mixing chamber, a GasTorr 
model 154 membrane degasser,  and an autosampler model Endurance 
from Spark Holland (Emmen, The Netherlands). Liquid chromatography 
was performed using a Waters (Milford, MA) 150 x 3 mm i.d. Symmetry 
column packed with 5 µm C18 material. The column effluent was split 
toward two identical Gilson (Villiers-le-Bel, France) model FC203B 96-
well fraction collectors. Identification was performed using a Waters 
Acquity UPLC system equipped with a 50 x 2.1 mm i.d. column packed 
with 1.7-μm BEH C18 material. The LC column was directly interfaced 
with a Micromass (Manchester, U.K.) model QTOF micro MS system.  
 
Procedures 
Sample Preparation and Solid Phase Extraction 
Chicken muscle samples were extracted by homogenizing 1 g of chicken 
breast tissue with 10 mL of water. The homogenate was centrifuged and 
the supernatant was filtered through a 0.45 μm filter. 2 mL of the 
filtrate were ultrafiltrated with a 30 kD cutoff filter and the filtrate was 
measured with the dual BIA. The chicken extracts were concentrated 
using SPE cartridges, conditioned with 2 mL of methanol, equilibrated 
with 2 mL of water and washed with 2 mL of water/methanol (9.5/0.5). 
After that, 2 mL of a mixture of chicken extract/formic acid (99.8/0.2; 
v/v) were loaded on to the cartridge, the cartridge was washed with 2 
mL of water, dried and eluted with 1 mL of methanol/acetonitrile (8:2; 
v/v). The eluate was evaporated to dryness and resuspended in 250 μl 
of water/formic acid (99.8/0.2; v/v). 
 
Biosensor Chip Preparation and BIAs 
The Biacore 3000 biosensor allows the possibility to immobilize and 
measure in four serially connected flow channels (Fc). Therefore up to 
four different assays can be simultaneously performed. We combined 
two BIAs in a competitive inhibition format, a multi-FQ BIA for the 
detection of five FQ (Nor, Cipro, Enro, Diflo and Sara), and a specific BIA 
for Flu. For the multi-FQ BIA we immobilized a Nor-NH2 derivative (see 
Figure 2) to the carboxymethylated sensor chip surface in Fc2. The Nor-
NH2 derivative was prepared by coupling Nor with ethylenediamine as 
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follows. Oxalyl Chloride (164 µL) was added dropwise to a solution of 
Nor (20 mg mL-1 (15 mL)) in DMF and stirred for 2 h. DMF excess was 
evaporated by reduced pressure, the residue was redisolved in pyridine 
(10 mL) and 200 µL ethylenediamine were added.  
 
 
Figure 2. Structures of the FQs, the Nor-COOH and Nor-NH2 derivatives used in this study 
and of the Nor prodrug. 
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The solution was stirred overnight at room temperature and pyridine 
was evaporated under a stream of nitrogen. The residue was washed 
three times with 10 mL ether. The procedure to immobilize the Nor-NH2 
derivative was as follows. The CM5 sensor chip surface was activated by 
injecting 100 μl of a mixture of 0.4 M EDC and 0.1 M NHS (1:1; v/v) at 
a flow rate of 5 μl min-1, followed by the injection of 40 μl of 0.5 mg ml-1 
Nor-NH2 in borate buffer pH 8.5 at a flow rate of 2 μL min-1. After 
several short injections of 50 mM NaOH, about 2400 RU of Nor-NH2 
remained immobilized. For the specific Flu BIA, we immobilized Flu using 
its carboxylic group with a double spacer consisting of AVA and EDA. 
Briefly, the whole immobilization procedure was performed at a flow rate 
of 5 μL min-1, the sensor chip surface in Fc4 was activated with 
NHS/EDC as previously described followed by a 140 μL injection of 20 
mM AVA in carbonate buffer pH 9.6 and a further EDC/NHS activation 
step followed by a 140 μL injection of EDA, the second bifunctional 
spacer. Finally, Flu was activated by mixing 150 μL of a 0.01 M Flu in 
carbonate buffer pH 9.6 with 0.4 M EDC and 0.1 M NHS (1:1:1; v/v/v) 
and the mixture was injected over the sensor chip surface. The activated 
carboxyl group of Flu formed an amide bond with the free amines 
provided by the EDA spacer on the chip surface and 2200 RU could be 
immobilized. It should be noted that using a single di-amine spacer is 
also a feasible alternative which would lower the amount of 
immobilization steps of Flu. 
The assay is based on the inhibition immunoassay format in which the 
absence of FQ (or other compounds complexing with the antibody) 
results in maximum antibody binding to the derivatized sensor chip 
surface. Increasing concentrations of the cross-reacting FQ will compete 
for antibody binding with the hapten immobilized on the sensor surface 
and the signal will drop proportionately. The assay procedure was as 
follows; sample or standard solutions in HBS-EP buffer and a mixture of 
the antibodies (antiserum PAb CA65 (dilution factor (d.f.) 160) and 
antiserum PAb MH41 (d.f. 50)) were mixed (4/1; v/v) by the Biacore 
3000 and 50 μL were injected over the four Fcs at a flow rate of 25 μL 
min-1. The sensor chip surface was regenerated with 15 μL of 0.2 M 
NaOH/ACN (4/1; v/v). Fc 1 and 3 were left unmodified to monitor the 
non-specific binding of the sample matrix to the carboxymethylated 
dextrane surface, the responses obtained were used as a reference for 
subtraction of Fcs 2 and 4 respectively. The results obtained with the 
dual-BIA are always the mean of at least duplicate measurements 
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except for the screening of the immunoactive well positions where one 
measurement/well is performed. 
 
Instrumentation 
Gradient LC fractionation and splitting 
Liquid chromatography was performed using a mobile phase consisting 
of (A) water/formic acid (99.8/0.2) and (B) acetonitrile. Gradient elution 
was performed at a flow rate of 0.4 mL min-1, starting at 10% B 
isocratically for 18 min and linearly increasing up to 55% B in 7 min, to 
80% B in 5 min, to 10% B in 3 min and finally conditioning isocratically 
for 7 min. The column effluent was split and the fractions were collected 
every 30s (100 μl/well) with two identical 96-well fraction collectors. 
One well-plate was used for FQs immunoactivity detection. These 
fractions were evaporated overnight at room temperature and the 
residues re-dissolved in 100 μl of HBS-EP buffer. Only the immunoactive 
wells in the duplicate well plate were subjected to identification with 
high-resolution LC/TOFMS.   
 
High Resolution LC-TOF MS Identification 
Gradient LC separation was performed using a mobile phase consisting 
of (A) water/formic Acid (99.8/0.2) and (B) acetonitrile. Gradient elution 
was performed at a flow rate of 0.75 mL min-1, starting at 10% B 
isocratically for 2.5 min and linearly increasing up to 40% B in 1.5 min, 
to 80% B in 1 min and decreasing to 10% B in 1 min. The effluent from 
the LC column was splitted 1:1 and interfaced with a QTOF micro MS 
system equipped with a dual electrospray ionization (ESI) probe and 
operated in the positive ion mode at a resolution of 5000 (fwhm), source 
temperature 150 °C, desolvation temperature 400 °C, and a cone 
voltage of 30 V. The second LockSpray ESI probe provided an 
independent flow of the lock mass calibrant consisting of 0.1% 
phosphoric acid in acetonitrile/water (1/1; v/v), at 10 μL min-1. The lock 
calibrant data were acquired at a frequency 0.2 S-1 and using a cone 
voltage of 5 V. Data were acquired in the continuum mode from 100 to 
600 Da with a scan time of 0.44 s and processed using Masslynx v. 4.0 
software. 
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Results and Discussion  
BIAs Performance  
The biosensor chip surfaces in the different Fcs were first evaluated with 
the separate injection of PAb CA65 (d.f. 800) and PAb MH41 (d.f. 250) 
in the biosensor. No binding was observed of PAb CA65 to the Flu 
conjugate (AVA-EDA-FLU) immobilized in Fc4 or of PAb MH41 to the Nor 
conjugate immobilized in Fc2, indicating that the antibodies are specific 
for their respective conjugates. A mixture of the two antibodies injected 
over the 4 Fcs resulted in maximum relative responses of 700 Response 
Units (RU) in Fc2 minus Fc1 and 890 RU in Fc4 minus Fc3 (Figure 3A).  
 
 
Figure 3. BIAs for FQs. (A) Reference-subtracted sensorgrams of a 50 μl injection of PAb 
CA65 (d.f. 250) and PAb MH41 (d.f. 800) at 25 μL min-1 (B) Calibration curves obtained in 
buffer with different FQ with the multi-FQ BIA and (C) with Flu in the specific Flu BIA. 
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Fc1 and Fc3 were left unmodified and were further used for reference 
subtraction of non specific binding (NSB). After regeneration with a 
mixture of 0.2 M NaOH/acetonitrile (4/1; v/v), the responses in both Fcs 
returned to baseline and a new sensorgram could be produced with 
similar binding responses indicating repeatable sensor chip surface 
binding capacities in both Fcs. The assay time including mixing the 
reagents, sample injection and the regeneration of the surface was 8.5 
min per sample.  
The following step to evaluate the dual BIA performance was the 
measurement of the sensitivity, cross-reactivity and matrix effects. 
Injections of a mixture (1:4; v/v) of the antibodies and chicken muscle 
extract (prepared according to section 2.4.1) diluted in HBS-EP buffer 
(up to 50%) showed a NSB of less than 50 RU in the reference Fcs. This 
indicates that for this specific application with low NSB, the two Fcs 
could be omitted and potentially used for the setup of other 
simultaneous BIAs for the detection of additional compounds.Calibration 
curves for the six FQ (for the structures see Figure 2) were prepared in 
buffer (Figure 3B-C) and in a solution containing 50% chicken muscle 
extract and were measured with the dual BIA. Full inhibition of the 
multi-FQ BIA was observed with Nor, Cipro, Enro, Diflo and Sara at 
concentrations in the range of 10-300 μg L-1 in buffer and in chicken 
muscle extract. The specific Flu BIA only showed inhibition with Flu. 
The 50% inhibition concentration (IC50) values and the crossreactivities 
are presented in Table 1 show that the assay was more sensitive toward 
Nor (IC50= 2 µg L-1) in buffer and the affinity ranking for the other 
crossreacting FQs was Nor > Cipro > Enro > Diflo > Sara. This ranking 
is similar to that previously obtained with this antibody in an enzyme 
linked immunosorbent assay (ELISA) [17] except for Enro which showed 
the highest affinity in the ELISA. The assay setup and the immobilization 
of the hapten to the sensor chip surface probably played a role in the 
affinity ranking differences because previous FQ affinity ranking with this 
antibody in a competitive assay format strongly depended on its affinity 
for the tracer-hapten conjugate used in the ELISA [17]. 
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Table 1. Sensitivity and cross-reactivity of the multi-FQ and specific Flu BIAs for six FQ in 
HBS-EP buffer and in chicken muscle extract diluted in HBS-EP (1:1; v/v). 
 
 
n.d. = not detected 
 
As shown in Table 1, the calibration curves in 50% spiked blank chicken 
muscle extract showed higher IC50 values for Nor and Cipro, equal 
values for Enro and lower values for Diflo and Sara therefore changing 
the affinity ranking to Sara > Nor > Enro > Cipro > Diflo. The ratios 
between the IC50 values from the calibration curves in buffer and those 
in chicken extract for the different FQs seem to increase with decreasing 
FQ polarity. One might consider that the differences found in IC50 could 
be a matter of solubility of the FQs and that small soluble proteins 
present in the chicken extract matrix are acting as a surfactant 
improving the solubility of the less polar FQs and therefore improving 
the sensitivity of the multi-FQ BIA toward those compounds. However, 
this explanation does not apply to the specific Flu BIA which showed an 
IC50 value for Flu 40% higher in chicken muscle extract than in buffer. 
Further experiments evaluating different sample dilution buffers might 
solve this issue. No cross-reactivity was found with the other FQs tested 
in the specific Flu BIA.  
Although the initial concentration of the FQs in the chicken muscle 
samples are diluted ten times during the extraction method, the 
sensitivities of these BIAs are well suited for the detection of FQs below 
the MRLs established by the EU for FQs in poultry (100 µg kg-1 for Sara 
(only set for chicken liver and 10 µg/kg for skin and fat) and up to 400 
µg kg-1 for Flu) [22]. The multi-FQ BIA was able to detect Enro in 
chicken muscle samples incurred with Enro at 0.5 MRL (100 µg kg-1, 
 Multi-FQ BIA Specific Flu BIA 
IC50 (μg L-1) Crossreactivity (%) IC50 (μg L-1) Crossreactivity (%)
Compound 
Buffer Extract Buffer Extract Buffer Extract Buffer Extract 
Norfloxacin 2 2.8 100 100 n.d. n.d. n.d. n.d. 
Ciprofloxacin 2.4 3.7 83 79 n.d. n.d. n.d. n.d. 
Enrofloxacin 3.4 3.4 58 85 n.d. n.d. n.d. n.d. 
Difloxacin 10 5.9 20 48 n.d. n.d. n.d. n.d. 
Sarafloxacin 6.6 2.7 30 108 n.d. n.d. n.d. n.d. 
Flumequine n.d. n.d. n.d. n.d. 2.7 3.8 100 100 
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MRL set as the sum of Enro and Cipro) in 50% of the extract and the 
recovery was 82% compared with the LC-MS/MS confirmatory method 
previously used to determine the concentration of Enro in the incurred 
chicken samples [13]. To evaluate the average recovery of the six FQs, 
blank chicken muscle samples were spiked with a FQ mixture (100 ng g-
1 each). The samples were extracted as described above and measured 
with the dual BIA. The concentration was calculated using a calibration 
curve prepared with the six FQs mixture in a solution containing 50% 
chicken muscle extract. The average recovery of the Nor, Enro, Cipro, 
Diflo, Sara, and Flu mixture was 74% in the Multi-FQ BIA and 88% in 
the specific Flu BIA.  
 
BIA-directed identification of FQs 
Reporter gene bioassays in yeast have been used for screening the 
presence of bioactive chemicals like estrogens and androgens [18, 19]. 
These bioassays were used after the screening phase to direct the MS 
identification efforts of known and unknown chemicals showing 
bioactivity. In this bioassay format the starting point is a biospecific 
interaction, a biospecific molecule (i.e. estrogen receptor or androgen 
receptor) present in the genetically modified yeast binds a hormone (i.e. 
estradiol or testosterone) or a similar bioactive compound and following 
a series of interactions of the hormone-receptor complex with 
responsive elements in the yeasts engineered DNA, a reporter gene is 
activated and a fluorescent probe is expressed and measured. 
Likewise, in the present study the starting point is the immuno specific 
interaction between antibodies and antibiotics. The yeast and the 
fluorescent probe were replaced by a SPR-based biosensor system 
where the dual BIA was used for FQ screening and to direct the 
identification efforts of chemicals cross-reacting with the antibodies due 
to structural similarities with the antigen conjugate used to raise the 
antibodies. This approach was evaluated with the chicken muscle 
extracts, previously measured with the dual BIAs (blank, blank spiked 
with the FQ mixture and incurred with Enro at 0.5 MRL). The samples 
were further concentrated using SPE (see 2.4.1), the concentrated 
extracts were fractionated using gradient LC, the effluent of the column 
was splitted in two and the fractions were collected by identical fraction 
collectors in 96-well plates featuring a resolution of 30 s/well. The 
fractions were evaporated overnight at room temperature and the 
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residues redisolved in 100 µL HBS-EP buffer for the immunoactivity 
screening with the dual-BIA.   
 
 
Figure 4. Immunograms of (A) mixture of Nor, Cipro, Enro, Diflo, Sara and Flu standards 
(100 µg L-1 each in buffer). (B) Blank chicken muscle sample, (C) Chicken muscle sample 
incurred with Enro (50 µg kg-1) and (D) Blank chicken muscle sample spiked (before 
extraction) with Nor, Cipro, Enro, Diflo, Sara and Flu (100 µg kg-1 each). The ordinate axis 
represents the percentage of inhibition of the measured wells on the abscissa axis in the 
multi-FQ BIA (white bars) or the specific Flu BIA (filled bars). 
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The second 96-well plate fractions were kept at -20 °C after evaporation 
until the immunoactive fractions were redisolved in water/formic acid for 
chemical identification with high-resolution LC/TOFMS. The bar graph 
shown in Figure 4A is an immunogram of the gradient LC effluent from a 
FQ mixture injection. The peak width in this immunograms is 
determined by several factors, the quality of the gradient LC 
chromatography, the final concentration of the FQ in the well and the 
crossreactivity of the dual BIA toward the specific fractions.  
Immunoactivity is therefore expected in more than one well per FQ, in 
consequence adjacent wells showing high immunoactivity (i.e. belonging 
to the same chromatographic peak) are pooled for the chemical 
identification with high-resolution LC/TOFMS. 
 
 
Figure 5.  BIA-directed identification of a chicken muscle blank sample spiked with a 
mixture of the six FQs standards (100 µg kg-1 each). (A) Base peak intensity (BPI) of a 
mixture of the six FQs standards (100 µg L-1 each Nor, Cipro, Enro, Diflo, Sara and Flu in 
solvent). (B) Overlayed reconstructed ion chromatograms (0.05-Da mass window) 
obtained with high-resolution LC/QTOFMS from pooled immunoactive wells belonging to 
the same chromatographic peak present in the spiked blank chicken muscle sample (see 
Figure 4D) that matched the immunoactive wells positions obtained with the chemical 
standards immunogram (see Figure 4A).  
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The immunogram of the mixture of the six FQ shows four peaks in the 
multi-FQ BIA and one peak in the specific Flu BIA. The accurate mass 
measurement with high-resolution LC/TOFMS and elemental composition 
calculation showed that wells 22 + 23  corresponded to the Nor fraction, 
wells 25 + 26 to Cipro, wells 38 + 39 + 40 to Enro and wells 46 + 47 to 
Diflo and Sara which were coeluting in those fractions. Wells 56 + 57 
were immunoactive only in the specific Flu BIA and corresponded to Flu 
as expected. The base peak intensity (BPI) chromatogram (Figure 5A) of 
the six FQ shows that they could be fully separated in a short analysis 
time (6 min) with high-resolution LC/TOFMS. 
Although the column chemistry of the gradient LC was not identical to 
that of the high-resolution LC, a similar elution order for the FQs was 
found (Figure 5A-B).  
Even though the blank chicken muscle sample was found negative 
during the dual BIA screening phase, the immunograms obtained with 
the blank chicken muscle extract showed two immunoactive peaks 
(Figure 4D). The presence of these peaks could be explained by the 
presence of compounds from the sample extract which cross-reacted in 
the multi-FQ BIA after the SPE concentration and splitting step. These 
sample extracts had a concentration 8-fold higher than in the dual BIA 
screening. The immunogram of the chicken sample incurred with Enro 
(Figure 4C) showed three immunoactive peaks, one of them in 
coincidence with the first peak position found in the blank chicken 
sample, a second immunoactive peak in front and a third immunoactive 
peak corresponding to the position of Enro. Finally, the immunogram of 
the chicken sample spiked with the six FQ showed three unknown 
immunoactive wells matching the other unknown positions (see Table 2 
and Figure 4D) in addition to the same immunoactive well positions 
present in the immunogram of the chemical standards.  
All the immunoactive well positions of the different chicken samples 
were measured in the second 96-well plate with high-resolution 
LC/TOFMS. The peaks of the reconstructed ion chomatograms (0.05 Da 
mass window) obtained from the immunoactive wells with the spiked 
blank chicken sample matching those of the chemical standards (Figure 
5B) showed similar retention times (Rt) and errors in the order of 0.01 
s. These peaks matching those of the chemical standard were 
background subtracted and mass measured with the lock mass provided 
by the second electrospray probe. The accurate masses of the [M + H]+ 
ions were used to calculate the elemental composition and the following 
restrictions were applied: the mass accuracy window was set to ± 5 
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mDa, the ring and double-bond equivalents number (DBE) was set in 
the range of 5.5-20 and the elements were restricted to C0-30, H0-40, N0-5, 
O0-5, F0-3 because no evident isotope pattern originating from chlorine, 
bromine or sulfur atoms was seen beyond the [M+H]+ ion. The accurate 
masses of the [M + H]+ ions of the peaks from Figure 5B were 
320.1416, 332.1404, 360.1725, 386.1283, 400.1423, 262.0876 
corresponding to the elemental compositions C16H19N3O3F, C17H19N3O3F, 
C19H23N3O3F, C20H18N3O3F2, C21H20N3O3F2, C14H13NO3F respectively. These 
elemental composition corresponded with Nor, Cipro, Enro, Diflo, Sara 
and Flu respectively, indicating that it was possible to confirm the 
identity of the known immunoactive compounds in chicken muscle 
samples.  
 
Table 2. BIA-directed identification of immunoactive wells with high resolution 
LC/QTOFMS* of (A) Chemical standard of a Nor, Cipro, Enro, Diflo, Sara and Flu mixture 
(100 µg L-1 each). (B) Blank chicken muscle sample, (C) Chicken muscle sample incurred 
with Enro at 0.5 MRL (50 µg kg-1) and (D) Blank chicken muscle sample spiked with Nor, 
Cipro, Enro, Diflo, Sara, Flu (100 µg kg-1 each). Shaded cells indicate immunoactivity of 
those wells in that specific sample. 
 
Sample Immunno-
active wells A B C D 
[M+H]a 
(m/z) 
Element 
composition DBE 
Error 
(mDa) b 
Compound 
Proposed 
3-5     123.0493 C6H7N2O 4.5 6.4 ± 0 Vitamin B3 
14-16     276.1317 C14H18N3O3 7.5 -3.1 ± 1 Prodrug 
19-20     - - - - - 
22-24     320.1416 C16H19N3O3F 8.5 0.6 ± 0.5 Norfloxacin 
25+26     332.1404 C17H19N3O3F 9.5 0.6 ± 0.6 Ciprofloxacin 
38-40     360.1725 C19H23N3O3F 9.5 2.6 ± 1.4 Enrofloxacin 
46+47     
386.1283 
 
400.1423 
C20H18N3O3F2 
C21H20N3O3F2 
12.5 
12.5 
3.3 ± 0.3 
 
5.0 ± 1.5 
Difloxacin 
Sarafloxacin 
56+57     262.0876 C14H13NO3F 8.5 1.5 ± 0.9 Flumequine 
 
a Restrictions used for elemental composition calculation; Mass accuracy window ± 5 mDa 
(except for m/z 123.0493 where 7 mDa was used), ring and double-bond equivalents 
number (DBE) range 0.5-20, elements C5-30, H5-40, N(0 or 1)-3, O0-5, F0-3.  
b Average of the absolute error ± SD of all the immunoactive fractions were the specific 
mass was present. 
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The unknown compounds in the immunoactive wells from the chicken 
muscle extracts eluting before Nor during the fractionation should also 
have shorter retention times (Rts) than Nor in the high-resolution 
LC/TOFMS. Hence, the mass spectra of the time window between 0 and 
0.98 min (before the RT for Nor) were combined, the adjacent time 
window (1-2 min) was used for substraction. The mass spectra obtained 
were compared between similar well positions showing immunoactivity 
in the different sample immunograms looking for coincident high 
intensity [M + H]+ ions which might be responsible for immunoactivity. 
The elemental composition search of the [M + H]+ ions was restricted 
considering the common piperazinyl moiety and oxoquinoline core 
structure of the Nor conjugate used as antigen for raising PAb CA65 and 
the FQs cross-reacting in the multi-FQ BIA (Figure 2). We considered 
that the structure of any chemical showing immunoactivity in the Nor 
BIA immunograms should at least contain one ring structure with at 
least 5 carbon atoms. The number of nitrogen atoms was always 
restricted by the maximum number present in crossreacting FQs (N=3) 
and the nitrogen rule was applied. The proposed elemental compositions 
were used for formula search in SciFinder and the number of hits was 
refined to compounds with calculated Log P values below that of Nor. 
The main [M + H]+ ion found in the mass spectra from the 
immunoactive wells 3-5 after background subtraction had an accurate 
mass of 123.0494. The reconstructed ion chromatogram (0.05 Da mass 
window) showed that this ion had a peak Rt of 0.25.  
The element composition search was performed with a 7 mDa mass 
tolerance restriction because at lower m/z, a lower accuracy is expected 
in the TOF MS system. The double bond equivalent (DBE) number was 
set in the range of 0.5 to 20 and the elements were restricted to C5-10, 
H5-40, N0-3, O0-5, F0-3. Four chemical formulas were obtained for this ion, 
however only two of them yielded matches in SciFinder after the 
restrictions described above were applied. The chemical formulas were 
C7H6O2 and C6H6N2O with mass errors of 4.8 and -6.4 mDa respectively. 
The search of the C7H6O2 yielded 123 matches of which only 13 
contained an aromatic ring as part of the structure and 3 where 
benzaldehydes with references to biological activity like antibacterial 
agents or insecticides. However, no resemblance of these structures 
with any part of the crossreacting FQs was found.  
The search of the chemical formula C6H6N2O in SciFinder yielded 229 
compounds, no partial homology of the piperazinyl moiety was found 
with any these compounds. Therefore, a further search was performed 
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looking for homology with the oxoquinoline core by restricting the 
formula search only to heterocyclic aromatic compounds containing at 
least one nitrogen in the ring structure. This yielded 30 matches of 
which only 20 are commercially available including several pyridine 
derivatives, the most notorious one was nicotinamide (Niacin, vitamin 
B3), a compound commonly found in chicken muscle [23].  
The immunoactive wells 14-16 in the different samples showed one 
main [M + H]+ ion in common with a mass of 276.1317 and a peak Rt of 
0.73 min in the reconstructed ion chromatograms (0.05 Da mass 
window). The elemental composition search was restricted to a 5 mDa 
mass error tolerance, the DBE number range was set to 0.5-20, the 
compounds and the elements were restricted to C5-30, H5-40, N1-3, O1-5, 
F0-3. Four element composition possibilities were obtained C15H16N3F2, 
C11H19N3O4F, C12H17N3OF3 and C14H18N3O3 with mass errors 0.5, -4.3, -
0.7 and -3.1 mDa respectively. Database search with SciFinder yielded 
no hits for C15H16N3F2 after the search was refined as described above 
and the search of C11H19N3O4F yielded 5 very saturated ring structures 
without any partial homology with the FQs. 
The search for C12H17N3OF3 yielded 12 compounds after the LogP 
restriction, none with an homology to the piperazinyl or oxoquinoline 
group. About 9 compounds were obtained with the formula C14H18N3O3 
in the SciFinder database, these compound structures fulfilled the 
piperazinyl homology restrictions imposed using the rationale described 
above. From these compounds, only 2 had biological references but 
none was related to antibacterial activity. However, when the search for 
this formula was restricted to substructure homology with the 
oxoquinoline group present in all the FQs, 8 matches were obtained with 
high structural similarity to the FQs core structure. Four of these 
compounds had references to antimicrobial activity and one of them as a 
prodrug of norfloxacin and nalixidic acid [24] (see Figure 2).  Ordering 
or synthesizing the compounds suspected for immunoactivity and 
further testing in the system in addition to MS/MS experiments of the 
standards and the chicken sample extracts might confirm the presence 
of these compounds in chicken muscle in the near future. 
The immunoactive wells 19 + 20 (see table 2) did not show any high 
abundance [M + H]+ ions in common. It is therefore possible that this 
specific compound was not detected with the TOF MS because it did not 
ionize in the electrospray in positive mode. 
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Conclusions 
A fast dual BIA screening method for FQ was coupled in parallel with 
high resolution LC/QTOF MS identification of known and unknown 
compounds in noncompliant chicken muscle samples. A simple sample 
preparation of the chicken muscle samples was necessary prior to the 
dual BIA screening which was very sensitive allowing the detection of 
the FQs below MRL levels and therefore saving time during the 
screening process of known compounds. However, it was shown that the 
measurement of concentrated muscle samples with the dual BIA 
resulted in three unknown immunoactive peaks, showing the potential 
applicability of the system for finding unknown structurally related 
compounds. Further work will focus in testing the best candidate 
compounds with the Dual-BIA and with the high resolution LC-TOF MS 
system for the elucidation of the unknown immunoactive compounds 
origin present in these samples.  
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Abstract 
The on-line nanoscale coupling of a surface plasmon resonance (SPR)-
based inhibition biosensor immunoassay (iBIA) for the screening of low 
molecular weight molecules with nano-liquid-chromatography 
electrospray ionization time-of-flight mass spectrometry (nano-LC ESI 
TOF MS) for identification is described. The interface is based on a 
reusable recovery chip (RC) that contains a nanoscale biosorbent 
composed of a hydrogel layer modified with antibodies raised against 
the analyte featuring the unique possibility of performance 
characterization using the SPR biosensor. Various hydrogel chemistries 
were evaluated, and the standard Biacore CM5 chip showed the highest 
capture capacity in combination with affinity-purified polyclonal 
antibodies. The procedure has four stages: the samples are prepared (1) 
and screened using a screening chip (SC) in the iBIA (2). Suspected 
noncompliant samples are reinjected over the RC, and the analyte is 
captured at subnanogram level (3). The captured analyte is released, 
and the eluate is analyzed with nano-LC ESI TOF MS via a loop-type 
interface (4). The coupling of the technologies proved effective for 
screening enrofloxacin, a model compound, in incurred chicken muscle 
samples followed by identity confirmation in suspected noncompliant 
samples. Ciprofloxacin, a known metabolite of enrofloxacin, was 
identified as well in incurred chicken samples. This demonstrates the 
potential of the technologies coupled by means of a RC for the rapid 
screening and identification of known as well as unknown compounds. 
Finally, we demonstrate the feasibility of combining the two biosensor 
chips (SC and RC) with a robust chip-based nano-LC chip TOF MS 
system, thus providing a robust alternative triple-chip system. 
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Introduction  
A wide variety of surface plasmon resonance (SPR)-based biosensor 
applications have been reported during the last decade [1, 2].  These 
applications exploit biorecognition events of (at least) two binding 
partners that interact at the sensor chip surface where one of them is 
immobilized. The binding of the partners increases the total mass and 
the density of the molecules at the chip surface, hence resulting in a 
local refractive index change that is proportional to the SPR biosensor 
signal output. A major advantage is that the interaction can be 
monitored in real time allowing the determination of the kinetic 
parameters. The concentrations of interacting biomolecules can be 
quantitatively estimated either by the direct binding of the analyte to 
the chip surface (direct binding assay (DBA)), or by constructing an 
inhibition (competitive binding) assay.  Since the signal output depends 
directly on the mass of the interacting analyte, the DBA format is widely 
used for fishing high molecular weight biomolecules out of complex 
biological matrices. Nevertheless, with the proper experimental 
forethought, this approach has also proven effective for the 
determination of kinetic parameters of low molecular weight molecules 
binding to antibodies or receptors [2, 3]. Such antibody-based DBAs 
were developed for the direct detection of low molecular weight drug 
residues (aminoglycosides with molecular weights of 466 and 583 Da) in 
milk of dairy cows [4, 5]. However, for low molecular weight compounds 
the inhibition assay format is generally preferred in biosensor 
immunoassays (BIAs) because of its flexibility, higher response and 
robustness [4, 6]. In this format, the sample (containing the analyte/s) 
is mixed with the high molecular weight affinity biomolecule (i.e., 
antibody, receptor, etc) and injected over the chip surface previously 
coated with the analyte. The signal drop due to the inhibition of the 
binding of the biomolecule to the immobilized analyte on the chip 
surface will be proportional to the analyte concentration in the sample. 
The robustness of such a low molecular weight compound coated chip 
has been proven with a sulfamethazine derivative coated chip which was 
used for approximately 1100 cycles and no significant change in 
performance was observed [6]. 
The main drawback of the biosensor screening technology is the lack of 
information about the identity of the interacting analyte. Hence, its 
combination with mass spectrometry is a powerful approach that already 
yielded a number of successful attempts in the field of proteomics [7, 8], 
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where the presence of proteins retained during the direct assay 
interaction analysis can be unambiguously confirmed by coupling the 
SPR biosensor with matrix-assisted laser desorption ionization time-of-
flight mass spectrometry (MALDI-TOF MS) [9]. The SPR-MALDI-TOF MS 
analysis has evolved from the direct measurement of the interacting 
biomolecules from the chip surface (yielding the chip unusable after one 
binding cycle) to the further deposition of the biomolecules on MALDI 
plates for analysis upon elution [10, 11] to a small volume elution using 
automated commands [12-14] and lately to a bifunctional SPR/MS flow 
cell with removable MS probes [15]. Alternatively to MALDI-TOF MS 
analysis, the analysis of the chip eluate using liquid chromatography 
electrospray ionization MS (LC-ESI-MS) has been reported [16, 17]. 
Although these interfacing concepts have proven well suited for the 
identification of high molecular weight molecules in conjunction with 
DBAs, they are not functional for the screening of compounds of low 
molecular weight. 
Within the scope of the EU project BioCop (www.biocop.org), several 
inhibition biosensor immunoassays (iBIAs) are being developed as 
screening methods for chemical contaminants in food. Our challenge 
within this project is to couple the iBIA with MS for confirmation of 
identity and/or the identification of unknowns having activity in the 
iBIAs. We have recently reported a method for the parallel coupling of 
these technologies using a dual wellplate LC fractionator [18]. In the 
present study we demonstrate the proof of principle, using enrofloxacin 
(Enro) as the model analyte, for the serial coupling concept between the 
iBIA and nano-LC-ESI-TOF MS. Enro is an antibiotic widely used in cattle 
and poultry that should be monitored and is regulated in accordance to 
EC Council Directive 96/23/EC [19]. The proposed system is composed 
of the Biacore 3000 SPR biosensor that carries out the screening using a 
robust iBIA. When a suspected noncompliant sample is found, the 
system stops the screening procedure and an aliquot of the sample 
without antibody is reinjected into the accessory surface preparation 
unit (SPU) that accommodates a recovery chip (RC) containing anti-Enro 
antibodies. This RC contains a 100-200 nm thick porous polymer 
(hydrogel) layer modified with antibodies. The antibodies in the 
biosorbent specifically capture the analyte while the sample matrix flows 
through. The chip surface is washed and next, the captured analytes are 
eluted into a loop from where they enter the nano-LC system and routed 
toward a precolumn followed by an analytical column and finally 
electrosprayed in the TOF MS for mass analysis. Both an iBIA and a DBA 
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were developed for Enro (the latter for RC characterization). The 
hyphenated system was tested with standard solutions and with chicken 
muscle extracts in a regulatory-relevant concentration range. The 
detection of unknown compounds was addressed along with the viability 
of using high-capacity RC surfaces. Finally, a more robust chip-nano LC 
TOF MS alternative to the standard nano-LC Chip TOF MS set up was 
briefly studied in combination with the SC and RC to create a triple-chip 
approach. 
 
Experimental Section 
Chemicals and Materials  
Sensor chips (CM5), HBS-EP buffer [pH 7.4, consisting of 10 mM 4-(2-
hydroxyethyl) piperazine-1-ethanesulfonic acid, 150 mM sodium 
chloride, 3 mM EDTA, 0.005% (v/v) surfactant polysorbate (P20)], an 
amine coupling kit [containing 0.1M N-hydroxysuccinimide (NHS), 0.4 M 
N-ethyl-N-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), 
and 1 M ethanolamine hydrochloride NaOH (pH 8.5)], CNBr-activated 
Sepharose™ 4B and the SPR-based biosensor systems Biacore 3000 and 
Q,  the SPU accessory as well as the AKTA purifier and HI Trap protein G 
columns (1 mL) were supplied by GE Healthcare (Uppsala, Sweden). 
Sensor chips featuring other hydrogel chemistries were purchased from 
XanTec bioanalytics GmbH (Muenster, Germany). Ethylene diamine 
(EDA) was obtained from VWR International (Amsterdam, The 
Netherlands). Acetonitrile (ACN) HPLC far-UV grade was from Lab-Scan 
Ltd. (Dublin, Ireland). Water was purified using a Milli-Q gradient A10 
system (Millipore, Bedford, MA). The 0.45 μm Durapore filters and the 
30 kDa and 50 kDa Amicon cutoff filters were from Millipore. 
Ciprofloxacin (Cipro) and enrofloxacin (Enro) were from Fluka 
(Zwijndrecht, The Netherlands). All other reagents were obtained from 
Sigma–Aldrich (Zwijndrecht, The Netherlands) unless otherwise stated. 
The AKTA purifier and HiTrap protein G columns (1 mL) where provided 
by Amersham Biosciences (Uppsala, Sweden). Mouse anti-Enro/Cipro 
monoclonal IgM antibody (clone 72FIG1F7#1) (MAb72F) was obtained 
from Abcam (Cambridge, U.K.). The preparation and purification of the 
polyclonal antiserum (PAb MH40) is described in the Supporting 
Information at the end of this chapter.  
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Equipment 
The system (Figure 1) consists of the Biacore 3000 SPR biosensor 
containing both a CM5 chip coated with Enro for the iBIA screening 
(inset 2) and a SPU accessory containing the RC, a CM5 chip coated with 
antibodies, for analyte capture (inset 3). The flow cell carrier type 2 
(FCT2) on top of the RC features a serpentine-like flow cell (area 16 
mm2, height of 50 μm and volume of 800 nL). The SPU is connected to a 
10 μL loop-type interface with a Micro Tight® tubing sleeve (i.d. 535 
μm) and PeekTM tubing (i.d. 255 μm, 510 μm o.d., 9.6 cm). The inlet of 
the loop interface is connected to the Waters (Milford, MA) model 
Acquity UPLC pump.  The outlet of the loop-type interface is connected 
to the tee of a nano-LC switching system adapted from Meiring et al. 
[20] using 1/16 in. connections having short (0.02 in. i.d.) PeekTM 
sleeves and fused silica capillary tubing (360 μm o.d., 200 μm i.d., 60 
cm). The flow is split (1/2000), with this switching system, between 
the restrictor (360 μm o.d., 50 μm i.d., 50 cm) and the trapping column 
(Biosphere C18 120 Å 5μm 50 μm i.d., 360 μm o.d., 2 cm length) 
between the first and the second tee. Following the second tee, the 
analytical column (Biosphere C18 120 Å 3 μm 50 μm i.d., 360 μm o.d., 
20 cm) is directly butt-connected with the Nanoease emitter (Waters) 
through the universal NanoFlow™ Sprayer mounted on the Waters 
model QTOF-micro MS system. The nano-LC gradient separation was 
performed using a mobile phase consisting of (A) water/formic acid  
(99.8:0.2; v/v) and (B) ACN/water/formic acid  (89.8:10:0.2; v/v/v). 
Sample loading through the trapping column is performed at 10 μL min-1 
for 5 min with 100% solvent A.  Upon valve switch, the precolumn split 
is activated and the restrictor back pressure allows a flow in the order of 
300 nL min-1 through the analytical column. Details concerning nano-LC 
columns, capillaries, connectors, valves, solvent composition- and flow 
gradient and the MS settings can be found in the Supporting 
Information.  
The feasibility of the triple chip approach was carried out using the 
nano-LC chip TOF MS system of Agilent Technologies (Waldbronn, 
Germany) previously described elsewhere [21]. The chip trapping 
column had a volume of 40 nL and was packed with Zorbax 300SB C18 
5 m particles. The nano-LC chip column had a 75 x 50 m cross 
section, length of 43 mm and was packed with Zorbax 300SB C18 3.5 
m. Mobile phases were similar to those used with the capillary nano-LC 
TOF MS system described above. The electrospray voltage was set to 
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2400 V at the MS inlet capillary. Nitrogen drying gas at 350 °C and 4 L 
min-1 was used for spray desolvation.  
 
 
Figure 1. System setup overview with exploded view of key components. Muscle extracts 
(inset 1) are screened in the SPR Biosensor with the Enro iBIA using the screening chip 
(SC) (inset 2). The analytical efforts are focused only on the suspected noncompliant 
samples that are re-injected as they are detected over a recovery chip (RC) with 
immobilized antibodies (inset 3). Enro is captured on the RC surface and eluted into a 
loop-type interface (inset 4). The first valve is switched to the high-pressure side and the 
analyte is transferred from the loop-type interface to the trapping column. Once the 
analyte is trapped, the second valve is switched and the nano-LC gradient is started. 
Dashed frames in insets 2 and 3 depict the mirror-image immunochemistry nature 
between the SC and RC. 
 
Screening Chip Preparation and iBIA Procedure 
Enro was immobilized via its carboxyl group to the carboxymethylated 
chip surface using EDA as a bifunctional spacer. The SC surface was 
preconditioned by consecutive duplicate injections of 10 μL of HCl (10 
mM), NaOH (50 mM), sodium dodecyl sulfate (0.1% w/v) and water at 
100 μL min-1 in one flow channel (Fc2) of the Integrated µ-fluidic 
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cartridge (IFC) in the biosensor. Then,  the surface was activated with 
150 μL of a mixture of 0.4 M EDC and 0.1 M NHS (1:1; v/v) and then 
coated with 100 μL of 2 M EDA in water (pH 10), both at 10 μL min-1. 
Then, all remaining activated groups were blocked with 100 μL of EA (1 
M). The SC surface and the IFC were cleaned by two injections of 10 μL 
of a mixture of 0.2 M NaOH, ACN and water (1:1:3; v/v/v) using the 
“Wash needle” and “Wash IFC” wizards in the biosensor software.  
Meanwhile, the carboxyl group of Enro was activated by adding 10 μL of 
an Enro solution (10 mg mL-1 in methanol) to one vial containing 115 μL 
of 0.4 M EDC and to another vial containing 115 μL of 0.1 M NHS. Both 
freshly prepared vials were mixed (1:1; v/v) in the biosensor before the 
injection of 150 μL at 2 μL min-1 over the EDA-modified SC surface. 
Finally, the SC was washed with 0.05 M NaOH and HBS-EP. 
For the iBIA procedure, the sample extracts or standard solutions in 
HBS-EP buffer were mixed (4:1; v/v) with the antibodies (diluted 
antiserum PAb MH40 or its purified IgG fraction (SpMH40)) in the 
biosensor and 50 μL was injected at a flow rate of 25 μL min-1. The SC 
surface was regenerated with 15 μL of a mixture of 0.2 M NaOH and 
ACN (4:1; v/v).   
 
Recovery Chip Preparation  
Antibodies (SpMH40 or MAb72F) were immobilized onto the entire 
carboxymethylated surfaces of the sensor chips (Biacore CM5 or XanTec 
chips assembled in Biacore frames as described by the manufacturer). 
Preconditioning was the first step and the second step involved the 
activation of the sensor chip surface and the immobilization of the 
antibodies. For the preconditioning step, 100 μL aliquots of the 
preconditioning solutions (HCl (10 mM), NaOH (50 mM), and sodium 
dodecyl sulfate (0.1% v/v)) were successivelly pipetted over the chip 
surface. The chip surface was thoroughly rinsed with distilled water and 
activated with 100 μL of a mixture of 0.4 M EDC and 0.1 M NHS (1:1; 
v/v) for 20 min. Finally, SpMH40 antibody was diluted (1:10; v/v) in 
acetate buffer (pH 5) and 100 μL was placed onto the activated chip 
surfaces, left to react for 90 min, and the remaining active groups where 
deactivated by pipetting 100 μL of 1 M EA. The immobilization levels 
were evaluated by measuring the relative responses of the chips in the 
biosensor before and after immobilization. The characteristics of the 
sensor chip hydrogel chemistries used for preparing the RCs (Table 2) 
are presented in Table 1.  
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Table 1. Evaluation of screening chips with different hydrogel properties in the inhibition 
SPR biosensor immunoassay (iBIA) for Enro .  
 
 
a Carboxymethylated dextran chip from Biacore 
b Carboxymethylated dextran chip from XanTec 
c Linear carboxylated hydrogel matrix from XanTec 
 
Samples and Standards  
Muscle samples from untreated broilers and broilers treated with Enro 
were obtained from an animal experiment that is described elsewhere 
[22]. The chicken breast samples (1 g) were extracted by homogenizing 
with 10 mL of water. The homogenate was centrifuged and the 
supernatant was filtered through a 0.45 μm filter. Two milliliters of the 
filtrate were passed through a 30 kDa cutoff filter and diluted (1:1; v/v) 
in HBS-EP buffer for further experiments. Enro and Cipro standard 
solutions were prepared by dissolving 10 mg in 10 mL of a mixture of 
methanol and formic acid (99.9:0.1; v/v) and subsequently diluted with 
HBS-EP buffer to relevant concentrations.  
 
Results and Discussion 
Screening Chip Performance 
Different screening chips (SCs) were prepared by immobilizing Enro on 
sensor chips having different hydrogel properties (see Table 1). The 
amount of immobilized Enro is proportional to the increase in response 
units (RU) measured on the different chip surfaces and these varied 
from 300 RU in SC B to 1400 RU in SC F. To assess the maximum 
Inhibition BIA 
Chip Hydrogel  
Immobilized Bound Sensititvity 
Code Lenght (nm) Chain density Enro (RU) PAb MH40 (RU) IC50 (pg μL-1) 
A a 100 - 200 Low 600 11700 7.1 
Bb 150 High 300 3800 4.8 
Cb 200 Low 800 10000 5.3 
Db 200 High 700 4000 3.3 
Ec 500 High 400 6400 5.5 
Fc 1000 Medium 1400 6700 6.6 
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binding capacity of the Enro-modified chips, high amounts of antibodies 
(raw antiserum PAb MH40 diluted in HBS-EP buffer (1:10; v/v)) were 
injected (50 L at 25 μL min-1) over each chip, and the maximum 
response varied from 3800 RU for SC B to 11700 RU for chip A. After 
regeneration with a mixture of 0.2 M NaOH and ACN (4:1; v/v), the 
responses returned to baseline and a new sensorgram could be 
produced with similar binding responses.  
 
  
Figure 2.  (A) Calibration curve of Enro in the iBIA with SC A (see Table 1 and the 
Screening Chip Performance section). (B and C) Evaluation of the direct binding of Enro to 
SpMH40 immobilized on the RC A (see Table 2 and the Recovery Chip Performance 
section). (B) Overlaid sensorgrams of complete ligand/wash/regeneration cycles obtained 
in the direct binding assay (DBA) format  measured with the Biacore Q. (C) Blank-
subtracted (i.e., dashed line in B subtracted from the Enro sensorgrams) sensorgrams of 
duplicate injections of Enro at various concentrations to evaluate the maximum capacity 
and saturation time of RC A. 
 
A calibration curve for Enro was measured for each chip (data not 
shown) as described in the iBIA procedure using diluted raw antiserum 
PAb MH40 (1:40; v/v). More than 2-fold difference in sensitivity (defined 
as the concentration at 50% inhibition (IC50)) was observed between SC 
A (IC50 = 7.1 pg μL-1) and SC D (IC50 = 3.3 pg μL-1). However, the high 
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maximum response obtained for the blank (B0 = 1950 RU) with SC A 
allowed a further 3-fold PAb MH40 antiserum dilution with a concomitant 
maximum response decrease for the blank (670 RU) and a 2-fold 
increase in sensitivity (IC50 = 3.7 pg μL-1). The measurement of a 
calibration curve (see Figure 2 A) using the purified antiserum fraction 
(SpMH40) (1:50; v/v) in SC A resulted in an additional increase in 
sensitivity (Enro IC50 = 2.2 pg μl-1) with a robust maximum response of 
750 RU. All further iBIA experiments were performed using SpMH40 in 
combination with SC A. The sensitivity of the iBIA for Cipro, a known 
Enro metabolite, was lower (IC50 = 85.4 pg μL-1), and the cross-
reactivity (CR) was 3%. The iBIA assay time, including mixing the 
reagents, sample injection, the regeneration of the surface and washing 
steps, was 8.5 min per sample. 
 
Development of the Recovery Chip Procedure 
The Biacore 3000 software was modified by GE Healthcare to allow the 
development of a method for the injection of suspected noncompliant 
samples over the RC mounted in the SPU, followed by washing steps 
and analyte forward-elution. The procedure for the recovery of the 
analyte from samples suspected as being noncompliants in the iBIA 
started with the injection of 40 µL of sample without antibody over the 
RC at 10 µL min-1. The RC was washed for 2 min with water, then 10 µL 
of formic acid (1%) were injected to disrupt the interaction of the 
analyte with the biosorbent followed by the injection of a transfer 
volume (water) to position the eluate in the loop-type interface leading 
toward the nano-LC TOF MS. In order to reduce carryover issues, two 
washing steps were added in the RC controlling software after the 
elution step. The first one was the elution solvent (i.e., formic acid 1%) 
and the second one was water to condition the antibodies for the next 
recovery cycle. 
The transfer volume required to position the 10 μL RC eluate plug from 
the SPU into the loop-type interface was optimized using a glass chip 
(instead of a functionalized RC) that was fitted in the SPU and connected 
to the loop-type interface and the nano-LC TOF MS system. Injections of 
10 μL of a standard solution of Enro (100 pg μL-1) in 1% formic acid 
were followed by increasing transfer volumes. A transfer volume of 13 
μL showed that the area counts of the Enro peak in the chromatogram 
matched the area counts of an injection of Enro from the nano-LC TOF 
MS autosampler. With the same procedure, a calibration curve injected 
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from the SPU and the loop-type interface was constructed by measuring 
increasing concentrations of  Enro standards (0- 500 pg) with the nano-
LC TOF MS system.  The Enro calibration curve was used for all further 
estimations of the RC capacity. 
 
Recovery Chip Performance 
If compared with traditional affinity extraction columns, the RC concept 
features the unique advantage of being able to characterize the affinity 
sorbent using the SPR biosensor. Using the DBA format we can study 
the performance of the RC in detail and obtain useful information to 
select the biomolecule best suited for each application. Robust 
biomolecules, with high affinity, low dissociation rate, and an interaction 
with the analyte that can be disrupted with MS-compatible buffer, are 
desired. The optimal density of immobilized biomolecules, capacity, 
affinity constants and saturation time can also be evaluated. 
Additionally, the non-specific binding of matrix components to the RC 
and the wash and elution steps can be scouted without compromising 
the nano-LC TOF MS system. As a model, the interaction between Enro 
and the antibodies (SpMH40) immobilized in RC A (see Table 2) was 
evaluated using a Biacore Q SPR biosensor. This biosensor features a 
flow cell height of 50 µm, comparable to the FCT2 flow cell used with the 
RC in the SPU.  Figure 2B depicts the representative sensorgrams 
obtained with the injection of 40 μL of (100 pg μL-1) Enro standard 
solution. The bulk response jump upon injection caused by the blank 
and the Enro standard solution are due to the lack of a reference 
channel in the Biacore Q for subtraction. The maximum response of Enro 
binding to the immobilized antibodies was 16 RU as observed from the 
difference between the Enro and the blank buffer injection. The Enro 
response decays when the dissociation of the lower strength interactions 
occurs after the injection ends. About 12 RU of Enro remain captured on 
the RC A surface after the dissociation and the 1 min washing step. The 
interaction can be disrupted for elution purposes using a 1 min injection 
of MS compatible solvent (formic acid 1%, pH 2). The response returns 
close to its baseline values with a loss of <20 RU (<0.1%) of 
immobilized SpMH40 after each cycle. Figure 2C depicts sensorgrams of 
duplicate injections of standards solutions with increasing concentration 
of Enro after the subtraction of sensorgrams of blank injections (at least 
one for each concentration). The SpMH40-based biosorbent in RC A 
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showed to be robust and preserved its binding properties for more than 
50 cycles under these wash-elution conditions.  
In Biacore SPR measurements an equivalence of 1 RU to 1 pg mm-2 is 
assumed for proteins [23]. Hence, the 19000 RU of SpMH40 immobilized 
in RC A are roughly equivalent to 2 pmol on the complete surface of 16 
mm2. 
 
Table 2. Evaluation of chips with different hydrogel properties for the production of Enro 
recovery chips. a 
 
DBA Biosensor Nano-LC TOF MS  
Chip 
Immobilized Captured Captured 
Code Antibody (RU) a Enro  (RU) Enro (pg mm-2) 
A  19600 12 31 
A1 18900 0 3 
B 16400 10 - 
D 4800 4 - 
E 8200 0 13 
F 9200 9 14 
 
a The chips having a surface of 16 mm2 were evaluated using both the direct binding assay 
format in the SPR biosensor and the nano-LC TOF MS system.  
b PAb SpMH40 immobilized except in chip A1 where monoclonal antibody (MAb72F) was 
immobilized. 
- not measured  
 
The maximum theoretical response of a ligand (RUL MaxPred) binding to 
immobilized macromolecules (RUM, response of the macromolecule 
immobilized) is predicted for proteins using: RULMaxPred = 
RUMn(MwL/MwM). With n being the number of binding sites in the 
macromolecule (2 for antibodies), MwL being the molecular weight of the 
ligand (359 Da for Enro), and MwM being the molecular weight of the 
macromolecule (150 kDa for antibodies). Hence, given the 
immobilization level of SpMH40 in RC A (see Table 2), one would expect 
to measure a response of about 90 RU upon saturation of all binding 
sites with Enro (4 pmol on the 16 mm2). Nevertheless, Figure 2, parts B 
and C, show that about 16 RU of Enro are bound and 12 RU remain 
captured after the washing step. Nano-LC TOF MS measurements of 
Enro actually eluted from RC A  (Table 2 and Figure 3) revealed that the 
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maximum Enro capture capacity of the chip after dissociation and wash 
step is approximately 500 pg (1.4 pmol of Enro), which is 34% of the 
theoretical maximum. This lower capacity is partly due to the 
nonspecific immobilization method used, that renders many binding 
sites inactive because it couples primary amines (N-terminal and 
possibly lysine groups) of the macromolecule with the dextran surface 
[24]. The actual maximum capacity of the RC as measured with nano-LC 
TOF MS is approximately 500 pg (30 RU), higher than the 190 pg (12 
RU) expected from the SPR measurement. This underestimation of the 
maximum capacity arise possibly from two erroneous presumptions. The 
first is the correlation of RU = 1 pg mm-2. This correlation cannot be 
applied to small molecules because the SPR response depends on the 
molecular structure as well as the molecular weight [25]. Second, the 
distribution of the antibodies in the hydrogel is homogeneous. Instead, 
the antibodies in this highly packed affinity biosorbent probably form a 
gradient perpendicular to the sensor surface, as previously suggested 
[26, 27]. This influences the SPR response because the evanescent 
wave intensity has a strong exponential decay within a few hundred 
nanometers next to the surface [23]. Hence, highly concentrated 
antibodies binding Enro in the distal regions of the hydrogel would 
contribute little to the final Enro SPR response and also limit the 
transport to the lower density layers under a higher evanescent wave 
intensity. 
 The linear binding curves of Enro to the antibodies in the sensorgrams 
of Figure 2C show that the reaction is strongly limited by mass transport 
under the conditions of low flow rate (10 μL min-1) and a high flow cell 
height (50 μm), in accordance with expectation [28]. The sensorgrams 
also suggest a further diffusion limitation at Enro concentrations below 
25 pg μL-1 where very low responses are obtained indicating low capture 
levels. An attempt to obtain the kinetic constants by fitting the Enro 
sensorgrams of Figure 2C to a simple 1:1 bimolecular model with mass 
transport, using CLAMP software [29], resulted as inconclusive, 
indicating a complex kinetic system influenced by additional diffusion 
limitations and a heterogeneous kinetic behavior of the polyclonal 
antibodies. SPR experiments using a lower capacity RC (8900 RU of 
immobilized antibodies) showed an Enro binding response of 15 RU. This 
binding response is comparable to the response obtained with the high-
capacity RC A and suggests either that a higher proportion of binding 
sites are active or that they are distributed more homogeneously at 
lower densities. 
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Figure 3. Overlaid chromatograms and mass spectra (see insets) of relevant peaks of RC 
eluates analyzed on-line by nano-LC TOF MS. Reagent blank (gray) and Enro standard 
solution (5 pg μL-1) (black)  in HBS-EP buffer were injected (40 μL, 10 μL min-1) over RC A 
and eluted with 10 μL of formic acid (1%). (A) Total ion current (TIC) (B) extracted ion 
chromatogram (0.05 Da mass window). Enro (360.17) elutes in the first peak. The second 
peak corresponds to a buffer interference (360.22) also present in the blank. (C) Nano-LC 
TOF MS analysis of RC eluates after injections with increasing Enro concentrations. (D) 
Recovery efficiency of the RC A at different concentrations of Enro injected over the RC. 
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The nano-LC TOF MS analysis of RC A eluates from injections of Enro 
below 25 pg μL-1 shown in Figure 3 demonstrates that Enro is indeed 
captured at levels that should be measurable with the biosensor. An 
increase in the concentration of Enro injected over RC A correlates with 
increasing amounts of Enro captured on the RC as shown in Figure 3C 
yielding a curve that mirrors the calibration curve obtained in the iBIA 
(Figure 2A). The analysis of the RC capture efficiencies shown in Figure 
3D clearly shows that there is an optimal concentration of Enro that 
maximizes the capture.  
Knowing the kinetic constants could have an additional analytical value 
in the characterization of the biosorbent since they predict the RC 
behavior and would correlate the estimated analyte concentration values 
of the suspected noncompliants selected with the iBIA screening with a 
binding rate and capture efficiency when injected in the affinity chip 
interface. This would facilitate an automated adjustment of the sample 
concentration and volume needed in the RC to maximize the capture 
efficiency. The results presented show the potential insight to which the 
RC affinity sorbent can be studied using the present system. Last but 
not least, the predicted RC performance from the SPR measurements 
represents just a worst case (i.e. SPR can be exploited as a QA/QC 
check). More considerations about RC hydrogel immobilization capacity 
can be found in the Supporting Information section of this chapter. 
Future research will focus first on optimizing the immobilization 
chemistry and using recombinant antibodies that allow an oriented 
immobilization, a higher efficiency and a simpler estimation of the 
kinetic constants. The nano-LC TOF MS analyses presented in Figure 3 
demonstrate that the amount of Enro captured onto the RC is more than 
sufficient, even when Enro is injected onto the RC at low concentrations 
of 5 pg µL-1.  
The Enro capture capacities of sensor chips of different hydrogel lengths 
and branching densities (see Table 2) were studied. Again, the SPR 
biosensor and the on line biosensor-RC-nano-LC TOF MS system were 
used for measuring the amount of captured Enro.  The standard Biacore 
chip, RC A showed the highest antibody immobilization capacity (19.6 
ng mm-2) and Enro capture capacity (12 RU). A shorter hydrogel of 
higher density (RC B) lowered 16% the immobilization capacity and 
proportionally decreased the Enro capture capacity. However, a small 
increase in length of this high-density hydrogel (RC D) dramatically 
lowered the antibody immobilization capacity by 75%. RC E and RC F 
had a linear polymer hydrogel (undisclosed polymer chemistry by the 
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manufacturer) and showed 59% and 53% lower immobilization 
capacities, respectively.  Nevertheless, these hydrogels exceeded the 
evanescent wave sensing region and more antibodies than probed by 
SPR measurement were expected. The Enro capture capacities of RC E 
(high-density hydrogel) and RC F (lower density hydrogel) were 0 and 9 
RU, respectively, according to the biosensor. In contrast, the nano-LC 
TOF MS eluate analysis showed that Enro could be captured in RC E and 
RC F at a similar level of 13 and 14 pg mm-2 respectively.  This suggests 
that the diffusion of Enro in chip E was limited by the high-density 
hydrogel and that the SpMH40 interaction took place too far from the 
chip surface. Given the potential of a 5-10 fold higher hydrogel volume 
featured in RC F, this seems as a suitable candidate for a high capacity 
chip still allowing characterization using the biosensor. However, RC A 
was used throughout this study due to its high capacity and robustness. 
Further research will focus in optimizing the antibody immobilization 
procedure for this chip combined with recombinant antibodies currently 
under development. 
 
Multianalyte Capture 
In order to test the feasibility of capturing more than one analyte on the 
RC surface, a monoclonal antibody IgM (MAb72F) with high CR for Enro 
and Cipro was immobilized on a chip (RC A1). The level of 
immobilization (Table 2) was similar to that of RC A with the SpMH40 
although the IgM molecules have a molecular weight of 900 kDa. The 
SPR measurements resulted in a lack of Enro response. The nano-LC 
TOF MS analysis of eluates from RC A1 after the injection of a mixture of 
Enro and Cipro (100 pg μL-1) showed that about 3 pg mm-2 of Enro (CR 
100%) and 1.6 pg mm-2 of Cipro (CR 53%) were captured. 
Comparatively, 30.6 and 1.8 pg mm-2, respectively, were obtained (CR 
6%) when the same experiment was repeated using the PAb SpMH40-
based RC A described above. These results prove that more than one 
analyte can be captured and measured with the RC nano-LC TOF MS 
system, even with an RCA1 based on MAb72F that is an unstable MAb 
isotype where few binding sites remained active after immobilization. 
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Figure 4. (A) iBIA calibration curve obtained with chicken muscle extract spiked with Enro 
using SC A. Black triangles show the muscle extract samples from chicken samples either 
incurred or spiked with Enro. Following the iBIA screening, 40 μL of muscle extract was 
reinjected into the RC A for affinity extraction and the eluate is used for nano-LC TOF MS 
analysis. (B-D) Chromatograms and mass spectra (see insets) of relevant peaks of an RC 
A eluate obtained from muscle extract incurred with Enro at 1 MRL (5 pg μL-1 in the 
extract). (B) TIC and (C) XIC (0.05 Da mass window) of Enro (360.17). The second peak 
corresponds to a buffer interference (360.22) also present in the blank. (D) XIC (0.05 Da 
mass window) of Cipro (332.14), a Enro metabolite.  
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Screening, Recovery and Identification of Enro in Chicken 
Samples 
The applicability of this iBIA for the screening of Enro in chicken muscle 
extracts was further evaluated by measuring a calibration curve of Enro 
in chicken muscle extracts diluted (1:1; v/v) in HBS-EP buffer (Figure 4 
A). Similar sensitivity (Enro IC50 = 2.4 pg μL-1) was obtained compared 
to the calibration curve in buffer (Figure 2A), and no nonspecific binding 
of the sample matrix to the SC surface was observed.  
Extracts of chicken samples incurred or spiked with Enro at regulatory-
relevant levels (maximum residue level (MRL) 100 μg kg-1 for the sum 
of Enro and Cipro) were measured with the iBIA in conjunction with SC 
A. Although, due to dilution during the extraction procedure of the 
chicken muscle samples, the concentration of the sample extract is 
lowered 20 times, all the chicken muscle extracts (at 0.5, 1 and 5 MRL) 
could be measured with the iBIA. These samples were considered as 
suspected noncompliants and were reinjected into the SPU containing 
RC A for analyte capture and further analyzed with nano-LC TOF MS. 
Figure 4, parts B and C, shows the total ion current (TIC) and extracted 
ion current (XIC) chromatogram obtained during the analysis of the 
incurred chicken sample at 1 MRL. The mass spectra of some peaks 
between 12.6 and 14.2 min (see second inset in Figures 3B and 4B), 
display peaks separated by 44 and 22 Da. These correspond to single- 
and double-charged ethylene oxide residues of the polyethylene glycol 
used as surfactant in the HBS-EP buffer used to dilute the extracts, 
suggesting that the washing steps implemented after the injection of the 
sample trough the RC surface were not sufficient to completely remove 
the surfactant. Surfactant removal from the buffer would invariably 
increase nonspecific binding issues. However, ongoing efforts will further 
optimize the buffer conditions. Nevertheless, even with these surfactant 
interferences, the XIC chromatogram clearly displays a peak 
corresponding to the mass of the [M+H]+ ion of Enro (360.17) at 13.4 
min. The second peak at 14 min corresponds to the elution of one of the 
surfactant isomers having a similar m/z (360.22). We considered the 
possibility that Cipro might be captured in this sample using RC A with 
PAb SpMH40. The XIC chromatogram in Figure 4D shows a peak with a 
mass that corresponds to the [M+H]+ ion of Cipro (332.14) that elutes 
shortly (13.3 min) before Enro. This finding implies that Cipro, an Enro 
metabolite, is present at a low concentration in the incurred chicken 
muscle sample. This result was independently confirmed by an 
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LC/MS/MS confirmatory analysis method (data not shown). These 
results strongly suggest the potential use of the serial SPR RC nano-LC 
TOF MS coupling concept for the identification of biologically relevant, 
but yet unknown, analytes in the samples. Optimization of the buffer 
surfactant interferences and the use of accurate masses will allow an 
untargeted analysis of relevant peaks, facilitated by the biosorbent 
featured on the RC that provides a selective cleanup, greatly reducing 
the number of irrelevant peaks in the mass spectra and minimizing ion 
suppression. 
 
Triple-Chip Feasibility 
The common drawbacks of the classical capillary nano-LC setup 
described above are nano-ESI spray positioning, blocking of capillaries, 
dead volumes, etc.  
 
 
Figure 5. Triple-chip system. Chromatograms and mass spectra (see insets) of an RC A 
eluate obtained from the injection of 10 μL of muscle extract from chicken incurred with 
0.5 MRL level of Enro (2.5 pg μL-1 in the extract) and analyzed of-line by chip-LC TOF MS. 
(A) TIC and (B) XIC (0.05 Da mass window) of Enro (360.17). The second peak in B 
corresponds to a buffer interference (360.21) also present in the blank. 
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Due to these issues, specific skills of the operator are required for 
troubleshooting. Recently a microfluidic nano-LC chip TOF MS system 
was introduced which overcomes these traditional nano-LC limitations 
[21]. We briefly evaluated the feasibility of introducing such a third chip 
into the system aiming for a more robust overall setup.  
Chicken muscle samples spiked and incurred with Enro at levels as low 
as 0.5 MRL were injected over the RC A, and the eluates were analyzed 
(off-Line) with the chip LC TOF MS system as described in the 
Experimental Section. As a typical example, Figure 5 shows the TIC 
(Figure 5A) and XIC (Figure 5B) of the SpMH40 RC eluate from a 
chicken muscle sample incurred with Enro at 0.5 MRL. The XIC clearly 
displays two peaks, the first one (Rt = 4.3 min) corresponding to the 
[M+H]+ ion of Enro (m/z 360.1723), and the second one of lower 
intensity corresponding to the buffer impurity discussed above.  The 
high mass accuracy of TOFMS allowed elemental composition calculation 
of the analyte of interest. Within the restrictions of m/z  5 mDa, ring 
plus double bond equivalent number 5-20, atoms C0-30H0-40N0-5F0-5 nine 
elemental composition options remain, C19H23N3O3F being on top of the 
list having the smallest difference between the theoretical and 
experimentally determined accurate mass. Subsequent data mining for 
C19H22N3O3F using the comprehensive SciFinder database confirmed the 
presence of Enro in the incurred sample. Such a robust chip format 
nano-LC ESI system would be probably the only realistic option for 
routine food analysis laboratories. It should be emphasized that no 
theoretical limitation would limit the integration of the RC and the nano-
LC ESI chip.  
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Conclusions 
A new concept for coupling an iBIA screening of low molecular weight 
analytes with nano-LC ESI TOF MS for confirmation of identity using an 
affinity chip interface has been presented. The interface features the 
unique advantage of allowing an in depth characterization of the 
biosorbent and its interaction with the analyte and sample matrix 
components. This interface provides a highly selective sample cleanup 
which greatly reduces the number of irrelevant peaks in the subsequent 
nano-LC TOF MS analysis. For the application selected, the optimal 
hydrogel thickness for the RC interface was 100-200 nM. With this RC 
the interfaced system was able to detect our model analyte in 
noncompliant samples below the regulatory limits during the screening 
in incurred chicken muscle samples. Reinjection of relevant samples in 
the affinity chip interface provided a good recovery and a concentration 
step of the analyte to be identified in the nano-LC MS analysis, even 
with a minor biosorbent crossreactivity for a bioactive metabolite of Enro 
present in the non-compliant sample. The metabolite was captured in 
the RC at a suitable level for nano-LC TOF MS analysis.  
This is a promising outcome that shows the potential of designing 
multianalyte affinity chips for multianalyte inhibition BIAs followed by 
multi analyte recovery. Finally, a more robust triple chip approach 
seems feasible. The concept presented can be easily extended to other 
applications requiring both a fast bioactivity-based screening and 
accurate mass assessment with subsequent elemental composition 
calculation, for example in the fields of natural toxin analysis and 
security applications. 
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Supporting Information 
Experimental details about the preparation of PAb MH40 antiserum and 
the preparation of the specific fraction of PAb MH40 antiserum necessary 
to produce the recovery chip (RC) are described in this section. In 
addition, we present details relevant to the Nano-LC Equipment setup 
and some considerations about the RC hydrogel immobilization capacity. 
 
Preparation of PAb MH40 Antiserum 
The polyclonal antiserum was raised in a rabbit against an Enro-keyhole 
limpet hemocyanin (KLH) conjugate.  The immunization was performed 
at the Laboratory of Hormonology (Marloie, Belgium) according to their 
standard protocol. The sera obtained were stored at -80°C until further 
use. 
 
Preparation of the PAb MH40 Antiserum Specific Fraction  
The total IgG fraction (2 mL) from 20 mL of raw antiserum (PAbMH40) 
was obtained using a protein G column (1 mL) according to the 
manufacturer’s instructions. The specific anti-Enro IgG fraction 
(SpMH40) was isolated from this total IgG fraction using an Enro-
sepharose column (1.25 mL). Enro was coupled to CNBr-activated 
Sepharose™ 4B using ethylene diamine as a bifunctional spacer. After 
loading the total IgG (diluted 10 times in PBS) at a flow rate of 1 mL 
min-1, the chromatography continued using two mobile phases 
consisting of (A) PBS buffer (pH 7.4) and (B) 1% formic acid  (pH 2). 
The SpMH40 fraction was eluted with a gradient starting at 0% B 
isocratically for 5 min, followed by a linear increase to 100% B in 2 min 
and then step-wise to 0% B and conditioning for 5 min. This affinity 
chromatography was repeated with the pooled effluent until total 
depletion of SpMH40. The SpMH40 eluates were pooled, buffer 
exchanged to PBS and concentrated to 1 mg mL-1 (total end volume was 
0.5 mL) using a 50 kDa Amicon cutoff filter and stored at -20 ºC until 
use. 
 
Nano-LC Equipment Details 
The pump flow during the gradient was steadily increased to 375 μL 
min-1 and 20% of solvent B until 5.5 min, linearly increased to flow 400 
μL min-1 and 25% of B at 9 min, to flow 600 μL min-1 and 70% of at 12 
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min, decreased to flow 500 μL min-1 and 30% B at 14 min, to flow 550 
μL min-1 and 0% B at 18 min, then isocratically until 24.5 min for 
preconditioning and finally to flow 10 μL min-1 at 25 min.  Thus the split 
flow in the nano LC column was on average in the order of 300 nL min-1. 
The Nano ESI probe was operated in the positive ion mode, source 
temperature 90 °C, a cone and capillary voltage of 30 V and 2.8 kV 
respectively. Data were acquired in the continuum mode from 100 to 
1200 Da with a scan time of 0.44 s at a resolution of 5000 (fwhm) and 
processed using Masslynx v. 4.0 software.  
The polyimide coated fused silica capillaries were obtained from 
Polymicro (Phoenix, Arizona, USA). Tubing connections were made with 
Micro Tight® fittings, unions, tees and sleeves were provided by 
Upchurch (Oak Harbor, Washington, USA). Two six ports-two position 
valves were used. One with a manual actuator for the loop type 
interface fitted with a PEEK 10 μL loop, provided by VICI AG 
International (Schenkon, Switzerland) and a Lab Pro (PR-700-100-01) 
with an electric actuator obtained from Rheodyne (California, USA). The 
nano LC columns were provided by Nano Separations (Nieuwkoop, The 
Netherlands).   
 
Considerations About the RC Hydrogel Immobilization Capacity  
Considering that the dextran hydrogel layer contains flexible polymer 
chains of nonuniform length between 100 to 200 nm long [23], the 
hydrogel volume in the RC flow cell would be 1.9x1015 – 3.8x1015 
nm3.  Hence, the estimated number of SpMH40 IgG molecules 
immobilized on on the 16 mm2 of RC A would be 1.2x1012, or one IgG 
molecule per 1500 - 3000 nm3 of dextran. Assuming an ideal cubical 
and homogeneous distribution, the average distance between every two 
IgG molecules would be 12 -15 nm. As a reference, the IgG dimensions 
are 10 nm long, 7 nm wide and 2 nm thick, therefore suggesting a 
densely packed biosorbent. In consequence, future efforts to increase 
the capture capacity of the RC should focus on increasing the hydrogel 
volume and on the antibody immobilization chemistry.   
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Summary 
 
The term bioactive contaminant refers to chemicals introduced in to a 
given system at levels above a certain frame of reference causing 
adverse effects to living matter due to their inherent biological activity. 
Bioactive contaminants are ubiquitous in the environment and in food, 
nevertheless, they can have very different origins. Those from industrial 
sources may enter the food chain through the environment or from their 
use in household products. Chemicals used for pharmacological 
purposes may, on the other hand, enter the food chain as drug residues 
in treated livestock or through contaminated drinking water.  
Screening the environment and food for the presence of multiple 
bioactive contaminants simultaneously and in a short time, whilst 
obtaining data about their biological potency, is a challenge. If, 
confirmation of the identity of these bioactive chemicals is required, the 
challenge grows exponentially. 
 
The general introduction presented in chapter one of this thesis puts in 
perspective the importance of the bioactive contaminants studied as well 
as the background of screening methods within the greater context of 
analytical chemistry. Some historic and basic concepts of biosensors are 
described with a special emphasis on optical biosensors, specifically 
those SPR-based biosensors considered in this thesis. Background and 
challenges concerning the different strategies for interfacing biosensors 
with mass spectrometric identification is included at the end of the 
introduction.  
 
Part I deals with the development of various biosensor screening 
assays for bioactive contaminants.  
The first biosensor screening assay developed was against the 
ubiquitous estrogenic compound Bisphenol A (BPA) and is described in 
chapter two. Several polyclonal and monoclonal antibodies were 
characterized as biorecognition elements. The monoclonal antibody 
showing the best kinetic parameters was selected and tested using 
direct and indirect (inhibition) assay formats. Although the direct assay 
was the most sensitive, the inhibition assay was the most robust. Using 
the latter in combination with solid phase extraction (SPE) allowed the 
determination of BPA in tap water at the ppt (ng L-1) level. 
Even though antibody-based screening assays were sensitive and 
robust, they were very specific and provided no clue of the total 
biological potency when a mixture of bioactive contaminants is 
measured in a complex sample. In consequence, an alternative 
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biorecognition element was sought in chapter three. Two human 
thyroxine (T4) transport proteins; T4 binding globulin (TBG) and 
transthyretin (TTR), were selected as biologically relevant biorecognition 
elements to screen for compounds with T4-like activity. An inhibition 
assay was developed by immobilizing T4 with a spacer to the biosensor 
chip surface. The use of recombinant TTR was validated by measuring 
the equilibrium dissociation constants of both binding sites for T4 with 
the biosensor. The application was further evaluated by analyzing a 
small library of nine known bioactive chemicals and comparing their 
relative potencies to T4 using both recombinant and purified TTR. Both 
T4 transport proteins provided suitable biosensor assays with a higher 
sensitivity and shorter analysis time than radioligand binding assays 
using comparable biorecognition elements.  
Further optimization of the assay conditions, as described in chapter 
four, provided the correct working conditions for long unattended 
operation of the biosensor assays. The robustness and short analysis 
time were suitable for high throughput screening of the relative 
potencies of a sixty two chemicals library. This library included 
important bioactive contaminants like polychlorinated bisphenyls (PCBs), 
polybrominated diphenyl ethers (PBDEs), their hydroxylated 
metabolites, bisphenol A and its halogenated congeners, 
pharmaceuticals and other environmentally relevant compounds.  Ten 
new bioactive compounds were identified to bind to TBG with a high 
affinity and were also confirmed to bind to TTR. Strikingly these 
bioactive compounds were hydroxylated metabolites of PBDEs (BDE 47, 
49, 99) and polyhalogenated biphenyls, usually present in human blood. 
Suggesting that these hydroxylated metabolites of halogenated diphenyl 
ethers not only are disrupting T4 transport at the transthyretin level, but 
also at the T4 binding globulin level, responsible for most of the T4 
transport. The toxicological relevance of these findings remains to be 
determined, nevertheless this biosensor technology proved very 
applicable and promising for toxicological research. 
 
The drawbacks of the technology used in part I concern the high cost 
the of the SPR systems and the lack of portability. Therefore, part II 
deals with the implementation of the assays previously developed in 
part I to evaluate a similar SPR technology having a low-cost 
instrumentation and potential portability. In chapter five, a miniature 
Spreeta SPR sensor was combined with a simple fluidic system and 
adapted to function with commercial biosensor chips. The assays were 
quickly implemented in this low-cost prototype system with a 
comparable sensitivity to the commercial systems used in part I. 
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The fast, online and (potentially) bioeffect related information provided 
by the biosensor technology can be synergistically coupled with 
traditional analytical techniques such as liquid chromatography (LC) and 
mass spectrometry (MS). These hyphenated techniques are able to 
separate the analytes based on their physico-chemical properties and 
unequivocal structural information can be obtained using MS. Such a 
coupling would be applicable for the discovery of unknown bioactive 
compounds interacting with the biorecognition element in complex 
samples. Additionally, the confirmation of identity of known analytes, 
regulated by law could be achieved in a short time because all the 
analytical efforts are focused only on samples pinpointed during the 
screening as suspected non-compliants.  
 
The main challenge of such hyphenation is to find a suitable strategy for 
coupling inhibition biosensor assays with MS. Consequently, part III of 
this thesis deals with the strategies investigated for interfacing SPR 
inhibition biosensor assays with mass spectrometric detection. 
Fluoroquinolone antibiotics were selected as model analytes because the 
monitoring of these antibiotics are regulated by law because they are 
widely used for the treatment of bacterial infections in farm animals.  
In chapter six, a parallel interfacing strategy is presented. The 
feasibility of this strategy was proven by coupling the simultaneous 
screening of six fluoroquinolones using a dual SPR biosensor 
immunoassay with ultra high resolution LC- electrospray ionization (ESI) 
Time-of-Flight (ToF) Mass Spectrometry (MS) for their identification.  
The dual SPR biosensor immunoassays enabled the screening of 
norfloxacin, ciprofloxacin, enrofloxacin, difloxacin, sarafloxacin and 
flumequine at, or below, their maximum residue levels in chicken 
muscle. The biorecognition elements used in these assays were 
polyclonal antibodies, a specific antibody against flumequine and a 
generic antibody recognizing the other five structurally related 
fluoroquinolones.  
Samples considered noncompliant during the biosensor screening were 
concentrated using solid phase extraction and fractionated with gradient 
LC. The effluent was split and fractionated in two identical 96-well 
plates. One was re-screened with the biosensor to identify the 
immunoactive fractions and directed the identification efforts with high 
resolution LC-ESI-ToF-MS only toward the relevant fractions in the 
second well-plate. The system could screen and identify known 
fluoroquinolones and also discover unknown chemicals of similar 
structure cross-reacting with the antibodies used as biorecognition 
elements in the biosensor assays.  
Chapter 8 
 
 
211
The main limitations of such an interfacing strategy were; the 
requirement of a relatively large sample volume, the extensive sample 
handling required, which increased the chances of sample 
contamination, and the limited fractionation resolution.  
As a result and considering these limitations, an online strategy 
physically coupling the systems was studied in chapter seven. The 
biosensor and a nano-LC- ESI ToF MS systems were coupled through a 
reusable affinity capture interface (recovery chip).  
The full procedure has four main stages. First, the samples are 
prepared. Second, the samples are screened using a screening chip with 
the inhibition biosensor immunoassay. Third, only those samples 
suspected of being noncompliant are reinjected over the recovery chip, 
and the analyte is captured at subnanogram level. Fourth, the analyte is 
released from the recovery chip into a loop-type interface and analyzed 
with nano-LC- ESI ToF MS system. 
The screening chip and the recovery chip both featured a similar 
hydrogel where mirror chemistries were immobilized. On the screening 
chip, the analyte was immobilized to implement the inhibition assay and 
on the recovery chip the complementary biorecognition elements were 
immobilized (affinity-purified polyclonal antibodies). The recovery chip 
operated as an immuno affinity column. The main differences were, first 
that the nanoscale biosorbent is immobilized in one of the walls of a flow 
cell. Second, the interaction of the biosorbent with the analyte and 
sample matrix were rapidly characterized using the biosensor. This 
advantage was particularly useful for optimizing the elution conditions 
and assessing the biosorbent robustness without engaging the complete 
hyphenated system. 
The strategy was tested for screening the fluoroquinolone antibiotic 
enrofloxacin in incurred chicken muscle samples as a model compound 
and matrix. Using the online strategy, we were able to detect and 
confirm the identity of enrofloxacin in noncompliant samples below the 
regulatory limits. A known metabolite of enrofloxacin, ciprofloxacin, was 
identified in incurred chicken samples. This demonstrated the potential 
of the online interfacing strategy for the rapid screening and 
identification of known as well as unknown compounds with an affinity 
for the biorecognition element.  
Additional advantages of interfacing with the recovery chip were a highly 
selective sample cleanup, a good recovery and concentration step.  
Finally, the feasibility of combining the biosensor with a robust chip-
based nano-LC- ESI ToF MS was tested offline and provided a robust 
alternative triple-chip system. 
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Conclusions and Future Perspectives 
 
The main goals in this thesis were three-fold. First, to develop screening 
assays for bioactive industrial contaminants with hormonal activity using 
SPR-based biosensor technology and various biorecognition elements. 
Second, to study the feasibility of implementing screening assays for 
bioactive industrial contaminants in a lower cost and potentially portable 
SPR biosensor system. Third and final, to evaluate different interfacing 
strategies for the hyphenation of inhibition assays in a SPR biosensor 
with liquid chromatography-mass spectrometry for the confirmation of 
analyte identity using bioactive pharmaceuticals as model analytes. 
 
In part one of this thesis three SPR biosensor inhibition assays were 
successfully developed and applied for the screening of bioactive 
industrial contaminants. A specific inhibition biosensor immunoassay 
(iBIA) was developed in chapter two for the ubiquitous estrogenic 
contaminant BPA. For a generic and bioeffect related screening, two 
inhibition biosensor T4 transport protein assays for contaminants with 
T4 transport disruption potential were developed in chapter three.  
In part III, previously developed iBIAs against fluoroquinolone 
pharmaceutical contaminants were quickly implemented with some 
modifications.  
 
Although using the direct assay format was evaluated, in general it was 
not suitable for the screening of bioactive contaminants due to the 
inherently low signals generated by these analytes of low molecular 
weight. Nevertheless, the kinetic parameters of the biorecognition 
element-analyte interactions obtained in the direct assay format were 
useful for predicting assay sensitivity and characterizing the immobilized 
or captured biorecognition elements. 
 
The inhibition biosensor assays were robust due to the high responses 
generated by the binding of the high molecular weight biorecognition 
elements and due to the extreme resistance of the sensor chip with a 
low molecular weight molecule immobilized which could resist over 1500 
measurements. Above 400 unattended measurements could be made in 
a single experiment if the reagents were premixed manually. The 
throughput of the inhibition biosensor assays was as high as 6 min per 
sample if the reagents were premixed manually, 8-10 min if the 
reagents were mixed by the biosensor and 15 min if combined with solid 
phase extraction. 
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The inhibition biosensor immunoassays (iBIAs) could be easily 
multiplexed as shown in chapter six where a specific iBIA was 
combined with a group-generic iBIA detecting six different 
fluoroquinolones in a single measurement of 8.5 min.  
Further throughput improvement can be obtained with currently 
commercially available SPR biosensor systems with higher multiplexing 
and parallelization capabilities. 
In the near future, imaging SPR in a microarray-type of format seems to 
be best suited for such purposes in combination with advanced 
microfluidic systems. 
 
The iBIA for BPA performed very good for measuring surface water 
samples with a minimum sample cleanup, showing the potential of this 
technology to rapidly screen environmental water samples.  If 
concentrations of the analyte in the order of  low ng L-1 need to be 
detected, the inhibition biosensor assays can be combined with solid 
phase extraction for sample concentration as shown in chapter two. 
Both inhibition biosensor T4 transport protein assays developed in 
chapter three were optimized and applied in chapter four to screen a 
library of chemicals. It was shown that both human purified and 
recombinant TTR can be used as robust biorecognition elements in 
inhibition biosensor assays. If compared with radioligand assays 
previously used [1, 2], the inhibition biosensor T4 transport protein 
assays provide comparable results at a much higher throughput and 
sensitivity. Thus, showing the potential of SPR biosensor technology for 
in-vitro toxicological research. As a matter of fact in chapter four, 
several hydroxylated metabolites of polyhalogenated diphenyl ethers 
and biphenyls were discovered to bind with strong affinity to TBG, the 
main T4 transport protein in humans. 
Most of the compounds previously tested using the radioligand binding 
assay and considered strong TTR binders were confirmed with the TTR-
based inhibition biosensor assay.  
All in all, from the chemicals tested in chapter four, the hydroxylated 
metabolites of the ubiquitous brominated flame retardants 
polybrominated diphenyl ethers (PBDEs) were the most active 
compounds toward both T4 transport proteins. The toxicological 
relevance of these results is of concern given that the human fetus 
initially has no iodine reserve and  depends on the iodine transferred by 
the mother. Such an avid placental uptake is compensated by the 
mother during pregnancy with an increased concentration of T4-TBG [3, 
4]. TTR, on the other hand, mediates the maternal to fetal T4-transport 
through the placenta and the delivery of T4 across the blood–brain 
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barrier. Hence, compounds bound to TTR are transported to the fetal 
compartment and fetal brain decreasing fetal brain T4 levels [5, 6]. 
Altogether, these results suggest that the displacement of the T4-TTR 
and T4-TBG complex by the OH-PBDEs during ontogenesis may have 
consequences in fetal development.  
The inhibition biosensor T4 transport protein assays are valuable tools 
for the discovery and relative affinity ranking of bioactive chemicals with 
T4 transport disrupting activity. 
Focusing future research in multiplexing or parallelization of these 
bioeffect related assays with other human transport proteins and  
receptors for screening, will provide a wealth of information for the 
toxicological screening of compounds as required for EU regulations of 
toxic compounds such as REACH [7]. Furthermore, combining these 
assays with an in-vitro metabolization step will provide more 
toxicological relevance to the screening of environmental and food 
samples with potential thyroid activity.  
There is a tendency to switch from specific assays to generic or bioeffect 
related assays for the screening of food, environmental of biological 
samples. It is the author’s opinion that bioeffect-related assays are 
unlikely to replace specific assays, but on the contrary, they will merge 
into the same platform and provide highly complementary information. 
If bioeffect-related assays as those described in this thesis are 
multiplexed with specific assays such as those based on antibodies 
against regulated chemicals or those analytes considered of natural 
origin, the information obtained from the specific assays could provide a 
very useful frame of reference and become a very valuable complement 
to the bioeffect-related assays.  
Future research should focus in more in understanding the 
physicochemistry of the hydrogel and how the macromolecules behave 
in such an environment. A deep understanding of the surface chemistry 
will also support the development of more challenging applications 
where matrix interferences are high.  
 
As shown in part two, is possible and relatively simple to transfer the 
inhibition biosensor assays developed in part one to a simple and 
potentially portable SPR biosensor platform. The SpreetaTM –based 
prototype biosensor system, optimized and tested in chapter five had a 
low cost instrumentation and was combined with commercially available 
sensor chips. The assays developed in the Biacore 3000 in chapters 
two and three were easily implemented with comparable sensitivities. 
Combining this human biorecognition elements with a fast, simple and 
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affordable SPR biosensor is a novel approach for the bioeffect-related 
screening of compounds with endocrine disrupting activity.   
Recent developments of systems achieving portability are very 
promising for on site deployment for the detection of bioactive 
contaminants [8, 9]. Considerable sensitivity increase is of SPR 
biosensors is necessary to achieve on-site measurement of 
environmental bioactive contaminants. Such sensitivity increase can be 
obtained by engineering the biorecognition elements for higher analyte 
affinity in combination with the ten-fold increase in sensitivity that can 
be obtained using noble metal nanoparticles [10]. 
Advances in micro and nano fabrication and the adoption of localized 
SPR will aid mass production possibilities of the optical and microfluidic 
parts and provide further reduction of SPR biosensor costs. 
 
The synergy of combining SPR biosensor screening with analytical 
techniques like LC-MS was explored in part three of this thesis. A 
parallel coupling strategy was explored in chapter six where a duplex 
inhibition biosensor immunoassay for screening six fluoroquinolones was 
coupled with high resolution LC TOF MS for identification of analyte 
identity. Known and unknown compounds having affinity for the 
biorecognition element were identified in chicken muscle samples 
evidencing the potential of this approach for screening regulated 
bioactive compounds in food. 
 
The use of antibodies as biorecognition elements in these assays allows 
for the detection of unknown compounds structurally related to the 
target analyte. A bioeffect related detection and identification of 
compounds with biological activity could be achieved in the future if 
biologically relevant biorecogntion molecules are used instead of 
antibodies. 
The dual iBIA screening was compatible with a simple sample 
preparation and allowed the detection of fluoroquinolones below MRL in 
a complex matrix like chicken muscle extract.  
It was also shown that the identity of potential bioactive contaminants 
can be detected using the concentration, fractionation and re-screening 
steps in this parallel strategy.  
 
Further work should be focused on validating this parallel interfacing 
strategy for the elucidation of unknown immunoactive compounds.  
Concerns regarding the extensive sample handling required in the 
parallel interfacing strategy led to the development of a serial strategy 
in chapter seven. The serial iBIA-MS coupling strategy was achieved 
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by using a recovery chip interface. This interface had the biorecognition 
element immobilized on its surface and was able to capture the relevant 
analyte(s). The analyte(s) was (were) further eluted and analyzed online 
with nano-LC TOF MS and the recovery chip could be reused. 
Advantages of the recovery chip are; a highly selective sample cleanup, 
in depth characterization of the biosorbent including its interaction with 
the analyte and sample matrix components.   
Using the serial interfacing strategy we were able to detect our model 
analyte, enrofloxacin and even ciprofloxacin, a bioactive metabolite, in 
noncompliant samples below the regulatory limits during the screening 
in incurred chicken muscle samples. 
The serial interfacing strategy was can be further improved by using a 
more robust nano-LC ESI on a chip as shown in chapter seven.  
Ongoing work focuses on multianalyte recovery chips for multi-analyte 
iBIAs for screening, identifying and potentially discovering natural 
toxins.  
 
In conclusion, the results presented in this thesis demonstrate various 
apects of the SPR biosensor technology applied to the screening of 
bioactive contaminants of small molecular weight. First, versatility for 
developing screening assays using either antibodies or human transport 
proteins. Second, the feasibility of transferring these assays to other 
low-cost and potentially portable SPR biosensor platforms. Third, the 
hyphenation potential. i.e. with SPE, with (high resolution or nano-) LC 
and MS. 
The SPR biosensor screening-MS interfacing concepts presented can be 
easily extended to other applications requiring both, a fast bioactivity-
based screening and accurate mass assessment.  
Such hyphenated systems would be of interest not only for national 
inspection laboratories in the fields of food analysis, forensics and 
biosecurity, but also for drug discovery and toxicology research.  
MS technology is becoming a standard instrument in most laboratories 
and a must in bioanalytical laboratories. The cost-effectiveness of SPR 
biosensor screening and MS coupling will very likely grow for most 
laboratories together with the increase of labour costs and the decrease 
in the cost of SPR biosensor technology. 
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Biosensoren voor Bioactieve Contaminanten  
Test Ontwikkeling en Koppeling met 
Massaspectrometrie 
 
Samenvatting 
 
De term bioactieve verontreinigingen verwijst naar chemicaliën die in 
een bepaald systeem worden ingebracht in concentraties boven een 
bepaald referentiekader waarbij negatieve effecten worden uitgeoefend 
op levend materiaal als gevolg van hun inherente biologische activiteit. 
Bioactieve verontreinigingen komen overal in het milieu en in voedsel 
voor, maar ze kunnen van een zeer verschillende oorsprong zijn. Die uit 
industriële bronnen kunnen de voedselketen binnenkomen via het milieu 
of als gevolg van hun gebruik in huishoudproducten. Aan de andere kant 
kunnen chemicaliën die gebruikt worden voor farmacologische 
doeleinden, de voedselketen binnenkomen als geneesmiddelresten in 
behandeld vee of via verontreinigd drinkwater. 
Het tegelijkertijd kunnen screenen van materiaal uit het milieu en 
voedsel op de aanwezigheid van meerdere bioactieve verontreinigingen 
in een korte tijd, terwijl ook gegevens worden verkregen over hun 
biologische potentie, is een uitdaging. Indien bevestiging van de 
identiteit van deze chemicaliën vereist is, neemt de uitdaging 
exponentieel toe. 
 
De algemene inleiding die gepresenteerd is in hoofdstuk één van dit 
proefschrift, plaatst het belang van de onderzochte bioactieve 
verontreinigingen in perspectief, alsook de achtergrond van de 
screeningswerkwijzen binnen de grotere context van de analytische 
chemie. Enkele historische en basale concepten van biosensoren worden 
beschreven met speciale nadruk op optische biosensoren en dan vooral 
de op SPR-gebaseerde biosensoren die in dit proefschrift gebruikt 
worden. Achtergronden en uitdagingen betreffende de verschillende 
strategieën voor het verbinden van biosensoren met 
massaspectrometrische identificatie zijn beschreven aan het einde van 
de inleiding. 
 
Deel I  gaat over de ontwikkeling van diverse op biosensoren 
gebaseerde screeningsmethoden voor bioactieve verontreinigingen. 
De als eerste ontwikkelde screeningsmethode was tegen de alom 
voorkomende estrogene verbinding Bisfenol A (BPA) en wordt 
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beschreven in hoofdstuk twee. Verscheidene polyklonale en monoklonale 
antilichamen werden gekarakteriseerd als biologische 
herkenningselementen. Het monoklonale antilichaam dat de beste 
kinetische parameters vertoonde, werd geselecteerd en getest met 
behulp van directe en indirecte (gebaseerd op remming) methoden. 
Hoewel de directe methode het gevoeligst was, was de indirecte 
methode het meest robuust. Het gebruik van deze laatste in combinatie 
met vastefaseëxtractie (SPE)  maakt de bepaling van BPA in kraanwater 
mogelijk in de orde van grootte van ng/liter. 
Zelfs al waren de op antilichamen gebaseerde screeningsmethoden 
gevoelig en robuust, ze waren zeer specifiek en ze verschaften geen 
uitsluitsel over de totale biologische potentie, wanneer een mengsel van 
bioactieve verontreinigingen wordt gemeten in een complex monster. 
Dientengevolge werd gezocht naar een alternatief biologisch 
herkenningselement in hoofdstuk drie. Twee humane thyroxine- (T4) 
transporteiwitten, T4-bindend globuline (TBG) en transthyretine (TTR) 
werden geselecteerd als biologisch relevante herkenningselementen om 
te screenen op verbindingen met T4-achtige activiteit. Er werd een 
indirecte methode ontwikkeld door T4 met behulp van een spacer te 
immobiliseren op het biosensorchipoppervlak. Het gebruik van 
recombinant TTR (rTTR) werd gevalideerd door het meten van de 
evenwichtsdissociatieconstanten van beide bindingsplaatsen voor T4 
met de biosensor. De toepassing van TTR werd verder geëvalueerd door 
het analyseren van een kleine bibliotheek van negen bekende bioactieve 
chemicaliën en het vergelijken van hun relatieve potenties ten opzichte 
van T4 met behulp van zowel recombinant als uit plasma gezuiverd TTR. 
Beide T4-transporteiwitten verschaften geschikte biosensorbepalingen 
met een hogere gevoeligheid en kortere analysetijd dan de op 
radioliganden gebaseerde methoden, waarin gebruik wordt gemaakt van 
vergelijkbare biologische herkenningselementen. 
Verdere optimalisering van de bepalingsomstandigheden, zoals 
beschreven in hoofdstuk vier, verschafte de correcte 
werkomstandigheden voor langdurige en onbemande uitvoeringen van 
de biosensormethoden. De robuustheid en korte analysetijd waren 
geschikt voor het met hoge doorloop screenen van de relatieve 
potenties van een bibliotheek van 62 chemicaliën. Deze bibliotheek 
omvatte belangrijke bioactieve verontreinigingen zoals 
gepolychlorineerde bisfenylen (PCB’s), gepolybromineerde difenylethers 
(PBDEs), hun gehydroxyleerde metabolieten, BPA en gehalogeneerde 
soortgenoten, farmaceutica en andere voor het milieu relevante 
verbindingen. Er werden tien nieuwe bioactieve verbindingen 
geïdentificeerd die met hoge affiniteit binden aan TBG en ook werd 
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bevestigd dat ze binden aan TTR. Opvallend was, dat deze bioactieve 
verbindingen gehydroxyleerde metabolieten van PBDE’s (BDE 47, 49, 
99) en bifenylen waren die gewoonlijk aanwezig zijn in menselijk bloed. 
Dit suggereert dat deze gehydroxyleerde metabolieten van 
gehalogeneerde difenylethers niet alleen het T4-transport verstoren op 
het niveau van transthyertine, maar ook op het niveau van het T4-
bindend globuline, dat verantwoordelijk is voor het grootste gedeelte 
van het T4-transport. De toxicologische relevantie van deze bevindingen 
moet nog bepaald worden, maar niettemin bleek deze 
biosensortechnologie zeer toepasbaar en veelbelovend voor 
toxicologisch onderzoek. 
 
Enkele van de nadelen van de in deel I gebruikte technologie hebben 
betrekking op de hoge kosten van de SPR-systemen en de zeer beperkte 
mobiliteit. Daarom gaat deel II over de implementatie van de eerder in 
deel I ontwikkelde methoden in een goedkoop alternatief instrument 
met grotere mobiliteitsmogelijkheden. In hoofdstuk vijf werd een 
miniatuur Spreeta SPR-sensor gecombineerd met een eenvoudig 
vloeistoftransportsysteem en aangepast om te functioneren met 
commerciële biosensorchips. In dit prototype systeem werden de eerder 
ontwikkelde methoden snel geïmplementeerd en met een vergelijkbare 
gevoeligheid. 
 
De snelle, on-line en (potentieel) bio-effectgerelateerde informatie 
verkregen met de biosensortechnologie kan synergetisch worden 
gekoppeld met traditionele analytische technieken zoals 
vloeistofchromatografie (LC) en massaspectrometrie (MS). Met deze 
geavanceerde technieken kunnen de analieten worden gescheiden op 
basis van hun fysisch-chemische eigenschappen en eenduidige 
structurele informatie kan worden verkregen met behulp van MS. Een 
dergelijke koppeling zou toepasbaar kunnen zijn bij de ontdekking van 
onbekende bioactieve verbindingen die interageren met het biologisch 
herkenningselement in complexe monsters. Daarnaast zou de 
bevestiging van de identiteit van bekende analieten, gereguleerd in de 
wet, in een korte tijd bereikt kunnen worden, omdat alle analytische 
inspanningen alleen gefocust hoeven te zijn op monsters die tijdens de 
screening als verdacht naar voren komen. 
 
De belangrijkste uitdaging van een dergelijke koppeling is om een 
geschikte strategie te vinden voor het koppelen van indirecte 
biosensorbepalingen met MS. Derhalve gaat deel III van dit proefschrift 
over de strategieën die werden onderzocht om op SPR-biosensor 
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gebaseerde indirecte screeningsmethoden te verbinden met 
massaspectrometrische detectie. Fluoroquinolonen-antibiotica werden 
gekozen als modelstoffen, omdat het meten van deze antibiotica in de 
wet geregeld is en omdat ze wijdverbreid worden gebruikt voor de 
behandeling van bacteriële infecties in landbouwhuisdieren. 
In hoofdstuk zes wordt een parallelle koppelingsstrategie gepresenteerd. 
De haalbaarheid van deze strategie werd bewezen door het koppelen 
van een op SPR-biosensor gebaseerde duplex immunoassay, voor het 
gelijktijdig screenen van zes fluoroquinolonen, met ultra hoge resolutie-
LC-electrospray-ionisatie (ESI) Time-of-Flight (ToF) Massaspectrometrie 
(MS) voor hun identificatie. Met deze duplex biosensorimmunoassay kon 
gescreend worden op norfloxacine, ciprofloxacine, enrofloxacine, 
difloxacine, sarafloxacine en flumequine op of onder hun maximale 
residuconcentratie in spierweefsel van kippen. De in deze bepalingen 
gebruikte biologische herkenningselementen waren polyklonale 
antilichamen, een specifiek antilichaam tegen flumequine en een 
generiek antilichaam tegen de andere vijf structureel gerelateerde 
fluoroquinolonen. 
Monsters die beschouwd werden als verdacht tijdens de 
biosensorscreening, werden geconcentreerd met behulp van 
vastefaseëextractie en gefractioneerd met gradiënt-LC. Het effluent 
werd gesplitst en gefractioneerd in twee identieke 96-wells 
microtiterplaten. De ene werd opnieuw gescreend met de biosensor om 
de immuunactieve fracties te identificeren en de identificatie-
inspanningen met hoge resolutie-LC-ESI-ToF-MS alleen te richten op de 
relevante fracties in de tweede microtiterplaat. Met het systeem konden 
bekende fluoroquinolonen worden gescreend en geïdentificeerd en ook 
onbekende chemicaliën worden ontdekt met vergelijkbare structuur 
kruisreagerend met de antilichamen die gebruikt werden als biologische 
herkenningselementen in de biosensorbepalingen. 
 
De belangrijkste beperkingen van een dergelijke koppelingsstrategie 
waren: de vereiste van een relatief groot monstervolume, de uitgebreide 
monsteropwerking die vereist was en die de kansen op 
monsterverontreiniging verhoogde, en de beperkte scheiding in de 
fractionering. 
Deze beperkingen in ogenschouw nemend werd een on-line strategie, 
waarbij de systemen fysiek gekoppeld werden, onderzocht in hoofdstuk 
zeven. De biosensor en een nano-LC-ESI-ToF-MS-systeem werden 
gekoppeld via een herbruikbare op immunoaffiniteit gebaseerde 
interface (recoverychip). 
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De volledige werkwijze heeft vier hoofdstadia. Als eerste worden de 
monsters voorbereid. Als tweede worden de monsters gescreend met 
behulp van een screeningschip met de 
biosensorremmingsimmunoassay. Als derde werden alleen de verdachte 
monsters opnieuw geïnjecteerd over de recoverychip, en de analiet 
wordt ingevangen op subnanogramniveau. Als vierde wordt de analiet 
van de recoverychip losgemaakt en via een loop gebracht naar en 
geanalyseerd met het nano-LC-ESI-ToF-MS-systeem. 
De screeningschip en de recoverychip waren beide voorzien van een 
vergelijkbare hydrogel, waarop verschillende chemicaliën werden 
geïmmobiliseerd. Op de screeningschip werd de analiet geïmmobiliseerd, 
om de indirecte bepaling uit te voeren, en op de recoverychip werden de 
complementaire biologische herkenningselementen geïmmobiliseerd 
(affiniteitsgezuiverde polyklonale antilichamen). De recoverychip werkte 
als een immunoaffiniteitskolom. De belangrijkste verschillen waren, ten 
eerste dat het affiniteitsmateriaal op nanoschaal wordt geïmmobiliseerd 
aan één van de wanden van een vloeistofstroomcel. Ten tweede dat de 
interacties van het affiniteitsmateriaal met de analiet en de 
monstermatrix snel werden gekarakteriseerd met behulp van de 
biosensor. Dit voordeel was bijzonder bruikbaar voor het optimaliseren 
van de elutieomstandigheden en het bepalen van de robuustheid van 
het affiniteitsmateriaal zonder het complete gekoppelde systeem daarbij 
te hoeven betrekken. 
De strategie werd getest voor het screenen van het fluoroquinolon-
antibioticum enrofloxacine in verontreinigde kippenspiermonsters als 
modelverbinding en matrix. Met behulp van de on-line strategie waren 
we in staat de identiteit van enrofloxacine in verdachte monsters te 
detecteren en te bevestigen onder de regulatoire grenzen. Een bekende 
metaboliet van enrofloxacine, ciprofloxacine, werd geïdentificeerd in 
verontreinigde kippenmonsters. Hiermee werd het potentieel van de on-
line koppelingsstrategie voor de snelle screening en identificatie van 
bekende alsook onbekende verbindingen met een affiniteit voor het 
biologisch herkenningselement aangetoond. 
Additionele voordelen van de koppeling met behulp van de recoverychip 
waren een zeer selectieve opschoning van het monster, een goede 
recovery en een concentreringsstap. 
Tenslotte werd de haalbaarheid van het combineren van de biosensor 
met een robuuste chipgebaseerde nano-LC-ESI-ToF-MS off-line getest 
en dit verschafte een alternatief systeem met drie chips. 
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